# AUTHOR INDEX

## VOLUME 34


Abad, José P., 1908
Abraham, Paul A., 128
Acar, J. F., 899, 1783
Adams, L. D., 2086
Ahearn, D. G., 1331
Aiken, Stephanie, 1821
Akaniro, Joseph C., 1366, 1880, 2223
Åkesson-Johansson, Annelie, 2417
Alarcón, A., 881
Albrecht, Lisa M., 257, 792
Aldridge, Kenneth E., 179
Allen, Margaret A., 1026, 1381
Allenmark, S., 491, 1949
Almela, M. Jesús, 1259
Al-Nakib, W., 963
Al-Obeid, S., 252, 1901
Altwegg, M., 1605
Alvarez, Martha, 1429
Ambros, Reinhard J., 1744
Amemiya, Kouji, 2250, 2254
Amifloxacin Multi-Center Trial Group, 665
Amils, Ricardo, 1908
Amyes, S. G. B., 1819
Anadón, A., 2148
Anaissie, Elias J., 2420
Andrews, J., 232, 813, 1017, 1053, 1515
Andrews, R. J., 654
Angel de Pedro, Miguel, 539
Antoniskis, Diana, 470
Anwar, Hosmin, 1666, 2043
Appelbaum, Peter C., 1546, 2169
Appleman, Maria D., 2354
Arathoon, Eduardo G., 1655
Arca, P., 844
Archer, Gordon L., 1720
Argimon, Jorge, 321
Arguedas, Adriano G., 2223
Arika, Tadashi, 2250. 2254
Armstrong, Donald, 29
Armstrong, Todd A., 1257
Arneson-Rotert, Lynnett, 159
Aron, Gary M., 2034
Aronoff, George R., 1139
Arroyo, María, 2016
Arthur, Michel, 2024
Ashby, J. P., 813, 1017, 1515
Ashida, Noriyuki, 2431
Ask Eirik, 2277
Atmar, Robert L., 2228
Auckenthaler, Raymond, 2312
Auclair, Pierre, 889
Aulicino, Taryn M., 1766
Aumercier, Marc, 786, 2402
Awan, Aftab R., 709
Awni, W., 922
Ayers, Leona W., 2434

Baba, Masanori, 134, 2358
Bacchi, Cyrus J., 1183, 1485
Bacher, John, 1560
Bacracheva, N., 2375
Bailey, Elaine M., 2081
Bailey, Leonard C., 1007
Baker, Nigel, 2032
Bakken, Johan S., 1276
Baldwin, D. R., 1017
Balis, Frank M., 1281
Ballard, Ronald C., 1303, 1308
Bannatyne, Robert, 1150
Baqar, Shahida, 676
Baquero, F., 539, 2093
Barabás, Gy., 349
Barabás, J., 349
Barbet, Jacques, 2055
Barbhaiya, R. H., 202, 1118, 1198, 1204, 1210
Bard, Martin, 831
Barer, M. R., 1498
Barg, Neil L., 1827
Barnes, A. C., 1819
Barnishan, Jean, 2434
Baron, Laurent, 1955
Barrett, John F., 1, 8
Barriere, Steven L., 257, 823
Barry, Arthur L., 306, 914, 1830
Bartlett, Alfred, III, 1429
Bartlett, Karen H., 1642
Bartlett, Marilyn S., 1648
Baumann, Russell J., 722
Bayer, Arnold S., 1068
Beale, Angela S., 210
Beauchamp, Denis, 139, 576, 889
Beaulieu, Raymond, 206
Bedsole, Glenn, 65
Behlau, I., 1570
Bell, Constance A., 1381, 1678
Bella, F., 937
Belshe, Robert B., 25
Benes, Solomon, 148
Bennett, Peter M., 2429
Berenguer, J., 539, 2093
Berens, Randolph L., 1961
Berger, Bradley J., 1678
Berger, Stephen A., 376, 494
Berger-Bächi, B., 1703
Bergeron, Michel G., 139, 576, 889, 1699
Berglund, Birgitta, 361
Berkowitz, Leonard B., 1766
Berman, Julie R., 792
Bernard, E., 614
Bernard, Edward M., 29
Berne, Thomas V., 2354
Berron, Sonsoles, 2269
Betriu, Carmen, 671
Bhattacharya, M. K., 939
Bhattacharya, S. K., 939
Biagini, Graziella, 2019
Biavasco, Francesca, 911
Bies, M., 733
Bille, J., 2348
Billot-Klein, D., 2439
Binns, Bernard O., 1194
Bismuth, Roland, 1611
Bitonti, Alan J., 722, 1485
Biziagos, Evangélos, 1112
Black, William A., 1390
Blaser, Jurg, 98
Blaser, Martin J., 2381
Blaszczak, L. C., 718
Blewett, D. A., 1498
Block, Timothy M., 2337
Blouin, Robert A., 1318, 1744
Blum, Robert A., 2364
Blumer, Jeffrey L., 1172
Boaretti, M., 314, 1220
Boddy, Alex W., 751
Bodey, G. P., 1609, 2263, 2420
Body, Barbara A., 1648
Boeckh, Michael, 2407
Bogaert, M. G., 958
Bogaki, Mayumi, 1271, 1273
Boisivon, A., 1695
Bolard, Jacques, 1584, 2055
Bollaert, Willy, 496
Boon, R. J., 210
Boon, T., 2398
Boonkitticharoen, Vipa, 1035
Borin, M. T., 1094, 1944, 2369
Borner, Klaus, 1001, 2407
Bornet, M., 1691
Borriello, S. P., 1348
Bosso, John A., 487
Bouchard, Jacques, 206
Bouchenaki, Nadia, 21
Boudinot, F. Douglas, 1214
Bouvet, Philippe, 1244
Bowie, William R., 355
Boyko, Edward J., 665
Boyle, John F., 2050
Bozza, Mary A., 1938
Bradley, John S., 668
Brady, Michael T., 1633
Brady, William, 819
Brajtburg, Janina, 183, 381, 2415
Branch, Robert A., 1020
Brandimarte, Camillo, 2038
Brazier, Jon S., 2280
Breaux, Steven, 1100
Bredberg, Anders, 167
Bregman, Carla L., 637
Brier, Michael E., 1139
Brier, Richard A., 1139
Bringas, P., 2148
Bringman, Timothy, 875
Brismar, Bo, 481
Brisson-Noël, Anne, 924
Broder, Samuel, 82, 287
Bromet-Petit, Maguy, 2032
Brook, Itzhak, 1387
Brookshire, Kenneth W., 1237
Brossard, G., 901
Broughton, M. Christine, 831
Brouqui, Philippe, 1593
Brown, Barbara A., 65, 1816
Brown, Michael R. W., 1623, 1865
Brown, Orval, 2030
Brown, Richard B., 269, 654
Brown, Richard R., 751, 974
Bruguerolle, Bernard, 1921
Brumfitt, W., 1803
Brunham, Robert C., 1194
Brunnemann, Sherry R., 1422
Bryan, Joe P., 368, 819
Bryan, L. E., 363
Burd, Eileen M., 610
Buré, Anne, 581, 2070
Burman, Lars G., 361
Burns, Frank R., 2065
Buroker, Robert A., 637
Bush, Tammy L., 1485
Busso, Mariano E., 1991
Bustamante, Carlos I., 1814
Buu-Hoï, Annie, 985
Bye, Alan, 2342
Byers, Timothy L., 1485
Byrne, Dominic, 909
Byrne, Mary E., 2106
Byrne, Sean K., 1390

Cabronero, Carmen, 671
Cai, Yan, 651
Calderón, Inés, 1715
Campos, Esther, 671
Campos, Jose, 2269
Canepari, Pietro, 1220
Cannon, Deborah L., 1061
Cantón, E., 1268
Canton, P., 398
Cantoni, L., 2348
Cantú, Thomas G., 1459
Caperton, Erskine M., 1146
Capobianco, John O., 1787, 1973
Carbon, Claude, 150, 581, 2070, 2387
Carlier, Cecile, 1565, 2164
Caron, François, 581, 2070
Carrasco, Luis, 1259
Carreras, Isabel, 858
Carter, Stephen G., 1297
Casara, Patrick J., 1485
Casentini-Borocz, Denise, 875
Cassano, Karen, 954
Cathcart, K. Sue, 519
Catlin, Donald H., 823
Caufield, Page W., 153
Cavalieri, Stephen J., 1276
Cavaliero, A., 295
Celesk, Roger A., 281
Chaffin, D. O., 1480
Chambers, Henry F., 510, 1227, 1780
Chan, K. K., 1895
Chan, Tai-Kwong, 215, 1336
Chance, Graham W., 265
Chandler, Mary H. H., 442
Chang, Hernan R., 775
Chapman, H. D., 1498
Chappatte, Oliver, 909
Charreire, Jeannine, 2055
Chau, Pak-Yin, 215, 1336
Chaudhry, Arif Z., 1843
Chen, Hao-chia, 1824
Cheney, Carolyn M., 1414
Cheng, Nicholas, 1194
Cheng, Yung-chi, 808
Chenoweth, Carol E., 1800
Chernykh, Vladimir M., 1312
Chesebro, Bruce, 436
Chia, John K. S., 906
Chiewsilp, Dumrong, 2027
Childers, Noel K., 153
Chin, Alfred, 2354
Chiodini, P. L., 1498
Chiodini, Rodrick J., 366
Chipley, John R., 2177
Chirurgi, Valerie A., 1821
Chiu, Edmond, 1336
Chomel, B., 473
Chonan, Eiko, 1326
Chopra, Ian, 111, 2429

Chou, Ting-Chao, 82
Chow, Anthony W., 1642
Christenson, James G., 1895
Christou, Nicholas V., 269
Cialdella, J. I., 2086
Cisneros, J. M., 881
Citron, Diane M., 2280
Clark, Alice M., 529
Clark, Nancye, 739
Clark, Richard B., 159
Clarkson, Allen B., Jr., 1183, 1485, 1833
Clausen, C., 1480
Clavey, M., 398
Cleary, Timothy, 479
Cleeland, Roy, 1895
Clement, Jacob J., 1407
Clements, Mary Lou, 1633
Clemons, Karl V., 928
Clermont, Dominique, 1685
Cloud, Gretchen A., 1619
Clyde, David F., 676
Cobbs, C. Glenn, 1619
Coe, Edwin C., 1178
Coen, Donald M., 1285
Cohen, B. Eleazar, 1584
Cohen, Jack S., 808
Colacino, Joseph M., 2156
Colburn, Wayne A., 803
Cole, Carol D., 1642
Coleman, Dennis, 2240
Coll, Ramon, 2318
Collatz, E., 252, 2439
Collier, Phillip J., 1623, 1865
Collins, Jeffrey J., 2133
Collins, Michael T., 2300
Colmenero, J., 881
Compogiannis, Lisa S., 668
Comte, Raymonde, 775
Condomines, Myriam, 1921
Connolly, G. M., 1498
Connor, James D., 489, 668
Connors, John E., 1128
Conti, Cinzia, 460
Cook, Jack A., 751, 974
Cook, Rebecca A., 1542
Cooksey, Robert, 739
Cooper, John F., 1827
Cooper, M., 1515
Cooperman, Barry S., 71
Copeland, Jack G., 489
Cortes, Hiram, 2050
Cortese, Joseph, 676
Costerton, J. William, 1666, 2043
Couch, Robert B., 2228
Counts, George W., 269
Courvalin, P., 219, 681, 924, 1244, 1294, 1565, 1611, 1875, 2024, 2164, 2210, 2291
Coutant, Veronique, 1875
Coutrot, A., 899
Couture, France, 1725
Covino, Jean Marie, 148
Crance, Jean-Marc, 1112
Crawford, R. A., 161
Crokaert, Francoise, 505
Cronn, Richard C., 1505
Crowell, Mark, 2034
Crowle, Alfred J., 2217
Cuchural, G. J., 117, 479
Cuenca Valera, R., 657
Cummings, Marinella, 148, 2297
Currens, Michael J., 82
Currie-McCumber, Charlotte, 1570
Cynamon, M. H., 967, 1473

Daly, Jennifer S., 654
D'Amato, Richard F., 2256
Dameron, Guylène, 1733
Dan, Michael, 494, 849
Dangor, Yusuf, 1303, 1308
Dasgupta, Mrinal K., 2043
Daum, Timothy E., 1862
Davey, Richard T., Jr., 499
David, Hugo L., 759
Davies, Julian, 1915
Davis, Jonathan R., 676
Davis, Larry E., 651
De, S. P., 939
de Alba, Concepcion, 837
Dean, Deanne M., 1194
de Andres, Carmen, 2318
DeAngelis, Diane V., 1792
de Castro, Solange Lisboa, 1707
De Clercq, Erik, 134, 1326, 2358
Deenstra, M., 1885
Deeter, Robert G., 1007
Defaveri, Julio, 663
de Francquen, Philippe, 934
de Hond, J. A. P. M., 2398
Dejsirilert, Surang, 2027
Delbos, Françoise, 1447
Dellamonica, P., 614
del Mar Lleó, Maria, 1220
Deloince, Robert, 1112
DeLong, Donald C., 2156
Deloron, Philippe, 2327
De Maeyer, S., 2260
Denis, C., 2260
DePamphilis, Jean, 1633
De Pedro, M. A., 164
Deppermann, Karl M., 1001, 2407
Derlot, Eliane, 2164
Derouin, Francis, 1467
Desaulniers, Denis, 1699
Desiderio, James V., 637
De Souza, Wanderley, 2097
Deuel, Dianne M., 568
Diaz, M. J., 2148
Dick, James D., 1459
Dickinson, Ronald G., 1797
Dieckmann-Schuppert, Angela, 1529
Dionian, Barbara, 176
DiPiro, Joseph T., 1128
Dismukes, William E., 1619
Distlerath, Linda, 432
Diver, J. M., 2331
Dix-Holzknecht, Barbara, 1895
Dobson, Richard A., 568
Doern, Gary V., 2075
Domínguez-Gil Hurlé, A., 455
Dopff, C., 398
Doran, Colette C., 426
Dorr, Mary Beth, 2122
Doshi, Kokila J., 1214
Douce, G., 232
Dournon, Eric, 1733
Draft, Kenneth, 148
Drancourt, M., 1512
Dreitz, Matthew J., 1749
Dromer, Francoise, 2055
Drugeon, H. B., 614
Drusano, George L., 1031
Dubach, Ulrich C., 1556
duBouchet, Lorraine, 1766
Dudley, M. N., 98, 1491, 1966
Dunne, W. Michael, Jr, 390
DuPont, Herbert L., 515
Dureux, J. B., 398
Duriex, Dennis E., 25
Dutka-Malen, Sylvie, 924, 1875
Dutta, A., 939
Dutta, D., 939
Dutta, P., 939
Duval, Jean, 1875
Dworkin, R., 1014
Dykstra, Christine C., 1678

Eadie, Mervyn J., 1797
Echols, Roger M., 1858
Edebo, L., 491, 1949
Edelstein, Howard, 954
Edelstein, Martha A. C., 2122
Edelstein, Paul H., 2122
Edlund, Charlotta, 481
Edwards, Fitzroy F., 29
Eftimiadi, C., 295
Egbaria, K., 107, 2118
Egersegi, Patricia, 1150
Ehninger, G., 1048
Ehrhardt, James C., 1035
Eiger, Leonard L., 668
Elberg, Svetlana, 2415
Eliopoulos, G. M., 728, 827, 1154, 1792, 1849, 2193
Elliott, David E., 1459
El Saghir, Nagi S., 702
Eltorai, Ibrahim M., 1422
Endotracheal Tobramycin Study Group, 269
Enright, Melissa A., 1079
Enthoven, Dirk, 1146
Ericsson, Charles D., 515
Escriva, Enrique, 321
Espejo, E., 937
Espinel-Ingroff, Ana, 1648
Esteban, M. J., 1268
Esteve, Montserrat, 2318
Estrella, Daniel, 343
Everett, Martin J., 2429
Evron, Ruth, 1600

Facinelli, Bruna, 2277
Facklam, R. R., 543
Fantin, Bruno, 581, 2387
Faro, Sebastian, 1399
Farrish, Herbert H., Jr., 1895
Fasola, Elizabeth L., 2007
Fasoli, M. O. F., 1996
Fass, Robert J., 1855, 2256, 2267, 2434
Fava, Pilar, 321
Fear, David, 1150
Feldman, Stuart, 2228
Fernandez, Carmen L., 71
Fernandez, Francisco, 321
Fernandez, M. C., 2148
Ferraro, M. J., 1154
Ferré, B., 1783
Fesik, Stephen W., 426
Field, Hugh L., 709
Fierer, Joshua, 13, 343
Filep, M., 349
Filippini, Oscar, 2019
Fillastre, J. P., 17
Fine, Robert L., 82, 287
Finegold, Sydney M., 179, 479, 2246
Finley, Fred, 13
Fiore, Lucia, 460
Firsov, Alexander A., 1312
Fitzsimmons, William E., 235
Flor, Soledad, 2436
Fong, Mina, 1429
Font, B., 937
Fontana, Roberta, 314, 1518
Foo, Kimberly A., 1165
Forenza, Salvatore, 1237
Forgue, S. T., 1118
Forrest, Alan, 1031
Forsgren, Arne, 167
Foucault, Paule, 1699
Fourche, J., 901
Fourel, I., 473
Foweraker, Juliet E., 1501
Fox, J. J., 473
Fox, James G., 1232
Francom, Steven F., 2342
Franklin, Richard M., 1529
Franzblau, Scott G., 229
Friedman, M., 2118
Friedrich, Lawrence V., 1257
Fromtling, Robert A., 1648
Frost, R. Wayne, 823
Fuchs, Peter C., 914
Fujita, Kozo, 1045
Fukasawa, Masatomo, 484
Fukuda, Hideyuki, 1757
Fukuoka, Yoshikazu, 94
Fuller, Sarah, 467, 2283
Fuller, Steven H., 550
Furney, S. K., 1629
Furukawa, Yasuo, 994

Gaar, Gregory G., 489
Galera, Maria, 321
Galgiani, John N., 1542, 1648
Gangeness, David, 1276
Gangji, Diamon, 934
Gao, Wen-yi, 808
Garau, Javier, 321
Garbarg-Chenon, Antoine, 1444
Garcia, Isabel, 277
García Lobo, Juan M., 2016
García-Patrone, M., 796
García-Rodríguez, J. A., 1262
García Sánchez, J. E., 1262
Gargallo-Viola, Domingo, 2318
Garraffo, R., 614
Garrelts, James C., 931
Garrison, Mark W., 1925
Garst, Paul D., 1402
Gaudin, Claudie, 2327
Gay, Elaine, 739
Geddes, Glenna L., 1390
Gelfand, Michael S., 1780
Gelfusa, Vincenzo, 2038
Geller, H. M., 1360
Genovese, Domenico, 460
Gentry, Layne O., 40
George, B., 1491

George, Robert C., 1769
Geratz, J. Dieter, 1026
Gerbaud, G., 219, 1244
Gerberding, Julie L., 1780
Gerding, Dale N., 2007
Gerlach, E. H., 931
Ghazzouli, Ismail, 637
Gikas, Achille, 1508
Gilbert, Deborah, 98
Gilbert, Peter, 1623, 1865
Gill, Gurnam S., 660
Gill, Mark A., 2354
Gillespie, Matthew T., 2106
Gilligan, P. H., 161
Ginsberg, R. S., 235, 967
Giovanetti, Eleonora, 2019
Gladue, R. P., 1056
Glauser, M. P., 2348
Gleason, C. R., 202, 1118, 1198, 1204, 1210
Gluzman, Yakov, 1590
Göbel, M., 1048
Godard, C., 2260
Godard, Véronique, 1444
Godek, Christopher P., 1473
Godley, Paul J., 931
Godson, G. Nigel, 2273
Goh, Khye Seng, 759, 2061
Goldberg, Andreina A., 1821
Goldenberg, Samuel, 1707
Goldman, Robert C., 426, 1787, 1973
Goldring, Anita M., 1194
Goldstein, Ellie J. C., 2280
Goldstein, F., 899, 1783
Goldstein, William, 1699
Gombert, Myles E., 1766
Gómez, Zaida M., 1371
Gomez-Lus, Rafael, 1915
Gomez Sanchez, J. C., 455
Gonzales-Perdomo, Magaly, 1707
González, M. Eugenia, 1259
Gootz, Thomas D., 1, 8
Gorby, Gary L., 2445
Gordee, Robert, 2240
Gorea, Alfred, 376, 494
Görög, Sándor, 134
Gouin, François, 1921
Gourde, Pierrette, 139, 889
Grady, Robert W., 1833
Grafstrom, Robert H., 2337
Graham, Donald R., 65
Gray, Robert D., 2065
Gray, Valerie L., 225
Graybill, John R., 663
Grayson, M. Lindsay, 1792
Greenberg, Richard N., 2392
Greenberg, Stephen B., 2228
Greenstein, Michael, 1450
Gregory, William W., 2256
Griffiths, J. William, 1769
Griffiths, Jeffrey W., 1806
Grineisen, Sabine, 2407
Grogl, Max, 1381
Gros, Isabelle, 150
Gross, Joel S., 1007
Grossato, A., 314, 1518
Grosset, Jacques, 1508
Gu, Jian-Wei, 189
Guay, David R. P., 519, 2436
Guesdon, Jean-Luc, 1611
Guilloton, Michel, 989
Guinea, Jesus, 2318
Guiot, Henry F. L., 1932
Guizie, Miriam, 1600
Gull, Ilan, 376
Gunderson, Dan, 697
Gutman, Ruth, 494
Gutmann, L., 252, 1691, 1695, 1783, 1901, 2070, 2169, 2439
Gutteridge, Winston E., 225
Guzelian, Philip S., 594
Györgyi-Edelényi, Judit, 134

Haas, Curtis E., 1637
Hächler, Herbert, 2381
Hacker, Keith, 111
Hadley, W. Keith, 2442
Haemers, Achiel, 496
Hahn, Elliot F., 1061
Hall, Gerri S., 1648
Hall, James Edwin, 1026, 1381, 1678
Hall, M. C., 1088
Halligan, N. G., 718
Halstenson, Charles E., 128, 385, 519
Hamilton, John R., 1655
Hamilton-Miller, J. M. T., 1803
Hammett, Janis L., 235
Hampel, Barbara, 1001
Hanberger, Håkan, 102
Hand, Debra L., 863
Hand, W. Lee, 863, 1189
Handwerger, Sandra, 358
Hanes, Richard N., 808
Hansen, Eric, 837
Hanson, Linda H., 928
Hanson, William L., 722, 918
Hantz, O., 473
Hardisson, C., 844
Hardy, Dwight J., 1407
Hare, Roberta S., 2381
Harmenberg, Johan, 2417
Harris, Alan A., 971
Harris, Anne M., 1806
Harrison, Earl C., 1165
Hart, Georgina C., 1061
Hart, H. C., 1885
Hartz, Arthur, 610
Hase, Toyoji, 2250
Hasegawa, Takaaki, 1739
Hashimoto, Masahisa, 89
Hastings, T. S., 1819
Hatlen, Loren, 343
Hawkey, Peter M., 1501
Haworth, Charles S., 245
Hayasaki, Motoki, 1160
Hayashi, Seiji, 82, 287
Hayes, Kathleen A., 1414
Hayter, Ronald G., 1128
Hayton, W. L., 1318, 2375
Hazekamp-van Dokkum, Anne-Margreet, 1869, 1932
Healy, Daniel P., 550, 765
Hector, R. F., 448, 587, 1132
Heifets, Leonid B., 770
Heikkilä, Elina, 2013
Heim-Duthoy, K., 128, 922, 1146
Hejmanowski, Linda G., 2369
Held, Regine, 2407
Hench, Carmen E., 1655
Henry, Deborah A., 2128
Henry, Nancy K., 273
Herchline, Thomas E., 2434
Heritage, John, 1501
Hernádi, F., 349
Herrington, Deirdre A., 676
Herrmann, Mathias, 2312
Heseltine, Peter N. R., 2354
Hessen, Margaret Trexler, 1143
Heykants, Jos J. P., 402
Hikida, Muneo, 994
Hildebrand, Catherine, 1285
Hill, Gale, 479
Hillier, Sharon L., 261
Himes, Sandra L., 1456
Hira, Subhash K., 819
Hirai, Keiji, 1757
Hiramatsu, Keiichi, 600
Hiraoka, Masaki, 555
Hirata, Cheryl A. I., 128, 519
Hirsch, Daniel J., 971
Hishikawa, Tamotsu, 326
Hitchcock, Michael J. M., 637
Hizi, Amnon, 2009
Ho, Dai H., 1812, 2263
Ho, I., 385
Hodel-Christian, Susan L., 1278
Hodges, Teri L., 1849
Hoepelman, Andy I. M., 409
Hoepelman, I. M., 1885, 2398
Hoge, C. W., 161
Hohl, P., 1605
Honeybourne, D., 1017
Hoogeterp, Jaap J., 1869
Hooker, K. Dale, 1128
Hooper, David C., 1938
Hooper, Wayne D., 1797
Hoover, Edward A., 1749
Hoppe, Jörg E., 1442, 2287
Horaud, Thea, 985, 1447, 1685
Hori, Seiji, 58
Horrevorts, Alphonsus M., 2307
Hosaka, Masaki, 1757
Hostettler, Charles, 1402
Houang, Elizabeth T., 909
Houston, A., 2234
Howell, Anne W., 1290, 2075
Huang, C. M., 1824
Huber, M. L. B., 1535
Hufford, Charles D., 529
Huggler, Elzbieta, 21
Hughes, Carolyn E., 1648
Hughes, G. S., 1094
Hughes, Walter T., 225
Huletsky, Ann, 1725
Hull, Anne, 1570
Humbert, G., 17
Humphrey, Richard L., 1459
Hunt, Christine, 594
Hunter, Paul R., 1769
Huovinen, Pentti, 2013
Hurlbut, S., 117
Hurst, Agneta K., 1165
Hyndiuk, Robert A., 610

Iaconis, Joseph P., 44
Iannini, Paul, 479
Ichise, Katsuaki, 980
Iida, Seiu, 2358
Ijichi, Katsushi, 2431
Ikeda, Fumiaki, 2426
Ikeda, Yasushi, 94
Inoue, Matsuhisa, 173, 555, 1123, 1323
Iravani, Abdollah, 665
Irvin, James D., 2034
Isaac, Charles E., 121
Isaac-Renton, Judith L., 1390
Ishiguro, Edward E., 164
Ito, Kunihiko, 1160
Iversen, John O., 2423
Iyobe, Shizuko, 1757

Jacobs, Frédérique, 934
Jacobs, Michael R., 1546, 2169
Jacobson, Mark A., 176
Jacobus, Nilda V., 479
Jacoby, George A., 858, 2193, 2200, 2381
Jacquet, C., 473
Jaeger, Ruth, 467
Janda, J. Michael, 159
Jane, Javier, 321
Jelliffe, Roger W., 1165
Jenkins, Andrew, 2277
Jewesson, Peter J., 1642
Johnson, Caroline C., 1597
Johnson, Russell C., 2133
Jones, Alan, 121
Jones, Dennis M., 1523
Jones, Ronald N., 306, 914, 1830
Jones, Susan Kilgore, 1026
Jorgensen, James H., 1290, 2075
Jurkovich, Patti J., 2133
Juteau, Jean-Marc, 1354

Kaatz, Glenn W., 257, 1376, 2081
Kains, Jean-Pierre, 934
Kaiser, Allen B., 420
Kaji, Masanobu, 58
Kakehashi, Hitoshi, 1045
Kalbfleisch, John H., 1041
Kanai, Koomi, 2027
Kaneko, Satoshi, 58
Kapell, Kathi S., 971
Karkas, J. D., 1551
Karnes, H. Thomas, 594
Karst, Francis, 989
Kashman, Yoel, 2009
Katayama, Yuko, 600
Kauffman, Carol A., 1862
Kaye, Donald, 1143
Kays, Michael B., 1257
Kayser, F. H., 1703, 2381
Keller, Nathan, 332
Kelly, Patrick, 1560, 2240
Kennedy, S., 510, 697
Kenyon, Cynthia F., 265
Kern, Winifred, 697
Kernodle, Douglas S., 420, 2177
Kerridge, D., 1996
Kessler, Harold A., 971
Kessler, Joseph A., 1297
Kessler, R. E., 733
Khardori, N., 1609
Khuller, G. K., 1773
Kihlström, Erik, 102
King-Thompson, Neva L., 863, 1189
Kirchner, Peter T., 1035

Kirkland, Theo, 13
Kirst, H. A., 1535
Kiss, L., 349
Kitamura, Takashi, 605
Kittayanond, D., 107
Kitzis, M.-D., 1783
Klayman, Daniel L., 918
Klemens, S. P., 967
Kliegman, Robert M., 1172
Klimm, K., 1154, 1849
Knapp, Cynthia C., 1843
Kneer, Johannes, 1318, 1556, 1744
Knoppert, David C., 265
Knox, James R., 1342
Knupp, C. A., 1118
Ko, Howard, 519
Kobayashi, G. S., 183, 381, 524, 2415
Kociba, Gary J., 1414
Kodner, Carrie B., 2133
Koeppe, Peter, 1001, 2407
Kohno, Yoshiro, 562
Kojima, Kana, 1326
Kojima, Tsuyoshi, 1123
Koletar, Susan L., 2267
Kolokathis, Antonia, 358
Komuro, Katsutoshi, 605
Kondo, Eiko, 2027
Konno, Kenji, 1326
Konno, Masatoshi, 170, 994
Koornhof, Hendrik J., 1303, 1308
Koren, Gideon, 1150
Kornblum, John, 2273
Kornhauser, David M., 1459
Korting, H. C., 78
Korvick, Joyce A., 442
Kotera, Yasuo, 173, 1323
Koup, Jeffrey R., 803
Kovarik, J. M., 385, 1885, 2398
Kramer, Thomas H., 489
Krasemann, Christina, 2407
Krause, Peter J., 1100
Kreiswirth, Barry, 2273
Krieg, Richard, 368, 819
Kristiansen, Bjørn-Erik, 2277
Kron, M., 1570
Krug, Edward C., 1961
Krüger, H. U., 1048
Kruse, James A., 269
Kumiesz, Helen, 2152
Kunz, S., 1014
Kupferminc, Michael, 376
Kureishi, Amar, 1642
Kurobe, Nobuyuki, 89
Kusajima, Hisao, 58
Kusmiesz, Helen, 2030
Kusser, Wolfgang, 164
Kusunoki, Tadashi, 326
Kuzuya, Takafumi, 1739
Kwaga, Jacob, 2423
Kwok, Richard Y. Y., 1453
Kyle, Dennis E., 1381

Labia, Roger, 1444
Laborde, Alice L., 884
Lam, Selena, 1809
Lam, Wah-Kit, 215, 1336
Lambert, Thierry, 1244
Lambertus, Mark W., 1453
Lambrecht, Randall S., 2300
Lane, H. Clifford, 373
Langen, P., 1986
Lank, Kim M., 1619
Lansciardi, Jobie, 1836
Lapalus, P., 614
Lapointe, Normand, 206
Larder, Brendan A., 436
Larsen, Robert A., 470
Larson, H. E., 1348
Larson, Tom A., 1925
Latter, Victoria S., 225
Lavin, Philip T., 2246
Lavrijsen, Karel L. M., 402
Lazardi, Keyla, 2097
LeBel, Marc, 1249, 1254
LeBlanc, Barbara, 2263
Le Bouguenec, Chantal, 985
Le Bras, Jacques, 1981, 2327
Lecciones, Julius, 1560, 2240
Leclerc, Jean-Marie, 206
Leclercq, Roland, 924, 1875
Ledney, G. David, 1387
Lee, How-Sung, 1809
Lee, James W., 1281, 1560, 2240
Lee, Shoo Kim, 265
Lee, Tong, 2034
Leeds, J. P., 1535
Lees, Norman D., 831
Lefebvre, Katherine, 355
Leib, David A., 1285
Leitner, F., 733
Leng, B., 901
León, Javier, 2016
Leroy, A., 17
Lesher, George Y., 568
Lessard, Céline, 1699
Lessing, Joseph B., 376
Lester-McCully, Cindy, 1281
Levesque, Roger C., 1354, 1577, 1725
Levison, Matthew E., 1597
Levy, Maurice, 1150
Lew, Daniel P., 21, 2312
Lewin, C. S., 1819
Leying, Hermann, 628
Leysen, Dirk C., 496
Liang, Raymond, 215, 1336
Liassine, N., 1783
Libman, Michael D., 1795
Liggett, W. F., 2086
Ligozzi, M., 1518
Lin, Jan-Ping, 343
Linde, Annika, 2417
Lindholm-Levy, Pamela J., 770
Lindstedt, M., 1949
Lister, Philip D., 159
Liu, Shihchih, 529
Liu, Wei, 337
Livermore, D. M., 755
Livingston, Tracy, 1183
Lleò, M. M., 314
Lobos, Sergio R., 1715
Lode, Hartmut, 1001, 2407
Logan, M., 1515
Lombardy, Richard J., 1678
Longfield, Robert N., 1290
Lopez-Berestein, Gabriel, 241
Lorenz, R. Todd, 1660
Lovelace, James K., 918
Low, Donald E., 467, 2283
Löw, Miklós, 134
Loya, Shoshana, 2009
Lucet, Jean-Christophe, 2312
Lujan, Rodolfo, 2269
Luke, David R., 241
Luo, Nkandu, 819
Lupski, James R., 2273
Lüthy-Hottenstein, J., 1605

Mabilat, Claude, 1294, 2024, 2210
Machida, Haruhiko, 691, 2431
Macrae, Paul V., 909
Madan, Elio, 25
Maderazo, Eufronio G., 1100
Maeda, Tetsuya, 2250, 2254
Maher, Louise A., 2075
Maiese, William M., 1450
Maitra, A., 939
Malhotra, K., 1981, 2327
Maller, Rolf, 102
Mallet, Marie Noëlle, 1921
Malmborg, Anna-Stina, 481
Malouin, F., 363
Mamber, Stephen W., 1237
Manavathu, Elias K., 71
Manischewitz, Jody F., 373
Manning, Scott, 2030
Mansuri, Muzammil M., 637
Marbury, G. Dean, 1678
Marchal, Martine, 934
Marchbanks, C. Randall, 1966
Marcireau, Christophe, 989
Mariuz, Peter, 2050
Markiewicz, Zdzislaw, 33
Marks, Melvin I., 1366, 1880, 2223
Marossy, K., 349
Marr, J. Joseph, 1961
Marsh, Kennan, 1407
Marshall, V. P., 2086
Martin, Claude, 1921
Martin, John C., 637
Martin, R. R., 202, 1118, 1198
Martinez, C., 881
Martinez, J. L., 2093
Martinez-Ferrer, M., 2093
Martinez Lanao, J., 455
Martinez-Larrañaga, M. R., 2148
Martinez-Suarez, Joaquin V., 2269
Masecar, Barbara L., 281
Masur, Henry, 499
Mathes, Lawrence E., 871, 1414
Mathewson, John J., 515
Mathiason-DuBard, Candace K., 1749
Matsen, John M., 487, 2256
Matsuhashi, Michio, 170
Matsui, Hiroyuki, 555
Matsukura, Makoto, 287
Matsumoto, Keizo, 326
Matthes, E., 1986
Matthews, Peter, 1777
Mattie, Herman, 1869, 1932
Matzke, G. R., 128, 385, 519, 1146, 1885, 2436
Maugein, J., 901
May, Mary H., 2217
Mayer, Kenneth H., 1966
Mazzulli, Tony, 467
McAdam, K. P. W. J., 1498
McCabe, Robert, 954, 1821
McCann, Peter P., 722, 1485
McClure, Harold M., 1214
McCormack, William M., 148, 2297
McCracken, George H., Jr., 837
McDonald, V., 1498
McGee, Zell A., 2445
McGraw, Patricia A., 420, 2177
McHugh, Gail L., 1938
McIntyre, Kyle A., 1542
McLeod, Judith, 1194
McManus, Edward J., 906
Medeiros, Antone A., 2184, 2193, 2200
Medoff, G., 183, 381, 524, 2415
Megran, David W., 355
Meirelles, Maria Nazareth S. L., 1707
Mendelman, P. M., 1480
Merali, Salim, 1075
Mercier, Josée, 1577
Merlo, Antonio, 2050
Mertes, P. M., 398
Mertsola, Jussi, 837
Merz, H., 1986
Meshnick, Steven, 1075
Messer, Mark, 1812, 2137, 2263
Meuldermans, Willem E. G., 402
Meyer, Bernhard, 628
Michael, David F., 871
Michel, M. F., 674, 2307
Mihalko, Paul, 343
Mikolich, Dennis J., 1966
Milhaud, Jeannine, 1584
Miller, F. D., 1535
Miller, George H., 2381
Miller, Jeffery S., 765
Miller, Mark A., 1795
Miller, Steven D., 1303, 1308
Mills, John, V, 176
Minami, Shinzaburou, 949
Mine, Yasuhiro, 2426
Minnich, Linda, 489
Misulovin, Ziva, 111
Mitani, Gladys H., 1165
Mitsuhashi, Susumu, 173, 555, 994, 1123, 1323
Mitsuya, Hiroaki, 82, 287
Miyahara, Tadashi, 58
Miyake, Yoichiro, 1440
Miyasaka, Tadashi, 2358
Mizuochi, Toshiaki, 605
Mochizuki, Shinobu, 1326
Modin, G., 1014
Moellering, R. C., Jr., 728, 827, 1154, 1792, 1849, 2193
Mohler, Jacqueline, 581
Molinas, Catherine, 924, 2024
Molitoris, Eric, 2246
Monsey, David, 1806
Montanari, Maria Pia, 911
Monteiro, Edmund H., 1809
Moody, Julia A., 2007
Mora, Guido C., 1715
Moreau, Nicole J., 1955
Moreillon, Philippe, 33
Moros, Mariano, 2318

Morris, J. G., Jr., 161
Morris, P. G., 1996
Morrison, Christine J., 746
Morrison, Sharon D., 1026
Morse, Gene D., 394
Mortensen, Joel E., 1456
Motomura, Keiko, 94
Mourey, Robert J., 884
Mouton, Johan W., 2307
Mpoko, Godfrey, 819
Muder, Robert R., 442
Muirhead, G., 2375
Mulder, Paul G. H., 2307
Mulks, Martha H., 1762
Müller, Jochen, 1442
Müller, W. E. G., 1986
Mulligan, Maury E., 1453
Mullins, James I., 1749
Muñoz, T., 937
Muñoz Bellido, J. L., 1262
Muraoka, Isao, 1739
Murphy, James R., 676
Murray, Barbara E., 302, 515, 1278, 1287, 1429, 2047
Murray, Darryl M., 786
Mustafa, Mahmoud M., 837
Mutschler, E., 78
Muzzarelli, Riccardo, 2019
Mwale, Clement, 819
Myers, Carolyn M., 1172
Myles, Matthew H., 1749

Nachman, Sharon, 33
Nadai, Masayuki, 1739
Nagasaka, Nobuo, 1440
Nagatake, Tsuyoshi, 326
Nagy, Miklós, 134
Naigowit, Pimjai, 2027
Nair, Muraleedharan G., 1762
Nakae, Taiji, 685
Nakajima, Takeshi, 980
Nakamura, Mika, 1271, 1273
Nakamura, Shinichi, 89, 1271, 1273
Nakashima, Hideki, 2358
Nassos, Patricia S., 2442
Nathan, Henry C., 1183
Navas, Jesús, 2016
Navashin, Sergey M., 1312
Nelson, Janet R., 2156
Nelson, John, 2030, 2152
Nesin, Mirjana, 2273
Neu, Harold C., 189, 1839
Nguyen, Hieu, 2137, 2263
Nicolas, Jean-Claude, 1444
Nightingale, Charles H., 2114
Nikaido, Hiroshi, 52, 337
Niki, Yoshihito, 29
Nilsson, Lennart E., 102, 2142
Nishida, Nagako, 949
Nishiki, Katsuyuki, 994
Nishino, Takeshi, 94
Nitta, Issei, 2358
Nix, David E., 432, 974, 1637
Njogu, Adriel R., 1183
Noble, Lizanne, 896
Noe, Anson, 823
Nonoguchi, Ritsuko, 170
Norbeck, Daniel W., 287
Nord, Carl Erik, 481
Norman, Allyn, 432
North, Thomas W., 1505
Noumi, Toshihiko, 949
Novak, Ervin, 519, 2342
Nsiah, Y. A., 1551
Nye, K., 232, 1053

Oakes, Marion, 1633
O'Brien, William J., 1178
Odds, Frank C., 1648
O'Donnell, James J., 176
Oguntimein, Babajide, 529
O'Hanlon, P. N., 161
Ohemeng, Kwasi A., 1026, 1381
Ohnota, Hideki, 605
Ohta, Katsuji, 562
Ohue, Tomio, 89
Okada, Mitsugi, 1440
Okada, Yoshiaki, 605
Okamoto, Mark P., 2354
O'Keefe, J. Paul, 479
Okuda, Takao, 484, 980
Olanoff, Lawrence S., 519
Oldfield, Edward C., III, 1402
Olsen, Laura, 1846
Olson, John, 394
Olson, Julie A., 1435
Önay, O., 1480
O'Neill, P., 232, 1053
Ooie, Tsuyoshi, 58
Opferkuch, Wolfgang, 628
Opsahl, John A., 385, 519, 2436
Orbach, Hy, 971
Orlando, Patricia L., 823
Orme, I. M., 1629
Orsi, Nicola, 460
Osburne, Marcia S., 1450
Oster, Sharon, 954, 1821
Ostovari, Margareta I., 2280
Otal, Isabel, 1915
Otto, Glen, 1232
Ounissi, Houria, 2164
Outman, William R., 2114
Ou-Yang, Ke, 1961
Overbeek, Berry P., 332

Pablos-Mendez, Ariel, 2050
Pachón, J., 881
Pacini, David L., 1633
Pal, S. C., 939
Palmer, Kathleen, 676
Pangon, Béatrice, 581, 2070
Papanicolaou, Genovefa A., 2184, 2193, 2200
Pappagianis, D., 587, 1132
Parent, Marc, 1249
Park, T. S., 245
Parks, Leo W., 1660
Parr, T. R., Jr., 363
Paschal, J. W., 1535
Pascual, Alvaro, 277
Passagot, Jacques, 1112
Patel, I. H., 1895
Patel, R., 1094, 2342
Paterson, Christopher A., 2065
Patterson, Jan Evans, 302
Pattyn, Stefaan R., 496
Pauwels, R., 134, 958
Paxton, Linda M., 2342
Pearlman, Mark D., 1399
Pechère, Jean-Claude, 775
Pechinot, André, 2070
Peetermans, Willy E., 1869
Pellegrin, J. L., 901
Pellerin, Michel, 139
Peltier, G., 922
Pennell, Elizabeth, 1720
Pennington, James E., 1463
Pepper, Karen, 1447
Perea, Evelio J., 277
Pérez-Díaz, José Claudio, 539
Pérez Trallero, Emilio, 1523
Perine, Peter L., 368, 819
Perl, T. M., 2234
Perlman, Alon M., 928
Perronne, Christian, 1508
Peter, Joanne, 1560
Peterie, Jerry D., 931
Peters, Gary R., 1944
Peterson, Lance R., 2007
Peterson, Phillip K., 1146
Petit, A., 219
Pettigrew, Martine, 139
Peyser, M. Reuben, 376
Pfaller, M. A., 1648, 2234
Philippon, Alain, 581, 2169
Picard, Michele, 896
Picazo, Juan J., 671
Pickard, Michael A., 121
Pickering, Larry K., 1429, 2047
Piddock, Laura J. V., 1088, 2331
Pierre, J., 1691, 1695
Pierson, Carl, 479
Piketty, Christophe, 1467
Pinto-Alphandary, Huguette, 1294
Piriz Duran, S., 657
Pisabarro, A. G., 164
Pitlik, Silvio, 849
Pitsakis, Peter G., 1143
Pittman, K. A., 202, 1118, 1198, 1204, 1210
Pizzo, Philip A., 196, 1281, 1560, 1672, 2240
Plaisance, Karen I., 1031
Plank, Carol, 394
Plattner, Jacob J., 287
Plempel, M., 1132
Plescia, O. J., 1360
Plouffe, Joseph F., 2267
Pocidalo, Jean-Jacques, 1467, 1508, 1733, 2327
Polacheck, Itzhack, 1600
Polas, Phyllis J., 871, 1414
Polk, Ronald, 550, 594, 765
Pollock, Robert, 1146
Poplack, David G., 1281
Portmann, R., 2375
Portmore, Amy, 394
Posnick, Jeffrey C., 1150
Posvar, Edward, 803
Potel, Gilles, 581
Powderly, William G., 183, 381
Pratt, R. F., 1342
Prens, Eroll P., 2307
Preston, D. A., 718
Projan, Steven J., 2273
Proksch, B., 1048
Pucci, Michael J., 358
Pudney, Mary, 225
Pujadas, Ramon, 321
Puri, Surendra K., 385
Putnam, Alan R., 1762
Quarles, John M., 2228
Queen, Susan A., 1393
Queener, Stephen W., 943
Quinnan, Gerald V., Jr., 373
Quintiliani, Richard, 2114

Racis, S. P., 1360
Rådberg, Gunilla, 2142
Rademaker, C. M. A., 1885
Radin, L., 295
Radler, Ferdinand, 1615
Rådström, Peter, 2277
Rajagopalan-Levasseur, Premavathy, 1733
Rake, James B., 568
Ramachandran, C., 107
Ramilo, Octavio, 837
Ramos, Herlinda, 1584
Rankin, Catherine D., 1297
Raoult, D., 1512, 1593
Raponi, Giammarco, 332
Rapp, F., 1551
Rapp, Robert P., 442
Rasmussen, Beth A., 1590
Rastogi, Nalin, 759, 2061
Rathod, Pradipsinh K., 1371
Raviglione, Mario C., 2050
Ray, C. George, 489
Raz, Raul, 849
Redding, Judith S., 2075
Reddy, V. Vikram, 1026
Reddy, Veera N., 2081
Reed, Michael D., 1172
Reguera, J. A., 2093
Reichart, Cindy, 819
Reichman, Richard C., 394
Reiffers, J., 901
Remington, Kathryn Martin, 1505
Resnick, Lionel, 1991
Reuben, A., 1609
Reves, Randall R., 515, 1429, 2047
Reyes, Philip, 1393
Reynolds, P. E., 413
Rice, L. B., 728, 1154, 2193
Rich, R., 1014
Richards, Geoffrey K., 1795
Richman, Douglas D., 436
Richman, Joseph, 1602
Riddle, Gerald D., 1399
Riesbeck, Kristian, 167
Rinaldi, Michael G., 524, 1281, 1648
Rius, F., 1268
Robaux, Hubert, 1955
Robbiano, Ellen M., 1858
Roberson, Donna, 1041
Roberts, A. D., 1629
Roberts, Marilyn C., 261, 476, 1816, 1836
Robillard, N. J., 281, 1889
Robinson, Kristen A., 1800
Rode, Richard A., 1407
Rodriguez, Guillermo G., 40
Rodríguez, Manuel, 1715
Rodriguez-Avial, Carmen, 671
Rohner, Peter, 2312
Roilides, Emmanuel, 196, 1672
Rolston, K., 1609, 1812, 2137, 2263
Ronald, Becky, 432

Rosenbaum, B., 1609
Rosenberg, Emiko Y., 337
Rosenbrook, William, 287
Roser, Roberto, 2318
Rosner, Judah L., 786, 2402
Rosseel, M. T., 958
Rothstein, David M., 111
Rotschafer, John C., 1925
Rouse, Mark S., 273
Rousell, Ralph, 176
Rouveix, Bernard, 1467
Rozenberg-Arska, Maja, 332
Ruberg, Stephen J., 765
Rubin, Marc, 196, 1672
Ruffner, Katherine L., 1285
Russell, James A., 269
Russell, Jane A., 2267
Rustige, Cornelia, 1107
Rybak, Michael J., 257, 792, 2081
Ryffel, C., 1703

Saalmann, Vanessa, 1061
Saathoff, Albrecht, 1001
Sabra, Ramzi, 1020
Sachdeva, Meena, 697
Sáez-Llorens, Xavier, 837, 2152
Sáez Nieto, Juan A., 1523, 2269
Saginur, Raphael, 1699
Sahai, Jan, 550, 765
Sahm, Daniel F., 1846
Saito, Atsushi, 58
Saito, Hajime, 632
Saito, Shizuki, 58
Sakamoto, Hiroshi, 1611
Sakamoto, Tasuku, 326
Sakata, Hiroshi, 1045
Salauze, Damien, 1915
Salmon, Dominique, 1981, 2327
Samonis, George, 2420
Samorodin, Roberta, 1633
Sams, Richard, 871, 1414
Samuelson, Dwayne, 1402
Sanchez Navarro, A., 455
Sanchez Recio, M. M., 455
Sande, Eric R., 697
Sande, M., 1014
Sanders, Charles V., 65, 179
Sanders, Christine C., 44, 156, 622
Sanders, Cynthia A., 2442
Sanders, W. Eugene, Jr., 622
Sandin, M., 491
Sands, Michael L., 269
Sanglard, D., 831
Santanam, Partha, 2381
Santhosh-Kumar, Cheruppolil R., 702
Santoro, Regina, 460
Sareen, Monica, 1773
Saric, Muhamed, 1183, 1833
Sarkar, Mohamadi, 594
Sarubbi, Felix, 1041
Sasaki, Mikiko, 1440
Sastre, Bernard, 1921
Satake, Sachiko, 685
Sato, Katsumasa, 632
Satta, G., 314, 1220
Sauerschell, Richard, 751
Sawant, A. D., 1331
Saxon, Barbara A., 487
Sayer, Paul D., 1183
Schaadt, Ronda D., 371
Schaberg, Dennis R., 1800, 1862
Schäfer-Korting, M., 78
Schaffer, Priscilla A., 1285
Schaffner, C. P., 1360
Scheld, W. Michael, 245
Schelling, Donald J., 665, 974
Schentag, Jerome J., 974, 1637, 2364, 2369
Schinazi, Raymond F., 1061, 1214
Schito, G. C., 295
Schmidt, T., 349
Schmitt, Heinz-Josef, 29
Schmitt, Manfred J., 1615
Scholl, H., 398
Schols, Dominique, 134
Schröder, H. C., 1986
Schuler, U., 1048
Schultz, Robert W., 2364
Schwalbe, R. S., 161
Schwartz, Robert, 654
Schwenk, Michael H., 385
Sclar, David A., 2354
Sears, Stephen D., 1633
Sedlock, David M., 568
Sedman, Allen J., 803
Segal, Jack L., 1422
Segreti, John, 971
Segura, F., 937
Seitz, D. E., 718
Sekiya, Kouichi, 2358
Seo, Susan M., 257, 1376, 2081
Serra, Pietro, 2038
Serrano, J. A., 937
Sexton, Daniel J., 654
Shalit, Itamar, 494
Shearer, Michael H., 2034
Sheffield, Jaqueline, 368
Shelton, Mark J., 765
Shelton, Sharon, 2030, 2152
Shen, Jin-Kun, 651
Shiba, Kohya, 58
Shigeta, Shiro, 1326, 2358
Shimada, Jingoro, 58
Shimizu, Masanao, 89
Shipkowitz, Nathan L., 1407
Shlaes, David M., 1570
Shokry, Fuat, 2407
Shukla, U. A., 1198, 1204, 1210
Shyu, W. C., 202, 1198, 1204, 1210, 2152
Sieffer, A., 899
Siegman-Igra, Yardena, 849
Sierra-Madero, Juan, 1843
Sigmon, Marsha A., 702
Sikdar, S. N., 939
Silley, Peter, 1806
Silverman, Michael H., 665, 751, 974
Simon, Carsten G., 2287
Simor, Andrew E., 467, 2283
Sindhunata, I. R., 674
Singh, Kavindra V., 2047
Sirot, D., 219
Sirot, J., 219
Siwiwaliondo, Elizabeth, 819
Sjoerdsma, Albert, 722, 1485
Sköld, Ola, 642, 2277
Skurray, Ronald A., 2106
Slama, Thomas G., 904
Sloan, Donald, 1075
Sloan, Rebecca S., 1139
Small, Peter M., 1227
Smith, Barry, 148
Smith, Craig E., 1290
Smith, Gill M., 210
Smith, Gregory A., 1061
Smith, John, 65
Smith, John A., 2128
Smith, Kim R., 1619
Smith, Thomas C., 1944
Snider, M. E., 1056
So, Shun-Yang, 215
Sobieski, Michael W., 245
Soga, Hiroko, 781
Sommadossi, Jean-Pierre, 1061
Somner, E. A., 413
Song, Min Dong, 170
Soo, Whaijen, 1633
Sottile, William S., 1862
Spangler, Sheila K., 1546, 2169
Specian, A., 1895
Spillers, C. R., 1094
Spino, Michael, 1150
Spitzer, Wayne A., 2156
Spratt, Brian G., 1523
Stables, R., 1498
Standiford, Harold C., 1031
Stanfield, Johnny A., 1128
Starrett, John E., 637
Steckelberg, James M., 273
Steele, Lorraine C., 65
Stein, C. A., 808
Stein, Maria Luisa, 460
Steingrube, Vincent A., 1816
Sterzycki, Roman Z., 637
Stevens, David A., 746, 928, 1655
Stewart, Kathy A., 235
St-Germain, Guy, 2304
Stiver, H. Grant, 1194
St. John, Ann C., 534
St-Laurent, Maurice, 1249, 1254
Stoeckel, K., 1318, 1556, 1744, 2375
Stolear, J. C., 1491
Stolz, E., 674
Strässle, A., 1703
Stratton, Charles W., 420, 1780
Strong, Andrew, 1150
Stroshane, Ronald M., 751, 974
Stull, T. L., 1480
Stutman, Harris R., 1366, 1880, 2223
Suárez, J. E., 844
Suerbaum, Sebastian, 628
Suga, Tetsuya, 562
Sugar, Alan M., 896, 1648
Suginaka, Hidekazu, 1440
Sumita, Yoshihiro, 484
Sumter, Gwendolyn, 65
Sun, Sung H., 663
Sundström, Lars, 642, 2013
Sutcliffe, Joyce A., 1, 8
Suwa, Toshio, 562
Suzuki, Eiko, 600
Svarachorn, Ancharida, 781
Svec, Pamela, 2273
Svensson, Craig K., 792
Svensson, Stefan, 2142
Swanson, Keith A., 1007
Swanson, Robert N., 1407
Swartz, Morton N., 1938
Sweeney, Kevin R., 2114
Swenson, C. E., 235, 967
Swenson, Cheryl L., 871, 1414
Swenson, J., 543, 739
Szabó, I., 349

Tabary, Xavier, 1955
Tabernero Romo, J. M., 455
Tack, Kenneth, 2436
Takagi, Kenzo, 1739
Takano, Mitsuo, 781
Takashima, Hideaki, 2358
Takayama, Hiromi, 600
Takezawa, Junichi, 691
Tal, Ruth, 2009
Tally, F. P., 117, 479, 1590
Tam, Yun K., 1556
Tamaya, Teruhiko, 1160
Tan, Elsie, 1194
Tanaka, Hiromichi, 2358
Tandberg, Rolf T., 1505
Tang, Joseph, 2156
Tang-Liu, Diane, 1602
Tanio, Tomoharu, 980
Tar, A., 349
Tarasi, Agapito, 2038
Tardif, Dominique, 576, 889
Tarr, Melinda J., 1414
Tarsi, Renato, 2019
Tashiro, Keiko, 994
Tatsuta, Masaharu, 2426
Täuber, Martin G., 697
Taylor, Charlene, 394
Taylor, Diane E., 71
Taylor, Jerry L., 1178
Taylor, Nancy S., 1232
ter Maaten, J. C., 1885
Terpenning, Margaret S., 1862
Terreiro Delgado, M. M., 455
Tesch, W., 1703
Tessoro, Angelo, 1150
Thauvin-Eliopoulos, Claudie, 728, 827, 1792
Theodoropoulos, G., 1132
Thibodeau, Lise, 206
Thomas, Vanessa, 1560
Thompson, R. A., 1949
Thomson, Kenneth S., 622
Thornber, D., 813
Thornsberry, C., 543, 739
Thorpe, John E., 909, 2032
Thys, Jean-Pierre, 934
Ti, Teow-Yee, 1809
Tidwell, Richard R., 1026, 1381, 1678
Tillman, B. Susan, 1290
Tio, T. T., 674
Todd, David, 215, 1336
Toler, Steven M., 442
Tolman, R. L., 1551
Tomasz, Alexander, 33, 1777
Tomioka, Haruaki, 632
Tong, William P., 29
Tonin, E., 314, 911, 1518

Toothaker, Roger D., 803
Toro, Cecilia S., 1715
Torosantucci, A., 1996
Tortolero, Guillermo, 1399
Toscano, John P., 1925
Tóth-Martinez, B., 349
Traveria, J., 937
Travis, Sharon J., 524
Trepo, C., 473
Trias, Joaquim, 52
Trottier, Sylvie, 1699
Truesdell, Scott E., 884
Truffot-Pernot, Chantal, 1508
Trujillano, I., 1262
Tsai, Y. H., 733
Tsuchido, Tetsuaki, 781
Tsuchiya, Kanji, 326
Tu, Jeremy, 1068
Tullus, Kjell, 361
Turner, J. R., 1535
Tyler, Barbara, 2228
Tyrrell, D. A. J., 963

Ubasawa, Masaru, 2358
Ubukata, Kimiko, 170, 994
Uchida, Hiroshi, 58
Ulrich, R. G., 2086
Umezu, Kohei, 2358
Urbina, Julio A., 2097
Uriz, S., 937
Ushijima, Hiroshi, 605
Uzuka, Yoshio, 326

Vaara, Martti, 853
Vadiei, Kiumars, 241
Vadillo Machota, S., 657
Valcke, Y. J., 958
Valladares, Glenn, 1183
Vallée, Eric, 581
Vallée, François, 1254
Valle Manzano, J., 657
Vallois, Jean-Marie, 581, 2070
Van Boxtel, Rebecca M., 2300
Vance-Bryan, Kyle, 1925
Vandenberghe, Hilde M., 265
van den Broek, Peterhans, 1869
Van Der Auwera, P., 1491, 2260
Vander Jagt, David L., 1393
van der Linden, Marie-Paule, 505
Van Der Straeten, M. E., 958
Van Dyck, Dirk M. J., 402
van Furth, Ralph, 1932
Vanhoof, R., 2260
Van Houdt, Jos M. G., 402
van Kessel, Kok P. M., 332
Van Landuyt, Herman W., 1501
van Ogtrop, Marc L., 1932
van Strijen, Elisabeth, 1932
Varaldo, Pietro E., 911, 2019
Vaudaux, Pierre E., 21
Vazquez, Julio A., 2269
Vazquez-Padua, Miguel A., 808
Venditti, Mario, 2038
Venezia, Richard A., 1858
Vennerstrom, Jonathan L., 918
Venzon, David, 196, 1672
Verani, Regina R., 241
Verghese, Abraham, 1041
Verhoef, J., 332, 409, 1885, 2398
Vestris, G., 1512
Viachki, I., 2375
Vicente, M. Francisca, 539
Viciana, P., 881
Victor, Frantz, 2156
Vidaurre, Carolina E., 1366, 1880
Vieu, Jean-François, 1244
Vilde, Jean-Louis, 1508, 1733, 1981
Villemot, J. P., 398
Viñas, Miguel, 2269
Vlahov, V., 2375
Voiriot, P., 398
von Janta-Lipinski, M., 1986

Wade, James C., 1814
Wagenvoort, J. H. T., 674
Wagner, Jutta, 2407
Wagner, Kenneth, 368
Wahren, Britta, 2417
Waits, Virginia B., 918
Waldvogel, Francis A., 21, 2312
Walker, Jeanne B., 1194
Walker, Mary Clare, 206
Walker, Richard T., 2358
Wallace, Jack E., 1281
Wallace, Richard J., Jr., 65, 1816
Walsh, Thomas J., 196, 1281, 1560, 2240
Walters, R. N., 2331
Walton, Leslie, 1792
Wanger, Audrey, 302
Warbasse, Lawrence H., 792
Warhurst, D. C., 1498
Warlich, R., 78
Wasan, Kishor M., 241
Washington, John A., 1843
Watanabe, K. A., 473
Watanabe, Masato, 173
Watanabe, Yasuo, 949
Waters, Catherine, 368, 819
Weber, David A., 156, 622
Weidekamm, E., 2375
Weidenfeld, Joel, 2122
Weidler, D. J., 1118
Weiler, B. E., 1986
Weiner, N., 107
Weinstein, Melvin P., 1007
Weir, Matthew R., 1031
Welage, Lynda S., 2369
Wells, John T., 2065
Wels, Philip B., 2369
Wendeler, Michael, 1597
Wenzel, R. P., 2234
Wernicke, Karin, 2407
Westblom, T. Ulf, 25
Wexler, Hannah M., 179, 2246
Wharton, Rayner C., 1814
White, Kenneth E., 229
White, Martin, 1402
White, Roger L., 1257
Wiedemann, Bernd, 1107
Wilber, R. B., 202, 1198, 1204
Wilcox, Robert M., 273
Wiley, E. A., 1480
Will, H., 1986
Willetts, Val, 355
Willey, Sandra H., 2193
Williams, Vanessa C., 432
Williamson, R., 1691, 1901
Wilson, Elizabeth, 2128
Wilson, Samuel Z., 2228
Wilson, Walter R., 273
Wilton, John H., 432, 2369
Wind, J. A., 1535
Wise, R., 232, 813, 1017, 1053, 1088, 1515
Wittek, Alec E., 373
Wolfhagen, Maurice J. H. M., 409
Wolfson, John S., 1938
Woolfrey, Bert F., 1079
Woolley, Joseph L., 1792
Woronick, Charles L., 1100
Worthington, Michael G., 654
Wostenholme, M., 1053
Wright, Donald N., 2256
Wright, George E., 1285
Wright, Richard A., 665
Wu, C.-Y. E., 718, 2156
Wu, Pai-Yen, 1232
Wu, Peijun, 755
Wyka, Mary A., 534

Xicota, M. Angels, 2318
Xie, Meng-Yu, 1061

Yacout, Mohamed, 1259
Yagi, Betty Hannon, 371, 884
Yajko, David M., 2442
Yakshe, Criss C., 931
Yamaguchi, Hideyo, 2250, 2254
Yamamoto, Tatsuo, 2027
Yamashita, Toyoko S., 1172
Yang, Youjun, 755
Yao, Joseph D. C., 827, 1792
Yasin, S. R., 963
Yasuda, Takashi, 94, 949
Yau-Young, Annie, 343
Yee, Emma, 448
Yellin, Albert E., 2354
Yeni, Patrick, 2055
Yocum, Diane M., 1858
Yokoo, Mamoru, 2250, 2254
Yokota, Takeshi, 600, 2027
Yokota, Tomoyuki, 1326
Yokota, Yoshiko, 2426
Yoshida, Hiroaki, 1271, 1273
Yoshida, Masuhito, 994
Yoshihara, Eisaku, 685
Yoshinaga, Monica A., 1165
Yoshioka, Hajime, 1045
Yoshizumi, Hideo, 1739
Yosue, Keiko, 173
Young, Lowell S., 2256
Young, Timothy R., 1128
Yourassowsky, Eugene, 505
Yu, Kwok-woon, 1839
Yung, Raymond, 215, 1336

Zak, O., 1014
Zaworski, Phillip G., 660
Zehavi, Uri, 1600
Zeidner, Nordin S., 1749
Zeitany, Raja G., 702
Zervos, Marcus J., 302
Zhang, Mingqiang, 496
Zhang, Qian-yun, 1523
Zhang, Yun, 1075
Zierdt, C. H., 1824
Zilhao, Rita, 1611
Zimmer, B. L., 587, 1132
Zinner, Stephen H., 98, 1966
Zolezio, Heraldo, 1602
Zollinger-Iten, J., 1605
Zscheck, Karen K., 302, 1287
Zurenko, Gary E., 371, 884, 2342
Zygmunt, Deborah J., 2177

# SUBJECT INDEX
## VOLUME 34


566C80
  comparative activity
    trimethoprim-sulfamethoxazole, 225
  *P. carinii*
    experimental pneumonitis, 225

A-56620
  *M. avium-M. intracellulare*, 1390
  *Pseudomonas* spp., 1812
  *X. maltophilia*, 1609, 1812
A-62412
  *M. leprae*, 229
A-63345
  *M. leprae*, 229
A-67937
  *M. leprae*, 229
A-69137
  *M. leprae*, 229
AAC-3-IV
  *Enterobacteriaceae*
    human and animal sources, 1915
AAC(3)-5
  *Enterobacteriaceae*
    gene probe, 1827
    nosocomial infections, 1827
*aacC4*
  *Enterobacteriaceae*
    human and animal sources, 1915
*aadA*
  *Campylobacter* spp.
    aminoglycoside resistance, 1294
*aadE*
  *Campylobacter* spp.
    aminoglycoside resistance, 1294
Acetyltransferase 3-IV
  *Enterobacteriaceae*
    human and animal sources, 1915
*Acinetobacter calcoacèticus* biovar anitratus
  amikacin, 494
  azlocillin, 494
  cefotaxime, 494
  ceftazidime, 494
  cross resistance, 494
  gentamicin, 494
  minocycline, 494
  tobramycin, 494
  trimethoprim-sulfamethoxazole, 494
*Acinetobacter* spp.
  amikacin resistance
    *aphA6*, 1244
  U-78608, 884
  WIN 57273, 306
Acquired immunodeficiency syndrome
  amphotericin B-pentamidine
    renal failure, 470
  cytomegalovirus retinitis
    ganciclovir, 176
    ganciclovir-intravenous immune globulin, 176
Acrylic acid-vinyl alcohol copolymer, sulfated
  human immunodeficiency virus
    giant cell formation, 134
    type 1, 134
    type 2, 134
Acyclouridines
  6-substituted derivatives
    human immunodeficiency virus type 1, 2358
    pharmacokinetics, 2358
Acyclovir
  combinations
    alpha interferon, 1178
    cell culture, 1178
    herpes simplex virus, 1178
  human herpesvirus 6, 2417
*Aeromonas hydrophila*
  tosufloxacin, 368
*Aeromonas salmonicida*
  CI934, 1819
  enrofloxacin, 1819
  oxolinic acid, 1819
  PD-117596, 1819
  PD-127391, 1819
  sarafloxacin, 1819
*Aeromonas* spp.
  β-lactamases
    purification and characterization, 44
Agar
  fastidious anaerobe
    comparative studies, 2280
    *Fusobacterium* spp., 2280
Agar dilution plate count method
  ampicillin
    *H. influenzae*, 1079
D-Alanyl-D-alanine peptidase
  cell wall peptide binding, 1342
Alkanolamines
  toxicity, selective, 491
*Allium sativum*
  cryptococcal meningitis
    humans, 651
  meningitis
    humans, 651
Alpha interferon
  combinations
    feline acquired immunodeficiency syndrome, 1749
    zidovudine, 1749
  feline acquired immunodeficiency syndrome, 1749
    pharmacokinetics, 1749
Aluminum-magnesium hydroxide
  fluconazole
    humans, 2032
    pharmacokinetics, 2032
Amifloxacin
  comparative activity
    trimethoprim-sulfamethoxazole, 665
  *M. leprae*, 229
  pharmacokinetics
    elderly subjects, 751
    humans, 974
  safety, 974
  urinary tract infections
    uncomplicated, 665
  *X. maltophilia*, 1609
Amikacin
  *A. calcoaceticus* biovar anitratus, 494
  *Acinetobacter* resistance
    *aphA6*, 1244
  bactericidal activity
    *E. cloacae*, 614
    *E. coli*, 614
    *P. aeruginosa*, 614
    *S. marcescens*, 614
  dosage, 614
  *E. coli*
    tricarboxylic acid cycle, 295
  *M. avium*
    letter to the editor, 378
  *M. paratuberculosis*, 366
  nocardiosis
    murine pulmonary, 1766
  *P. shigelloides*, 159
  pharmacokinetics
    humans, 614
    premature infants, 265
    spinal cord injury serum and pressure sore tissue, 1422
  resistance
    4′-aminoglycoside nucleotidyltransferase, 2381
    ANT(4′)-II, 2381
    gram-negative organisms, 2381
  *S. typhimurium* SS-B, 853
5′-{[(*Z*)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine
  *T. b. brucei*
    mice, 1485
  *T. b. rhodesiense*
    mice, 1485
3′-Amino-3′-deoxythymidine 5′-triphosphate
  feline immunodeficiency virus
    reverse transcriptase, 1505
4′,4″-Aminoglycoside nucleotidyltransferase
  *E. faecalis*, 1565
4′-Aminoglycoside nucleotidyltransferase
  amikacin resistance, 2381
  gram-negative organisms, 2381
  tobramycin resistance, 2381
Aminoglycoside-modifying enzymes
  gram-positive cocci
    gene homogeneity, 2164
Aminoglycosides
  *Campylobacter* resistance
    *aadA*, 1294
    *aadE*, 1294
  *E. coli*
    tricarboxylic acid cycle, 295
  *E. coli* susceptibility
    salicylate, 786
  *E. faecalis*
    resistance, 1565
  pharmacokinetics
    hematologic malignancy, 702
    neutropenic patients, 702
  resistance
    gram-positive cocci, 2164
    nucleic acid hybridization, 2164
  *Y. enterocolitica*
    pigs and pork products, 2423
3′-Amino-5-methyl-deoxycytidine
  hepatitis B virus, 1986
Amoxicillin
  *Bacteroides* spp., 1546
  combinations
    bismuth subsalicylate, 1232
    *H. mustelae*, 1232
    metronidazole, 1232
  comparative activity
    penicillin G-streptomycin and penicillin V, 321
  endocarditis
    rabbits, 321
  *Fusobacterium* spp., 1546
  *H. influenzae*, 2075
  *P. shigelloides*, 159
  *S. pneumoniae-S. aureus*

respiratory infection model, 210
*S. sanguis*, 321
Amoxicillin-clavulanic acid
*B. fragilis* group, 671
*Bacteroides* spp., 1546
comparative activity
cephradine, 1803
*E. coli*
trimethoprim resistant, 2047
*Enterobacteriaceae*
infrequent, 1605
*Fusobacterium* spp., 1546
*H. influenzae*, 2075
*M. catarrhalis*, 2075
*P. shigelloides*, 159
*S. lugdunensis*, 2434
*S. pneumoniae*, 2075
*S. pneumoniae-S. aureus*
respiratory infection model, 210
urinary tract infections, 1803
Amoxicillin-probenecid
comparative activity
cefixime, 355
gonorrhea
uncomplicated, 355
*ampC*
induction in *E. coli*, 2429
Amphotericin B
candidiasis
murine, 746, 1619
combinations
humans, 470
pentamidine, inhaled, 470
pentamidine, parenteral, 470
renal failure, 470
trimethoprim-sulfamethoxazole, 470
comparative activity
cilofungin, 746, 1619
delivery systems
minireview, 381
*H. capsulatum*, 524
high-performance liquid chromatography, 29
histoplasmosis
mice, 524
infusion duration
toxicity, 1402
*L. mexicana*
heat-transformed amastigotes, 1584
promastigotes, 1584
liposomal
cryptococcosis, 2055
mice, 2055
mechanisms of action
minireview, 183
minireviews
delivery systems, 381
mechanisms of action, 183
monomethyl ester derivative
toxicity for glial cells, 1360
nephrotoxicity
mechanism, 241
pentoxifylline, 241
rat model, 241
pharmacokinetics
aerosol, 29
intraperitoneal, 29
rats, 29
toxicity
egg lecithin-glycocholic acid mixed micelles, 2415
glial cells, 1360
infusion duration, 1402
mammalian cells, 2415
tumor necrosis factor induction assay, 906
Ampicillin
*Bacteroides* spp., 657
*C. difficile* enterocecitis
hamsters, 1348
inducement, 1348
comparative activity
trimethoprim-sulfamethoxazole, 1800
*E. coli*
*hipQ*, 1938
reduced killing, 1938
resistance, 361
*E. coli* lysis
amino acid deprivation, 164
*E. faecalis*, 1068
endocarditis
rabbits, 1068
*Enterococcus* resistance, 1821
*Fusobacterium* spp., 657
*H. influenzae*, 2075
agar dilution plate count method, 1079
killing curve patterns, 1079
*Klebsiella* spp.
resistance, 361
*M. catarrhalis*, 2075
neonatal infections, 361
*P. shigelloides*, 159
peritonitis
*Enterococcus* spp., 1800
murine, 1800
*S. lugdunensis*, 2434
*S. pneumoniae*, 467, 2075
*S. typhimurium* SS-B, 853
serum inhibitory activity, 1068
Ampicillin-sulbactam
alveolar lining fluid penetration, 958
comparative activity
oxacillin, 728
*E. faecalis*, 1068
endocarditis
rabbits, 1068
rats, 728
*H. influenzae*, 2075
*M. catarrhalis*, 2075
*P. shigelloides*, 159
respiratory infections, 958
*S. aureus*, 728, 1830
*S. lugdunensis*, 2434
*S. pneumoniae*, 2075
serum inhibitory activity, 1068
Anaerobes
E-3846, 1262
irloxacin, 1262
Antacids
cefetamet pivoxil
pharmacokinetics, 1744
fluconazole
humans, 2032
pharmacokinetics, 2032
norfloxacin absorption, 432
ofloxacin
bioavailability, 2436
humans, 2436
pharmacokinetics, 2436
Antifungal agents
3-methoxysampangine, 529
Antifungal screen
*S. cerevisiae*
β-galactosidase, 660
ANT(4′)-II
amikacin resistance, 2381
gram-negative organisms, 2381
tobramycin resistance, 2381
Antimicrobial effect kinetics
in vitro model, 1312
Antipyrine
metabolism
ciprofloxacin, 2148
rats, 2148
pharmacokinetics
ciprofloxacin, 2148
rats, 2148
Antiviral agents
bacteriological screening assay, 2337
*aphA6*
*Acinetobacter* spp.
amikacin resistance, 1244
1-β-D-Arabinofuranosyl-*E*-5-(2-bromovinyl) uracil
herpes simplex virus type 1
mice, 691, 2431
human herpesvirus 6, 2417
Aspergillosis
Bay R 3783, 448
fluconazole, 980
mice, 980
rodents, 448
SM-8668, 980
*Aspergillus fumigatus*
nikkomycin X, 587
nikkomycin Z, 587
Atropine
combinations
hepatitis A virus, 1112
protamine, 1112
hepatitis A virus
cell culture, 1112
Autobacteriography
mice
clarithromycin, 562
*S. aureus*, 562
Autolysins
*B. subtilis*
surfactants, 781
5-Azacytidine
human immunodeficiency virus type 1, 206
5-Azadeoxycytidine
human immunodeficiency virus type 1, 206
3′-Azido-3′-deoxythymidine
human herpesvirus 6, 2417
human immunodeficiency virus, 637
type 1, 1297
mouse toxicity, 637
murine acquired immunodeficiency syndrome, 605
nucleotide dimers
human immunodeficiency virus type 1-infected lymphocytes, 1061
Azidothymidine
*E. coli*
SOS response, 1237
Azithromycin
*H. influenzae*
accumulation, 1787
proton motive force, 1787
human fibroblasts
accumulation, 1056
intracellular accumulation
human fibroblasts, 1056
*N. gonorrhoeae*

piliation and attachment, 2445
ribosome binding rate constants, 426
sub-MIC
*N. gonorrhoeae* piliation and attachment, 2445
Azlocillin
*A. calcoaceticus* biovar anitratus, 494
*Bacteroides* spp., 657
ciprofloxacin pharmacokinetics
humans, 823
*Fusobacterium* spp., 657
Azoles
*C. albicans*
P-450-deficient mutant, 831
*S. cerevisiae*
lovastatin, 1660
Aztreonam
combinations
ceftazidime, 487
ciprofloxacin, 487
*Pseudomonas* spp., 487
descarboxy prothrombin, 1045
fecal flora, 1045
gram-negative organisms
serum, 2234
*K. pneumoniae*, 1783
*P. pseudomallei*, 2027
*P. shigelloides*, 159
urinary tract infections, 1045
vitamin K metabolism, 1045
*Y. enterocolitica*
pigs and pork products, 2423

*Bacillus cereus*
LY264826, 2137
*Bacillus* spp.
bacitracin
induced proteins, 796
resistance, 796
WIN 57273, 306
*Bacillus subtilis*
surfactants
aberrant morphology, 781
autolysins, 781
lysis, 781
Bacitracin
*S. typhimurium* SS-B, 853
Bacitracin-induced proteins
*B. subtilis*
resistance, 796
*B. thuringiensis*
resistance, 796
Bacteremia
gram-positive organisms
teicoplanin, 2392
vascular access associated, 2392
*K. pneumoniae*
β-lactamase, 1290
ceftazidime-amikacin failure, 1290
Bacterial blepharitis
mercuric oxide
efficacy and safety, 610
humans, 610
Bacteriological assays
antiviral agent screening, 2337
*Bacteroides distasonis*
β-lactamase
imipenem resistance, 117
imipenem
resistance, 117
*Bacteroides fragilis*
β-lactamase
class B, 1590
gene cloning and sequencing, 1590
*ccrA*
cloning and sequencing, 1590
LJC10,627, 994
Ro 23-9424, 189
*Bacteroides fragilis* group
amoxicillin-clavulanic acid, 671
cefmetazole, 671
cefoperazone, 479
cefotaxime, 479
cefotetan, 479, 671
cefoxitin, 479, 671
susceptibility testing, 2246
ceftazidime, 479
ceftizoxime, 479
chloramphenicol, 479, 671
clindamycin, 479, 671
imipenem, 479, 671
metronidazole, 479, 671
mezlocillin, 671
moxalactam, 479, 671
piperacillin, 479
piperacillin-tazobactam, 1858
susceptibility testing
cefoxitin, 2246
resistance rate differences due to different methods, 179
ticarcillin-clavulanate, 479
WIN 57273, 306, 1858
*Bacteroides* spp.
amoxicillin, 1546
amoxicillin-clavulanic acid, 1546
ampicillin, 657
azlocillin, 657
β-lactamase, 1546
cefoperazone, 657
cefotaxime, 657
cefoxitin, 657, 1546
cefuroxime, 657
foot rot in goats, 657
imipenem, 657, 1546
metronidazole, 1546
mezlocillin, 657
non-*B. fragilis*
β-lactamases, 2169
susceptibility patterns, 2169
oral
trospectomycin, 1597
penicillin G, 657
piperacillin, 657
ticarcillin, 1546
ticarcillin-clavulanic acid, 1546
Bay R 3783
aspergillosis
rodents, 448
blastomycosis
mice, 1132
candidiasis
rodents, 448
coccidioidomycosis
mice, 1132
comparative activity
amphotericin B, fluconazole, itraconazole, and ketoconazole, 448, 1132
cryptococcosis
rodents, 448
histoplasmosis
mice, 1132
Bay v 3522
*B. catarrhalis*, 813, 1855
comparative activity
amoxicillin-clavulanate, ampicillin, cefaclor, cefixime, cefuroxime, and cephalexin, 1849
amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, 1855
amoxicillin-clavulanate, cefixime, cefuroxime, and cephalexin, 813
*Enterobacteriaceae*, 813, 1855
*Enterococcus* spp., 1855
gram-negative organisms, 1849, 1855
gram-positive organisms, 1855
*H. influenzae*, 813, 1855
*P. multocida*, 1855
*S. pneumoniae*, 813
*Staphylococcus* spp., 813, 1849, 1855
*Streptococcus* spp., 1849, 1855
Bayesian method
vancomycin dosage
renal function, 1165
Benzylpenicillin
*S. typhimurium* SS-B, 853
Berberine
derivatives
leishmaniasis in hamsters, 918
leishmaniasis
hamsters, 918
Betaine esters
antimicrobial activities, 1949
β-Lactamases
*Aeromonas* spp.
purification and characterization, 44
*B. distasonis*
imipenem resistance, 117
*B. fragilis*
class B gene cloning and sequencing, 1590
*Bacteroides* spp., 1546
β-lactam resistance, 2169
non-*B. fragilis*, 2169
BK-218, 349
BMY-28232, 555
*C. freundii* group 1
induction in *E. coli*, 2429
*Capnocytophaga* sp., 1501
cephalosporins
resistance, 337
class I
clavulanate, 156
sulbactam, 156
tazobactam, 156
cloning, 1577
CTX-1
molecular epidemiology, 219
*E. coli*
β-lactams, 858
nosocomial, 739
*E. faecalis*
molecular epidemiology, 302
*Enterobacteriaceae*
cefoperazone-sulbactam, 622
ceftazidime resistance, 2193
oligotyping, 2210
piperacillin-tazobactam, 622
TEM, 2210
ticarcillin-clavulanate, 622
*Fusobacterium* spp., 1546
inhibition profiles
nitrocefin competition assay, 2184
*K. pneumoniae*, 2070

β-lactam resistance, 2200
ceftazidime resistance, 1290
extended spectrum, 1783
LJC10,627, 994
MIR-1
characterization, 2200
nitrocefin competition assay, 2184
OHIO-1, 1570
cloning, 1577
*P. aeruginosa*
fosfomycin, 2093
ROB-1
comparative studies, 1354
nucleotide sequence, 1354
*S. aureus*
cation-exchange and affinity chromatography, 2177
extracts versus whole-cell suspensions, 420
methicillin resistant, borderline, 911
*S. lugdunensis*, 2434
*S. marcescens*, 755
SHV-1
cloning and sequencing, 1577
SHV-1-like
*E. coli*, 581
sulbactam-ceftriaxone, 581
SHV-2
cloning, 1577
nucleotide sequence, 1444, 1725
phylogeny, 1725
SHV-5
nucleotide sequence, 2439
TEM
oligotyping, 2210
TEM-3
molecular epidemiology, 219
U-78608, 884
β-Lactams
*Bacteroides* resistance
β-lactamases, 2169
*C. freundii* β-lactamase induction in *E. coli*, 2429
*E. coli*
β-lactamases, 858
bioluminescence assay, 102
*hipQ*, 1938
K1 serum resistance, 628
nosocomial, 739
postantibiotic effect, 102
reduced killing, 1938
resistance patterns and mechanisms, 739
fosfomycin antagonism
*P. aeruginosa*, 2093
*K. pneumoniae* resistance
MIR-1, 2200
*L. monocytogenes*
penicillin-binding proteins, 539
*L. monocytogenes* resistance
PBP 3 alteration, 1695
*N. meningitidis* resistance
transmission from commensal neisseriae, 2269
*P. aeruginosa*
outer membrane porin diffusion, 685
*P. vulgaris*
paradoxical effect, 94
postantibiotic effect
bioluminescence assay, 102
*E. coli*, 102
*S. saprophyticus* resistance, 1780
Biliary pseudolithiasis
ceftriaxone, 1146
Bioassay
teicoplanin, 1642
vancomycin, 1642
Biofilm bacteria
susceptibility testing
minireview, 2043
Bioluminescence assay
*E. coli*
β-lactams, 102
postantibiotic effect, 102
postantibiotic effect
β-lactams, 102
*E. coli*, 102
Bis(benzyl)polyamine analog
*L. donovani*
antimony susceptible and resistant, 722
leishmaniasis
murine, 722
Bismuth subsalicylate
combinations
amoxicillin, 1232
*H. mustelae*, 1232
metronidazole, 1232
tetracycline, 1232
BK-218
β-lactamases, 349
comparative activity
cefamandole, cefoxitin, cefuroxime, and cephalexin, 349
*E. cloacae*, 349
*E. coli*, 349
*S. aureus*, 349
*Blastocystis hominis*
magainin
analogs, 1824
*Blastomyces dermatitidis*
nikkomycin X, 587
nikkomycin Z, 587
Blastomycosis
Bay R 3783, 1132
mice, 587, 1132
pneumonia, 896
nikkomycin X, 587
nikkomycin Z, 587
SCH 39304, 896
Blepharitis
mercuric oxide
efficacy and safety, 610
humans, 610
BMY-28100
*K. pneumoniae*, 1783
pharmacokinetics
humans, 202
phase I study, 202
*S. pneumoniae*, 467
safety, 202
tolerance, 202
BMY-28232
β-lactamases, 555
comparative activity
cefixime and cefteram, 555
gram-negative organisms, 555
*Staphylococcus* spp., 555
BMY-28271
comparative activity
cefixime and cefteram, 555
gram-negative organisms
mice, 555
*S. aureus*
mice, 555
Bone infections
gram-positive organisms
teicoplanin, 2392
*Bordetella parapertussis*
cefetamet, 1442
cefixime, 1442
cefpodoxime, 1442
cefprozil, 1442
ceftibuten, 1442
ciprofloxacin, 2287
enoxacin, 2287
fleroxacin, 2287
lomefloxacin, 2287
loracarbef, 1442
ofloxacin, 2287
pefloxacin, 2287
temafloxacin, 2287
*Bordetella pertussis*
cefetamet, 1442
cefixime, 1442
cefpodoxime, 1442
cefprozil, 1442
ceftibuten, 1442
ciprofloxacin, 2287
enoxacin, 2287
fleroxacin, 2287
lomefloxacin, 2287
loracarbef, 1442
ofloxacin, 2287
pefloxacin, 2287
temafloxacin, 2287
*Borrelia burgdorferi*
cefuroxime, 2133
*Branhamella catarrhalis*
Bay v 3522, 813, 1855
WIN 57273, 1154
*Branhamella* spp.
LJC10,627, 994
WIN 57273, 306
Bronchial mucosa
lomefloxacin concentrations, 1017
Bronchitis
bacterial exacerbation
cefixime, 1041
cephalexin, 1041
Brovavir
herpes simplex virus type 1
mice, 691
Brucellosis
doxycycline-streptomycin, 881
Burn patients
vancomycin pharmacokinetics, 792
Butenafine hydrochloride
comparative activity
bifonazole, clotrimazole, naftidine, and tolnaftate, 2250
bifonazole, clotrimazole, and tolnaftate, 2254
dermatophytosis
guinea pigs, 2250
tinea pedis
guinea pigs, 2254
Butylethanolamine
toxicity, selective, 491

Cadmium
accumulation and toxicity
*E. coli*, 2402
salicyl alcohol, 2402
salicylate, 2402

Calcium carbonate
ofloxacin
bioavailability, 2436
humans, 2436
pharmacokinetics, 2436
*Campylobacter jejuni*
rokitamycin, 1440
*Campylobacter* spp.
aminoglycoside resistance
*aadA*, 1294
*aadE*, 1294
spectinomycin resistance, 1294
streptomycin resistance, 1294
tosufloxacin, 368
Cancer patients
*Pseudomonas* spp.
quinolones, 1812
*X. maltophilia*
quinolones, 1812
*Candida albicans*
cilofungin, 196
fluconazole, 196
flucytosine, 196
gastrointestinal tract colonization
cefoperazone, 2420
ceftriaxone, 2420
mice, 2420
ticarcillin-clavulanic acid, 2420
ketoconazole, 196
P-450-deficient mutant
azole susceptibility, 831
hyphal formation, 831
pentamidine, 2304
pentamidine-itraconazole, 2304
pentamidine-ketoconazole, 2304
Sch-39304, 196
*Candida glabrata*
flucytosine
mechanisms of action, 1996
fluoropyrimidine metabolism
$^{19}F$ nuclear magnetic resonance, 1996
*Candida tropicalis*
enzyme immunoconjugates
cytotoxicity, 875
glucose oxidase-myeloperoxidase, 875
candidiasis, 1619
amphotericin B, 746
Bay R 3783, 448
cilofungin, 746
fluconazole, 980
murine, 746, 980, 1619
amphotericin B, 1619
cilofungin, 1619
oral
clotrimazole, 2267
fluconazole, 2267
rabbits
Sch-39304, 1560
rodents, 448
SM-8668, 980
vaginal
fluconazole, 909
Capillary gas chromatography-ion trap detection
fluconazole
small-volume samples, 909
*Capnocytophaga* sp.
β-lactamase, 1501
Carbohydrazones
streptomycin derivatives
synthesis, 1908
(−)-Carbovir
human immunodeficiency virus type 1, 1297
*N*-Carboxybutyl chitosan
antimicrobial properties, 2019
wound dressing, 2019
Cardiac surgery
teicoplanin concentrations, 1699
Carumonam
*P. pseudomallei*, 2027
Cat models
feline leukemia virus
2′,3′-dideoxycytidine, 1414
Catheters
chlorhexidine dihydrochloride
human albumin microspheres, 2118
Cats
phosphonoformate
age, 871
pharmacokinetics, 871
*ccrA*
cloning and sequencing, 1590
CD4, soluble
combinations
dextran sulfate, 82
2′,3′-dideoxynucleosides, 82
human immunodeficiency virus type 1, 82
Cefaclor
comparative pharmacokinetics
cefprozil, 1198
humans, 1198
*H. influenzae*, 2075
*K. pneumoniae*, 1783
*M. catarrhalis*, 2075
pharmacokinetics
food, 1210
humans, 1204, 1210
*S. pneumoniae*, 467, 2075
Cefadroxil
*K. pneumoniae*, 1783
Cefamandole
coagulase-negative staphylococci
biofilm, 390
*P. shigelloides*, 159
*S. aureus*
inoculum effect, 505
*S. epidermidis*
inoculum effect, 505
*S. pneumoniae*, 467
Cefatrizine
*K. pneumoniae*, 1783
Cefazolin
comparative activity
ceftriaxone, 1194
vaginal hysterectomy prophylaxis, 1194
*M. avium-M. intracellulare*, 1390
*M. paratuberculosis*, 366
*S. aureus*
inoculum effect, 505
*S. epidermidis*
inoculum effect, 505
tissue penetration
continuous intravenous infusion, 1128
humans, 1128
vaginal hysterectomy prophylaxis
efficacy, cost, and flora alterations, 1194
*Y. enterocolitica*
pigs and pork products, 2423
Cefbuperazone
*P. vulgaris*, 94
Cefcanel
*K. pneumoniae*, 1783
Cefepime
comparative activity
cefotaxime, ceftazidime, and moxalactam, 733
*E. coli*, 1932
mice, 1932
phagocytosis, 332
polysaccharides, capsular, 332
lower respiratory tract infections, 954
meningitis
mice, 733
*P. pseudomallei*, 2027
pharmacodynamics
in vitro-in vivo, 1932
pharmacokinetics
humans, 1118, 1885
rats, 733
respiratory tract infections, 1885
*S. typhimurium* SS-B, 853
safety, 954, 1118
skin infections, 954
soft tissue infections, 954
tolerance, 1118
urinary tract infections, 954
Cefetamet
*B. parapertussis*, 1442
*B. pertussis*, 1442
*Enterobacteriaceae*
infrequent, 1605
*K. pneumoniae*, 1783
pharmacokinetics
hepatic cirrhosis, 1318
Cefetamet pivoxil
bioavailability
food and fluid intake, 1556
pharmacokinetics
antacid, 1744
food and fluid intake, 1556
hepatic cirrhosis, 1318
humans, 1556, 1744
ranitidine, 1744
urethritis
dose-finding study, 674
gonococcal, 674
uncomplicated, 674
Cefixime
*B. parapertussis*, 1442
*B. pertussis*, 1442
bronchitis exacerbation, 1041
comparative activity
amoxicillin, amoxicillin-clavulanic acid, ampicillin, cefaclor, ceftriaxone, cefuroxime, and cephalexin, 1456
amoxicillin-probenecid, 355
cephalexin, 1041
gonorrhea
uncomplicated, 355
*H. influenzae*
β-lactamase- and non-β-lactamase producing, 1456
*H. pylori*, 2426
penicillin-binding proteins, 2426
*K. pneumoniae*, 1783
penicillin-binding proteins
*H. pylori*, 2426
Cefmenoxime
*P. vulgaris*
paradoxical effect, 94

Cefmetazole
*B. fragilis* group, 671
dose proportionality
young and elderly subjects, 1944
*N*-methylthiotetrazole
pharmacokinetics, 2369
production, 2369
pharmacokinetics
humans, 519
renal function, 519
young and elderly subjects, 1944
Cefonicid
comparative activity
nafcillin, 654
skin infections, 654
skin structure infections, 654
Cefoperazone
*B. fragilis* group, 479
*Bacteroides* spp., 657
*C. albicans*
mouse gastrointestinal tract colonization, 2420
combinations
*Enterobacteriaceae*, 2256
nonfermenters, 2256
sulbactam, 2256
*E. coli*, 1932
mice, 1932
*Enterobacteriaceae*, 2256
*Fusobacterium* spp., 657
gram-negative organisms
serum, 2234
*N*-methylthiotetrazole
pharmacokinetics, 2369
production, 2369
nonfermenters, 2256
*P. shigelloides*, 159
pharmacodynamics
in vitro-in vivo, 1932
pharmacokinetics
elderly patients, 1007
serum bactericidal activity
elderly patients, 1007
Cefoperazone-sulbactam
*Enterobacteriaceae*
β-lactamases, 622
*P. shigelloides*, 159
*S. aureus*, 1830
Cefotaxime
*A. calcoaceticus* biovar anitratus, 494
*B. fragilis* group, 479
*Bacteroides* spp., 657
*E. rhusiopathiae*, 2038
*Fusobacterium* spp., 657
gram-negative organisms
serum, 2234
*K. pneumoniae*, 1783
*M. avium-M. intracellulare*, 1390
*P. pseudomallei*, 2027
*P. shigelloides*, 159
pharmacokinetics
elderly patients, 1007
*S. typhimurium* SS-B, 853
serum bactericidal activity
elderly patients, 1007
*Y. enterocolitica*
pigs and pork products, 2423
Cefotetan
*B. fragilis* group, 479, 671
*N*-methylthiotetrazole
pharmacokinetics, 2369
production, 2369
Cefotiam
*K. pneumoniae*, 1783
Cefoxitin
*B. fragilis* group, 479, 671
susceptibility testing, 2246
*Bacteroides* spp., 657, 1546
*Fusobacterium* spp., 657, 1546
*P. shigelloides*, 159
pelvic peritoneal fluid penetration, 376
susceptibility testing
*B. fragilis* group, 2246
reader, 2246
replicates, 2246
trial, 2246
Cefpirome
gram-negative organisms
serum, 2234
*S. typhimurium* SS-B, 853
Cefpodoxime
*B. parapertussis*, 1442
*B. pertussis*, 1442
*K. pneumoniae*, 1783
pharmacokinetics
humans, 1094
Cefpodoxime proxetil
cefpodoxime pharmacokinetics
humans, 1094
comparative activity
ceftriaxone and cefuroxime, 371
inflammatory fluid penetration
humans, 232
*N. gonorrhoeae*, 371
pharmacokinetics
humans, 232
Cefprozil
*B. parapertussis*, 1442
*B. pertussis*, 1442
comparative pharmacokinetics
cefaclor, 1198, 1204, 1210
food, 1210
humans, 1198, 1204, 1210
pharmacokinetics
food, 1210
humans, 1198, 1204, 1210
infants and children, 2152
safety and tolerance, 1198
tissue penetration
humans, 1204
Ceftazidime
*A. calcoaceticus* biovar anitratus, 494
*B. fragilis* group, 479
combinations
aztreonam, 487
ciprofloxacin, 487
pharmacokinetics, 1139
*Pseudomonas* spp., 487
tobramycin, 1139
comparative activity
imipenem-cilastatin, 1336
*E. coli*, 1932
K1 serum resistance, 628
mice, 1932
*Enterobacteriaceae* resistance
β-lactamases, 2193
gram-negative organisms
serum, 2234
*K. pneumoniae*, 1783
resistance, 1290
neutropenic patients, 1336
*P. pseudomallei*, 2027
*P. shigelloides*, 159
pharmacodynamics
in vitro-in vivo, 1932
pharmacokinetics
continuous and intermittent infusions, 2307
elderly patients, 1007
humans, 1139, 2307
renal function, 1139
tobramycin, 1139
serum bactericidal activity
elderly patients, 1007
*Y. enterocolitica*
pigs and pork products, 2423
Ceftibuten
*B. parapertussis*, 1442
*B. pertussis*, 1442
*K. pneumoniae*, 1783
pharmacokinetics
humans, 1053
*S. pneumoniae*, 467
tissue penetration, 1053
Ceftizoxime
*B. fragilis* group, 479
*M. avium-M. intracellulare*, 1390
pharmacokinetics
elderly patients, 1007
serum bactericidal activity
elderly patients, 1007
Ceftriaxone
biliary pseudolithiasis, 1146
*C. albicans*
mouse gastrointestinal tract colonization, 2420
clearance
plasma exchange pheresis, 1276
comparative activity
cefazolin, 1194
ciprofloxacin, 819
ofloxacin, 148
degradation kinetics
diluted and undiluted human serum, 1268
temperature, 1268
*E. coli*, 1932
mice, 1932
phagocytosis, 332
polysaccharides, capsular, 332
*Enterobacteriaceae*
infrequent, 1605
gonorrhea
uncomplicated, 148
gram-negative organisms
serum, 2234
*N. gonorrhoeae*
penicillinase-producing and -nonproducing, 148
nocardiosis
murine pulmonary, 1766
*P. shigelloides*, 159
pharmacodynamics
in vitro-in vivo, 1932
pharmacokinetics
elderly patients, 1007
serum bactericidal activity
elderly patients, 1007
serum protein binding
broth dilution, 1257
supraphysiologic temperature, 1257
urethritis
gonococcal, 819
vaginal hysterectomy prophylaxis
efficacy, cost, and flora alterations, 1194
*Y. enterocolitica*
pigs and pork products, 2423

Ceftriaxone-sulbactam
*E. coli*
SHV-2-like β-lactamase, 581
endocarditis
*E. coli*, 581
rabbits, 581
*K. pneumoniae*
endocarditis, 2070
rabbits, 2070
Cefuroxime
*B. burgdorferi*, 2133
*Bacteroides* spp., 657
*C. difficile* enterocecitis
hamsters, 1348
inducement, 1348
comparative activity
amoxicillin, ceftriaxone, doxycycline, erythromycin, penicillin G, and tetracycline, 2133
*E. coli*
resistance, 361
trimethoprim resistant, 2047
*Fusobacterium* spp., 657
*H. influenzae*, 2075
*K. pneumoniae*, 1783
*Klebsiella* spp.
resistance, 361
Lyme disease/borreliosis
hamsters, 2133
*M. catarrhalis*, 2075
neonatal infections, 361
*P. shigelloides*, 159
*S. aureus*
inoculum effect, 505
*S. epidermidis*
inoculum effect, 505
*S. pneumoniae*, 2075
*S. typhimurium* SS-B, 853
tissue penetration
continuous intravenous infusion, 1128
humans, 1128
Cefuzonam
*P. pseudomallei*, 2027
Cell envelope synthesis inhibitors
*M. avium* complex
susceptibility, 759
Cephalexin
bronchitis exacerbation, 1041
comparative activity
cefixime, 1041
*E. coli*
trimethoprim resistant, 2047
*H. influenzae*, 2075
*K. pneumoniae*, 1783
*M. catarrhalis*, 2075
protein binding, extravascular
bactericidal activity, 98
in vitro capillary model, 98
*S. pneumoniae*, 2075
Cephaloridine
*E. coli*
K1 serum resistance, 628
Cephalosporins
β-lactamases
resistance, 337
biosynthesis
minireview, 943
molecular biology, 943
*K. ozaenae* resistance
SHV-2, 1725
outer membrane penetration, 337
pharmacokinetics
hysterectomy, 1160
lymphadenectomy, 1160
Cephalothin
*E. coli*
trimethoprim resistant, 2047
*H. influenzae*, 2075
*M. catarrhalis*, 2075
*P. shigelloides*, 159
*S. lugdunensis*, 2434
*S. pneumoniae*, 2075
*S. typhimurium* SS-B, 853
*Y. enterocolitica*
pigs and pork products, 2423
Cephapirin
*M. avium-M. intracellulare*, 1390
Cephradine
comparative activity
amoxicillin-clavulanate, 1803
*K. pneumoniae*, 1783
urinary tract infections, 1803
Cerebrospinal fluid
SCH-39304 penetration
monkeys, 1281
Chancroid
treatment
minireview, 1308
Chemostat system
*P. aeruginosa*
piperacillin, 1666
tobramycin, 1666
tobramycin-piperacillin, 1666
*Chlamydia trachomatis*
clindamycin-gentamicin, 1399
clindamycin-tobramycin, 1399
tosufloxacin, 971
Chloramphenicol
*B. fragilis* group, 479, 671
*E. rhusiopathiae*, 2038
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
*H. influenzae*, 2075
*H. mustelae*, 1232
human polymorphonuclear leukocyte
cytoplast uptake, 1189
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
*M. catarrhalis*, 2075
mitochondria, 167
*P. pseudomallei*, 2027
*Pediococcus* spp., 543
*S. pneumoniae*, 2075
*S. typhi*
outer membrane protein deficient, 1715
resistant, 1715
*S. typhimurium* SS-B, 853
typhoid fever, 1809
concentrations in serum, 1809
Chloramphenicol succinate
typhoid fever, 1809
chloramphenicol concentrations in serum, 1809
Chlorhexidine
membrane transfer assay, 153
mutans streptococci, 153
Chlorhexidine dihydrochloride
human albumin microspheres
catheters, 2118
*E. coli*, 2118
*P. aeruginosa*, 2118
*S. aureus*, 2118
urinary pathogens, 2118
3′-Chloro-5-methyl-deoxycytidine
hepatitis B virus, 1986
Chloroquine
combinations
isoniazid, 2217
pyrazinamide, 2217
streptomycin, 2217
tubercle bacilli, 2217
vitamin D$_3$ metabolites, 2217
*P. falciparum*
peroxidase-hydrogen peroxide system, 1981
susceptible *P. falciparum*
continuation of parasitemia, 676
humans, 676
tubercle bacilli
human macrophages, 2217
Cholecystectomy
fleroxacin
pharmacokinetics, 2375
Cholecystitis
ofloxacin
intraoperative concentrations in serum, bile, and gall bladder, 2354
Cholera
norfloxacin, 939
CI934
*A. salmonicida*, 1819
Cilastatin
pharmacokinetics
premature infants, 1172
Cilofungin
*C. albicans*, 196
candidiasis
murine, 746
comparative activity
amphotericin B, 196, 746, 1619
pharmacokinetics
rabbits, 2240
polymorphonuclear leukocytes, 196
tissue penetration
rabbits, 2240
Cinodine
DNA gyrase, 1450
Ciprofloxacin
antipyrine
metabolism, 2148
pharmacokinetics, 2148
rats, 2148
*B. parapertussis*, 2287
*B. pertussis*, 2287
bioavailability
humans, 931, 1031
renal function, 1031
sucralfate, 931
colorectal surgery, 481
combinations
azlocillin, 823, 1814
aztreonam, 487, 1814
ceftazidime, 487, 1814
*P. aeruginosa*, 1814
pharmacokinetics, 442, 823
*Pseudomonas* spp., 487
rifampin, 442
comparative activity
ceftriaxone, 819
cephalosporin, 40
gentamicin, rifampin, and vancomycin, 273
nafcillin-aminoglycoside, 40
pefloxacin, 2327
vancomycin and vancomycin-rifampin, 1014
cyclosporine concentrations and pharmacokinetics

bone marrow transplant patients, 1048
*E. aerogenes*, 40
*E. coli*
phagocytosis, 332
polysaccharides, capsular, 332
*E. rhusiopathiae*, 2038
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
endocarditis
rabbits, 273
*Enterobacteriaceae*
infrequent, 1605
gram-negative organisms
serum, 2234
*H. pylori*
resistance, 1637
heart tissue penetration, 398
*K. pneumoniae*, 40
*L. pneumophila*
intracellular multiplication, 1733
postantibiotic effect, 1733
serogroup 1, 1733
*M. leprae*, 229
*M. paratuberculosis*, 366
malaria
mice, 2327
mitochondria, 167
*Mycobacterium* spp., 65, 496
resistance, mutational, 65
nocardiosis
murine pulmonary, 1766
N-substitution analogs
*Mycobacterium* spp., 496
osteomyelitis, 40
*P. aeruginosa*, 849
rats, 1014
*P. aeruginosa*, 40
imipenem cross resistance, 2142
osteomyelitis, 849
quinolone cross resistance, 2142
resistance, 2142
resistance, acquired, 281
*P. pseudomallei*, 2027
*P. shigelloides*, 159
*P. yoelii*
mice, 2327
pharmacokinetics
azlocillin, 823
humans, 823, 1031
renal function, 1031
pleural fluid penetration, 934
resistance
acquired, 281
*P. aeruginosa*, 281
*S. aureus*
methicillin resistant, 1014, 2050
*S. aureus* resistance
emergence, 1862
*S. epidermidis*
methicillin resistant, 273
*S. pneumoniae*, 467
*S. typhimurium* SS-B, 853
serum sickness-like illness, 904
urethritis
gonococcal, 819
*X. maltophilia*, 1609
*Y. enterocolitica*
pigs and pork products, 2423
Ciprofloxacin-rifampin
comparative activity
vancomycin and vancomycin-rifampin, 1014
osteomyelitis
rats, 1014
pharmacokinetics
elderly patients, 442
*S. aureus*
methicillin resistant, 1014
*Citrobacter freundii*
β-lactamase
induction in *E. coli*, 2429
Ro 23-9424, 189
Clarithromycin
autobacteriography
mice, 562
combinations
*H. influenzae*, 1407
14-hydroxy-clarithromycin, 1407
comparative activity
erythromycin, 562
rifabutin, 1508
*H. influenzae*, 1407
otitis media, 1407
*M. avium* complex
human macrophages, 1508
*S. aureus*
mice, 562
Clavulanate
β-lactamases
class I, 156
*Cleistopholis patens*
3-methoxysampangine, 529
Clindamycin
*B. fragilis* group, 479, 671
*C. difficile* enterocecitis
hamsters, 1348
inducement, 1348
*C. trachomatis*, 1399
combinations
*C. trachomatis*, 1399
gentamicin and tobramycin, 1399
*E. rhusiopathiae*, 2038
*H. pylori*, 25
high-pressure liquid chromatography, 25
human polymorphonuclear leukocyte
cytoplast uptake, 1189
*M. hominis*, 2297
mitochondria, 167
pelvic peritoneal fluid penetration, 376
*S. pneumoniae*, 467
*S. typhimurium* SS-B, 853
*T. gondii*
mice, 1467
transport across gastric mucosa, 25
*Y. enterocolitica*
pigs and pork products, 2423
Clofazimine
*M. paratuberculosis*, 366
*Clostridium difficile*
enterocecitis
antibiotic induced, 1348
hamsters, 1348
LY 264826, 2007
*Clostridium perfringens*
Ro 23-9424, 189
Clotrimazole
candidiasis
oral, 2267
comparative activity
fluconazole, 2267
Cloxacillin
pharmacokinetics
children, 1150
*S. typhimurium* SS-B, 853
surgery with massive bleeding, 1150
Coccidioidal meningitis
murine, 663
SCH39304, 663
*Coccidioides immitis*
nikkomycin X, 587
nikkomycin Z, 587
Coccidioidomycosis
Bay R 3783, 1132
fluconazole, 13, 928
mice, 13, 587, 928, 1132
nikkomycin X, 587
nikkomycin Z, 587
SCH39304, 928
SDZ89-485, 13
Colistin
*M. avium* complex
susceptibility, 759
Colorectal surgery
ciprofloxacin, 481
ornidazole
pharmacokinetics, 1921
*Corynebacterium jeikeium*
LY264826, 2137
Co-trimoxazole
comparative activity
ofloxacin, 215
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
neutropenic patients
prevention of infection after chemotherapy, 215
*Coxiella burnetii*
doxycycline
lysosomotropic agents, 1512
P388D$_1$ cells, 1512
susceptibility testing, 1512
Cryptococcal meningitis
*A. sativum*
humans, 651
Cryptococcosis
Bay R 3783, 448
fluconazole, 980
mice, 980
liposomal amphotericin B, 2055
rodents, 448
SM-8668, 980
*Cryptosporidium parvum*
drug screening, 1498
halofuginone, 1498
in vitro cultivation, 1498
monensin, 1498
CS-533
*P. pseudomallei*, 2027
ddCTP
feline immunodeficiency virus
reverse transcriptase, 1505
CTX-1
molecular epidemiology, 219
8-Cyanodihydroberberine
leishmaniasis
hamsters, 918
Cyclobut-A
human immunodeficiency virus, 287
Cyclobut-G
human immunodeficiency virus, 287
Cyclosporine
ciprofloxacin interactions
bone marrow transplant patients, 1048
pharmacokinetics
bone marrow transplant patients, 1048
ciprofloxacin, 1048
Cyclosporins
*T. niveum*, production by, 121

Cystic fibrosis
  pathogens
    E-1040, 1366
  respiratory pathogens
    fleroxacin, 1880
    tosufloxacin, 2223
Cytochrome P-450
  fluconazole induction potential, 402
Cytomegalovirus
  foscarnet, 373
  ganciclovir, 373
  ganciclovir-foscarnet, 373
  retinitis
    ganciclovir, 176
    ganciclovir-intravenous immune globulin, 176

D4T
  human immunodeficiency virus, 637
  mouse toxicity, 637
Dapsone
  combinations
    oxacillin-resistant *S. aureus*, 1453
    trimethoprim, 1453
  *P. carinii*
    dihydropteroate synthetase, 1075
  *S. aureus*
    oxacillin resistant, 1453
Daptomycin
  comparative activity
    cloxacillin and vancomycin, 2348
    teicoplanin and vancomycin, 2081
    vancomycin, 245
  *E. rhusiopathiae*, 2038
  endocarditis
    rabbits, 2081
    rats, 2348
    *S. aureus*, 2081, 2348
  *Lactobacillus* spp., 543
  *Leuconostoc* spp., 543
  mode of action
    lipoteichoic acid, 1220
  *Pediococcus* spp., 543
  protein binding
    pharmacodynamic model, 1925
    *S. aureus*, 1925
  *S. aureus*, 245
    endocarditis, 2348
    pharmacodynamic model, 1925
    protein binding, 1925
    rats, 2348
  test conditions, 2348
  tobramycin nephrotoxicity
    rats, 139
  ventriculitis
    rabbits, 245
Day-care-center children
  multiresistant *E. coli*
    fecal colonization, 1429
    risk factors, 1429
Deferoxamine
  *P. carinii*
    rat pneumonia, 1833
Dehydropeptidase I
  LJC10,627, 994
Deoxyadenosine
  S-oligomers
    herpes simplex virus type 2, 808
Deoxycytidine
  S-oligomers
    herpes simplex virus type 2, 808
3′-Deoxy-2′,3′-didehydrothymidine
  pharmacokinetics
    rhesus monkeys, 1214
1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-ethyluracil
  woodchuck hepatitis virus, 473
1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine
  woodchuck hepatitis virus, 473
1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluracil
  woodchuck hepatitis virus, 473
Dermatophytosis
  butenafine hydrochloride, 2250
  G2, 1600
  guinea pigs, 1600, 2250
  *M. canis*, 2250
  *T. mentagrophytes*, 2250
Desacetylcefotaxime
  gram-negative organisms
    serum, 2234
Desacetylcefotaxime-cefotaxime
  gram-negative organisms
    serum, 2234
Descarboxy prothrombin
  aztreonam, 1045
Dextran sulfate
  combinations
    dideoxynucleosides, 1991
    2′,3′-dideoxynucleosides, 82
    human immunodeficiency virus, 1991
    human immunodeficiency virus type 1, 82
    soluble CD4, 82
  human immunodeficiency virus, 1991
*dhfrI*
  location, 642
Dichloroflavan
  poliovirus type 2
    mechanisms and activities, 460
6-(3,4-Dichlorophenoxy)-3-(ethylthio)-2-pyridincarbonitrile
  poliovirus
    mode of action, 1259
Dicloxacillin
  protein binding, extravascular
    bactericidal activity, 98
    in vitro capillary model, 98
2′,3′-Didehydro-2′,3′-dideoxythymidine
  hepatitis B virus, 1986
  human immunodeficiency virus, 637
  mouse toxicity, 637
2′,3′-Dideoxy-3′-fluorothymidine
  hepatitis B virus, 1986
Dideoxycytidine
  polymorphonuclear leukocyte function, 1672
    human immunodeficiency virus type 1, 1672
2′,3′-Dideoxycytidine
  feline leukemia virus, 1414
    cat model, 1414
    target cell dependence, 1414
  pharmacokinetics
    cats, 1414
  toxicity
    cats, 1414
Dideoxyinosine
  polymorphonuclear leukocyte function, 1672
    human immunodeficiency virus type 1, 1672
Dideoxynucleosides
  combinations
    dextran sulfate, 1991
    human immunodeficiency virus, 1991
  *E. coli*
    SOS response, 1237
2′,3′-Dideoxynucleosides
  combinations
    dextran sulfate, 82
    human immunodeficiency virus type 1, 82
    soluble CD4, 82
Diethanolamine
  toxicity, selective, 491
Difloxacin
  *M. avium-M. intracellulare*, 1390
DL-α-Difluoromethylornithine
  *T. brucei rhodesiense*, 1183
Dihydropteroate synthetase
  high-pressure liquid chromatography, 1075
Dimethylamino-methyl-propanol
  toxicity, selective, 491
Dirithromycin
  comparative activity
    azithromycin, clarithromycin, erythromycin, and roxithromycin, 1839
  *Enterococcus* spp., 1839
  *H. influenzae*, 1839
  *Listeria* spp., 1839
  *Staphylococcus* spp., 1839
  *Streptococcus* spp., 1839
Disk elution
  MICs and MBCs
    comparative studies, 2128
DNA fingerprinting
  *N. meningitidis*
    genetic diversity, 1523
    penicillin resistance, 1523
DNA gyrase
  cinodine, 1450
  *E. coli*
    KB-5246, 1323
DNA probes
  *N. meningitidis*
    serogroup B, 2277
    sulfonamide resistance, 2277
  OHIO-1, 1570
  SHV-1, 1577
  *Staphylococcus* spp.
    methicillin resistance, 1720
DNA repair processes
  quinolones
    mechanism of action, 2331
DNA-DNA hybridization
  *Staphylococcus* spp.
    tetracycline resistance gene heterogeneity, 1611
Doxycycline
  *C. burnetii*
    lysosomotropic agents, 1512
    P388D$_1$ cells, 1512
  combinations
    brucellosis, 881
    streptomycin, 881
  comparative activity
    josamycin, 937
    pyrimethamine and pyrimethamine-sulfadiazine, 775
  *E. sennetsu*
    P388D$_1$ murine macrophages, 1593
  *M. hominis*
    resistance, 2297

Mediterranean spotted fever, 937
*T. gondii*
macrophages, 775
mice, 775
Duck hepatitis B virus
nucleoside analogs, 1326

E1040
comparative activity
cefpirome and ceftazidime, 914
cystic fibrosis pathogens, 1366
*Enterobacteriaceae*, 914
*Enterococcus* spp., 914
*Streptococcus* spp., 914
*P. aeruginosa*, 914
*P. pseudomallei*, 2027
*Staphylococcus* spp., 914
susceptibility testing, 914
E-3846
anaerobes, 1262
comparative activity
ciprofloxacin, enoxacin, nalidixic acid, norfloxacin, ofloxacin, and pefloxacin, 1262
gram-negative organisms, 1262
gram-positive organisms, 1262
E-4441
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*
mice, 2318
*S. aureus*
mice, 2318
E-4474
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*
mice, 2318
*S. aureus*
mice, 2318
E-4480
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*
mice, 2318
*S. aureus*
mice, 2318
E-4500
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*
mice, 2318
*S. aureus*
mice, 2318
E-4501
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*
mice, 2318
*S. aureus*
mice, 2318
E-4502
comparative activity
ciprofloxacin, norfloxacin, and *S*-(−)-ofloxacin, 2318
*E. coli*
mice, 2318
*Enterobacteriaceae*, 2318
gram-positive organisms, 2318
*P. aeruginosa*, 2318
mice, 2318
*S. aureus*
mice, 2318
EDTA
*M. avium* complex
susceptibility, 759
Eflornithine
*P. carinii*
rat pneumonia, 1833
Egg lecithin-glycocholic acid
mixed micelles
amphotericin B toxicity to mammalian cells, 2415
*Ehrlichia sennetsu*
chloramphenicol, 1593
ciprofloxacin, 1593
co-trimoxazole, 1593
doxycycline, 1593
erythromycin, 1593
gentamicin, 1593
P388D$_1$ murine macrophages, 1593
penicillin, 1593
rifampin, 1593
*Eimeria tenella*
enzyme-linked immunosorbent assay in vitro development, 1435
Endocarditis
amoxicillin, 321
ampicillin, 1068
ampicillin-sulbactam, 728, 1068
*S. aureus*, 728
ciprofloxacin, 273
daptomycin, 2081, 2348
*E. faecalis*, 827
penicillin-netilmicin, 2387
rabbits, 2387
*K. pneumoniae*
ceftriaxone-sulbactam, 2070
rabbits, 2070
ofloxacin, 257
oxacillin, 728
penicillin V, 321
penicillin G-streptomycin, 321
rabbits, 510
ciprofloxacin, 273
*E. coli*, 581
*E. faecalis*, 1068
*S. aureus*, 2081
rats, 728, 827, 2348
*Enterococcus* spp., 1792
methicillin-resistant *S. aureus*, 1143
trimethoprim-sulfamethoxazole, 1792
*S. aureus*, 510, 2348
intravenous drug users, 1227
rabbits, 257, 2081
*S. epidermidis*
ciprofloxacin, 273
methicillin resistant, 273
*S. sanguis*, 510
rabbits, 321
sulbactam-ceftriaxone, 581
teicoplanin, 510, 827, 2081
temafloxacin, 1143
temafloxacin-rifampin, 1143
vancomycin, 1068, 1143, 1227, 2081
vancomycin-rifampin, 1143
Endotoxemia
gentamicin nephrotoxicity
rats, 889
Endotoxin
gentamicin
intracortical accumulation, 576
pharmacokinetics, 576
rats, 576
End-stage renal disease
netilmicin, 128
netilmicin-piperacillin, 128
piperacillin, 128
tobramycin, 128
tobramycin-piperacillin, 128
Enoxacin
*B. parapertussis*, 2287
*B. pertussis*, 2287
bioavailability
elderly patients, 1966
urinary tract infections, 1966
*M. leprae*, 229
*P. pseudomallei*, 2027
pharmacokinetics
elderly patients, 1966
humans, 1491
renal impairment, 1491
urinary tract infections, 1966
*S. pneumoniae*, 467
theophylline clearance
rats, 1739
renal and metabolic, 1739
theophylline coadministration, 803
Enrofloxacin
*A. salmonicida*, 1819
*Entamoeba histolytica*
magainin
analogs, 1824
*Enterobacter aerogenes*
ciprofloxacin, 40
osteomyelitis, 40
*Enterobacter cloacae*
amikacin, 614
BK-218, 349
lomefloxacin, 1088
quinolones
resistance, 173
Ro 23-9424, 189
*Enterobacteriaceae*
AAC(3)-5
gene probe, 1827
nosocomial infections, 1827
*aacC4*
human and animal sources, 1915
acetyltransferase 3-IV
human and animal sources, 1915
Bay v 3522, 813, 1855
β-lactamases

cefoperazone-sulbactam, 622
ceftazidime resistance, 2193
oligotyping, 2210
piperacillin-tazobactam, 622
TEM, 2210
ticarcillin-clavulanate, 622
cefoperazone, 2256
cefoperazone-sulbactam, 2256
ceftazidime
resistance, 2193
E1040, 914
E-4441, 2318
E-4474, 2318
E-4480, 2318
E-4500, 2318
E-4501, 2318
E-4502, 2318
faeriefungin, 1762
HPH-4-I
human and animal sources, 1915
*hphB*
human and animal sources, 1915
hygromycin B 4-I phosphotransferase
human and animal sources, 1915
infrequent
amoxicillin-clavulanic acid, 1605
cefetamet, 1605
ceftriaxone, 1605
ciprofloxacin, 1605
fleroxacin, 1605
trimethoprim-sulfamethoxazole, 1605
LJC10,627, 994
mice, 2318
quinolones
difluorinated, 2318
monofluorinated, 2318
Ro 23-9424, 189
sulbactam, 2256
WIN 57273, 306, 1154
Enterocecitis
*C. difficile*
antibiotic induced, 1348
hamsters, 1348
*Enterococcus faecalis*
ampicillin, 1068
ampicillin-sulbactam, 1068
β-lactamase producing
teicoplanin, 827
β-lactamases
genetic relatedness, 302
plasmids, 302
endocarditis
penicillin-netilmicin, 2387
rabbits, 1068, 2387
rats, 827
gentamicin resistance
gene mobilization, 1278
transposon, 1278
mercury resistance
staphylococcal-like gene, 1287
paradoxical response
penicillin, 314
penicillin
paradoxical effect, 314, 1518
tolerance, 1518
Ro 23-9424, 189
teicoplanin, 827
vancomycin, 1068
WIN 57273, 306, 1376
*Enterococcus faecium*
4′,4″-aminoglycoside nucleotidyltransferase, 1565
aminoglycoside resistance, 1565
glycopeptide resistance
*vanA* cloning and expression, 924
penicillin-induced lysis
lipoteichoic acid release, 1901
penicillin-binding protein saturation, 1901
plasmids
pheromone response, 358
R plasmid, 1565
vancomycin
resistance, 358, 924
WIN 57273, 1154
*Enterococcus* spp.
ampicillin resistant, 1821
BAY v 3522, 1855
dirithromycin, 1839
E1040, 914
endocarditis
rats, 1792
trimethoprim-sulfamethoxazole, 1792
glycopeptide resistance
determinants, 1875
minireview, 2291
LY264826, 2137
peritonitis
ampicillin, 1800
murine, 1800
trimethoprim-sulfamethoxazole, 1800
sparfloxacin, 2283
susceptibility testing
vancomycin, 1846
teicoplanin resistance
minireview, 2291
*vanA*, 1875
vancomycin resistance, 252
in vitro detection, 1846
minireview, 2291
WIN 57273, 568
Enzyme immunoconjugates
glucose oxidase-myeloperoxidase
*C. tropicalis* cytotoxicity, 875
Enzyme-linked immunosorbent assays
*E. tenella*
in vitro development, 1435
Equine herpesvirus 1
HPMPA, 709
(*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 709
Ergosterol biosynthesis
inhibitors
mode of action, 989
*erm*
polymerase chain reaction, 2024
*Erysipelothrix rhusiopathiae*
cefotaxime, 2038
chloramphenicol, 2038
ciprofloxacin, 2038
clindamycin, 2038
daptomycin, 2038
erythromycin, 2038
gentamicin, 2038
imipenem, 2038
netilmicin, 2038
pefloxacin, 2038
penicillin, 2038
piperacillin, 2038
teicoplanin, 2038
tetracycline, 2038
trimethoprim-sulfamethoxazole, 2038
vancomycin, 2038
Erythromycin
*E. rhusiopathiae*, 2038
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
*H. influenzae*, 2075
accumulation, 1787
proton motive force, 1787
*H. pylori*
resistance, 1637
human polymorphonuclear leukocyte cytoplast uptake, 1189
*M. catarrhalis*, 2075
resistance
polymerase chain reaction, 2024
ribosome binding rate constants, 426
*S. lugdunensis*, 2434
*S. pneumoniae*, 467, 2075
*S. typhimurium* SS-B, 853
*Y. enterocolitica*
pigs and pork products, 2423
*Escherichia coli*
amikacin, 295, 614
amino acid deprivation
ampicillin-induced lysis, 164
aminoglycoside susceptibility
salicylate, 786
aminoglycosides, 295
*ampC* induction
β-lactam entry into cytoplasm, 2429
ampicillin
resistance, 361
ampicillin-induced lysis
amino acid deprivation, 164
β-lactamases
β-lactams, 858
nosocomial isolates, 739
SHV-1-like, 581
β-lactams
bioluminescence assay, 102
postantibiotic effect, 102
reduced killing, 1938
resistance patterns and mechanisms, 739
bioluminescence assay
β-lactams, 102
postantibiotic effect, 102
BK-218, 349
cadmium accumulation and toxicity
salicyl alcohol, 2402
salicylate, 2402
*C. freundii* β-lactamase induction
β-lactam entry into cytoplasm, 2429
cefepime, 1932
capsular polysaccharides, 332
phagocytosis, 332
cefoperazone, 1932
ceftazidime, 1932
ceftriaxone, 1932
capsular polysaccharides, 332
phagocytosis, 332
cefuroxime
resistance, 361
chlorhexidine dihydrochloride
human albumin microspheres, 2118
ciprofloxacin
capsular polysaccharides, 332
phagocytosis, 332
DNA gyrase
KB-5246, 1323
E-4441, 2318
E-4474, 2318
E-4480, 2318
E-4500, 2318
E-4501, 2318
E-4502, 2318
endocarditis

rabbits, 581
fleroxacin, 1880
capsular polysaccharides, 332
phagocytosis, 332
gentamicin, 295
*hipQ*
reduced quinolone killing, 1938
K1 serum resistance
β-lactams, 628
ceftazidime, 628
cephaloridine, 628
imipenem, 628
kanamycin, 295
LJC10,627, 994
lomefloxacin, 1088
meningitis
rabbits, 697
mice, 2318
cefepime, 1932
cefoperazone, 1932
ceftazidime, 1932
ceftriaxone, 1932
WIN 57273, 568
multiresistant
day-care-center children, 1429
fecal colonization, 1429
risk factors, 1429
neonatal infections, 361
netilmicin, 295
capsular polysaccharides, 332
phagocytosis, 332
nosocomial isolates
β-lactam resistance, 738
β-lactamases, 739
plasmids, 739
outer membrane mutants
KB-5246, 1323
phagocytosis
cefepime, 332
ceftriaxone, 332
ciprofloxacin, 332
fleroxacin, 332
netilmicin, 332
piperacillin-tazobactam, 697
plasmids
nosocomial isolates, 739
polysaccharides, capsular
cefepime, 332
ceftriaxone, 332
ciprofloxacin, 332
fleroxacin, 332
netilmicin, 332
quinolone resistance, 173
*gyrA* region, 1271
quinolones
difluorinated, 2318
mechanism of action, 2331
monofluorinated, 2318
reduced killing, 1938
resistant
travelers not taking prophylaxis, 515
Ro 23-9424, 189
salicyl
cadmium accumulation and toxicity, 2402
salicyl alcohol
cadmium accumulation and toxicity, 2402
sisomicin, 295
SOS response
azidothymidine, 1237
dideoxynucleosides, 1237
streptomycin
abnormal membrane proteins, 534
sulbactam-ceftriaxone, 581
tosufloxacin, 2223
tricarboxylic acid cycle, 295
trimethoprim resistance
DNA hybridization studies, 2013
trimethoprim resistant
amoxicillin-clavulanic acid, 2047
cefuroxime, 2047
cephalexin, 2047
cephalothin, 2047
trospectomycin
serum sensitivity, 2086
U-78608, 884
WIN 57273, 568
Ethambutol
*M. avium* complex
susceptibility, 759
*M. paratuberculosis*, 366
*M. tuberculosis* $H_{37}Ra$ resistance
cell wall and membrane changes, 1773

Faeriefungin
*Enterobacteriaceae*, 1762
gram-positive organisms, 1762
*H. influenzae*, 1762
*N. gonorrhoeae*, 1762
*N. meningitidis*, 1762
*P. cepacia*, 1762
*Pseudomonadaceae*, 1762
FCE 22891
pharmacokinetics
humans, 1001
FddT
human immunodeficiency virus, 637
mouse toxicity, 637
FEAU
woodchuck hepatitis virus, 473
Feline acquired immunodeficiency syndrome
alpha interferon, 1749
alpha interferon-zidovudine, 1749
zidovudine, 1749
Feline immunodeficiency virus
reverse transcriptase
3′-amino-3′-deoxythymidine 5′-triphosphate, 1505
ddCTP, 1505
ddGTP, 1505
ddTTP, 1505
dTTP analogs, 1505
3′-fluoro-3′-deoxythymidine 5′-triphosphate, 1505
phosphonoformate, 1505
similarity to human immunodeficiency virus enzyme inhibitor sensitivity, 1505
Feline leukemia virus
2′,3′-dideoxycytidine, 1414
cat model
2′,3′-dideoxycytidine, 1414
Fenpropimorph
mode of action, 989
*S. cerevisiae*
sterol synthesis, 989
Ferrets
*H. pylori* model
gastroduodenal disease, 1232
FIAC
woodchuck hepatitis virus, 473

Fibroblasts
azithromycin
intracellular accumulation, 1056
Flavanoids
halogen substituted
mechanisms and activities, 460
poliovirus type 2, 460
Fleroxacin
*B. parapertussis*, 2287
*B. pertussis*, 2287
combinations
pharmacokinetics, 58
probenecid, 58
comparative activity
cefazolin, cefuroxime, chloramphenicol, ciprofloxacin, enoxacin, gentamicin, nafcillin, norfloxacin, ofloxacin, tetracycline, and trimethoprim-sulfamethoxazole, 1880
vancomycin, 21
cystic fibrosis respiratory pathogens, 1880
*E. coli*, 1880
phagocytosis, 332
polysaccharides, capsular, 332
*Enterobacteriaceae*
infrequent, 1605
*H. influenzae*, 1880
*M. leprae*, 229
*P. pseudomallei*, 2027
pharmacokinetics
cholecystectomy, 2375
dogs, 58
humans, 58, 2375
rabbits, 58
skin and skin structure infections, 922
*Pseudomonas* spp., 1880
renal handling, 58
*S. aureus*, 1880
guinea pig prophylaxis, 21
*S. pneumoniae*, 467
theophylline pharmacokinetics
humans, 1249
urinary tract infections
complicated, 409
dose range finding, 409
*X. maltophilia*, 1609
Flucloxacillin
*C. difficile* enterocecitis
hamsters, 1348
inducement, 1348
Fluconazole
*C. albicans*, 196
candidiasis
oral, 2267
vaginal, 909
capillary gas chromatography-ion trap detection, 909
coccidioidomycosis
mice, 928
murine, 13
comparative activity
amphotericin B, 196
clotrimazole, 2267
SCH39304, 928
SDZ89-485, 13
cytochrome P-450 induction
rats, 402
*H. capsulatum*, 524
histoplasmosis
mice, 524
metabolizing enzyme induction

rats, 402
pharmacokinetics
aluminum-magnesium hydroxide, 2032
antacid, 2032
humans, 2032
plasma and vaginal secretion levels, 909
polymorphonuclear leukocytes, 196
Flucytosine
*C. albicans*, 196
*C. glabrata*
mechanisms of action, 1996
comparative activity
amphotericin B, 196
polymorphonuclear leukocytes, 196
2′-Fluorinated arabinosyl-pyrimidine nucleosides
woodchuck hepatitis virus, 473
3′-Fluoro-3′-deoxythymidine
human immunodeficiency virus, 637
mouse toxicity, 637
pharmacokinetics
rhesus monkeys, 1214
3′-Fluoro-3′-deoxythymidine 5′-triphosphate
feline immunodeficiency virus
reverse transcriptase, 1505
3′-Fluoro-5-methyl-deoxycytidine
hepatitis B virus, 1986
5-Fluoroorotate
combinations
mice, 1371
*P. yoelii*, 1371
uridine, 1371
*P. yoelii*
mice, 1371
*m*-Fluoro-phenylalanine
*M. avium* complex
susceptibility, 759
Fluoropyrimidines
*C. glabrata*
metabolism, 1996
$^{19}F$ nuclear magnetic resonance, 1996
Fluoroquinolones
*M. leprae*, 229
theophylline metabolism
human liver microsomes, 594
FMAU
woodchuck hepatitis virus, 473
Foreign body infections
rat model
methicillin-resistant *S. aureus*, 2312
Foscarnet
combinations
cytomegalovirus, 373
ganciclovir, 373
cytomegalovirus, 373
human herpesvirus 6, 2417
Fosfomycin
β-lactam antagonism
*P. aeruginosa*, 2093
*P. aeruginosa*
β-lactam antagonism, 2093
β-lactamases, 2093
outer membrane proteins, 2093
penicillin-binding proteins, 2093
*P. pseudomallei*, 2027
resistance
glutathione *S*-transferase purification, 844
resistance gene
nucleotide sequence, 2016
protein intracellular location, 2016
Tn*2921*, 2016
*S. aureus*
methicillin resistant, 2260
Fungicides
ergosterol biosynthesis inhibition
mode of action, 989
Fusidic acid
mitochondria, 167
*S. aureus*
methicillin resistant, 2260
*S. typhimurium* SS-B, 853
*Fusobacterium nucleatum*
Tet M
transferable, 1836
tetracycline resistance
transferable, 1836
*Fusobacterium* spp.
amoxicillin, 1546
amoxicillin-clavulanic acid, 1546
ampicillin, 657
azlocillin, 657
β-lactamase, 1546
cefoperazone, 657
cefotaxime, 657
cefoxitin, 657, 1546
cefuroxime, 657
fastidious anaerobe agar
comparative studies, 2280
foot rot in goats, 657
imipenem, 657, 1546
metronidazole, 1546
mezlocillin, 657
penicillin G, 657
piperacillin, 657
susceptibility testing, 2280
ticarcillin, 1546
ticarcillin-clavulanic acid, 1546

G2
*T. mentagrophytes* var. *granulare*
guinea pigs, 1600
Ganciclovir
combinations
cytomegalovirus, 176, 373
foscarnet, 373
intravenous immune globulin, 176
retinitis, 176
comparative activity
ganciclovir-intravenous immune globulin, 176
cytomegalovirus, 176, 373
human herpesvirus 6, 2417
retinitis, 176
Ganciclovir-intravenous immune globulin
comparative activity
ganciclovir, 176
cytomegalovirus
retinitis, 176
retinitis
cytomegalovirus, 176
Gastritis
antibiotic transport across gastric mucosa
guinea pig model, 25
Gastroduodenal disease
*H. pylori*
ferret model, 1232
Gene probes
gyrase A, 1889
Gentamicin
*A. calcoaceticus* biovar anitratus, 494
combinations
*C. trachomatis*, 1399
clindamycin, 1399
*E. coli*
tricarboxylic acid cycle, 295
*E. faecalis* resistance
transposon, 1278
*E. rhusiopathiae*, 2038
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
endotoxemia
nephrotoxicity, 889
rats, 889
intracortical accumulation
endotoxin, 576
rats, 576
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
liposomal
beige mice, 967
*M. avium* complex, 967
mice, 343
pharmacokinetics, 235
rats and mice, 235
*S. dublin*, 343
*M. avium* complex
beige mice, 967
nephrotoxicity
endotoxemia, 889
endotoxin, 576
rats, 576, 889
*P. shigelloides*, 159
*Pediococcus* spp., 543
pharmacokinetics
endotoxin, 576
rats, 576
rats
endotoxemia, 889
nephrotoxicity, 889
*S. agalactiae* resistance
high-level chromosomal, 985
*S. lugdunensis*, 2434
*S. typhimurium* SS-B, 853
*Streptococcus* group B resistance
high-level chromosomal, 985
tear concentrations, 1602
Gentamicin-tobramycin-kanamycin resistance
*S. aureus* plasmids, 2106
transposonlike element, 2106
Glucose oxidase immunoconjugate
*C. tropicalis* cytotoxicity, 875
Glutathione *S*-transferase
fosfomycin resistance, 844
purification, 844
Glycopeptides
*E. faecium* resistance, 924
*Enterococcus* resistance
minireview, 2291
*Enterococcus* spp.
resistance determinants, 1875
gram-positive organisms
resistance determinants, 1875
Gonorrhea
uncomplicated
amoxicillin-probenecid, 355
cefixime, 355
ceftriaxone, 148
ofloxacin, 148
GR69153
mode of action, 1806
*tonB*-dependent iron transport system, 1806

Gram-negative organisms
amikacin resistance
4′-aminoglycoside nucleotidyltransferase, 2381
ANT(4′)-II, 2381
aztreonam
serum, 2234
BAY v 3522, 1849, 1855
BMY-28232, 555
BMY-28271
mice, 555
cefoperazone
serum, 2234
cefotaxime
serum, 2234
cefpirome
serum, 2234
ceftazidime
serum, 2234
ceftriaxone
serum, 2234
ciprofloxacin
serum, 2234
desacetylcefotaxime
serum, 2234
desacetylcefotaxime-cefotaxime
serum, 2234
E-3846, 1262
imipenem
serum, 2234
irloxacin, 1262
lomefloxacin, 1107
piperacillin-tazobactam, 1858
pneumonia, 269
sparfloxacin, 2263
ticarcillin
serum, 2234
tobramycin
endotracheal, 269
tobramycin resistance
4′-aminoglycoside nucleotidyltransferase, 2381
ANT(4′)-II, 2381
WIN 57273, 568, 1154, 1858
Gram-positive organisms
aminoglycoside resistance
gene homogeneity, 2164
nucleic acid hybridization, 2164
bacteremia
teicoplanin, 2392
vascular access associated, 2392
BAY v 3522, 1855
bone infections
teicoplanin, 2392
E-3846, 1262
E-4441, 2318
E-4474, 2318
E-4480, 2318
E-4500, 2318
E-4501, 2318
E-4502, 2318
faeriefungin, 1762
glycopeptides
resistance determinants, 1875
irloxacin, 1262
joint infections
teicoplanin, 2392
lomefloxacin, 1107
LY264826, 2137
mice, 2318
quinolones
difluorinated, 2318
monofluorinated, 2318
sparfloxacin, 2263
*vanA*, 1875
WIN 57273, 568, 1154
ddGTP
feline immunodeficiency virus reverse transcriptase, 1505
Guinea pig models
antibiotic transport across gastric mucosa
letter to the editor, 1462
antibiotic transport across gastric mucosa, 25
Gynecologic infections
cefoxitin, 376
clindamycin, 376
metronidazole, 376
*gyr*
*P. aeruginosa*
quinolone resistance, 1273
*gyrA*
*E. coli*
quinolone resistance, 1271
Gyrase A
gene probe, 1889

*Haemophilus ducreyi*
susceptibility testing
minireview, 1303
*Haemophilus influenzae*
amoxicillin, 2075
amoxicillin-clavulanic acid, 2075
ampicillin, 2075
agar dilution plate count method, 1079
killing curve patterns, 1079
amoxicillin-sulbactam, 2075
azithromycin
depressed proton motive force, 1787
transport, 1787
Bay v 3522, 813, 1855
β-lactamase- and non-β-lactamase producing
cefixime, 1456
cefaclor, 2075
cefixime, 1456
cefuroxime, 2075
cephalexin, 2075
cephalothin, 2075
chloramphenicol, 2075
clarithromycin, 1407
clarithromycin–14-hydroxy-clarithromycin, 1407
dirithromycin, 1839
erythromycin, 2075
depressed proton motive force, 1787
transport, 1787
faeriefungin, 1762
fleroxacin, 1880
14-hydroxy-clarithromycin, 1407
NAD analogs, 1473
nicotinamide riboside analogs, 1473
otitis media
clarithromycin, 1407
clarithromycin–14-hydroxy-clarithromycin, 1407
gerbils, 1407
14-hydroxy-clarithromycin, 1407
penicillin-binding proteins, 363
resistance patterns, 2075
sparfloxacin, 2283
susceptibility testing
problems with current recommendations, 1480
tetracycline, 2075
tosufloxacin, 2223
trimethoprim-sulfamethoxazole, 2075
WIN 57273, 1154
*Haemophilus* spp.
LJC10,627, 994
WIN 57273, 306, 568
Halofuginone
*C. parvum*, 1498
Heart surgery
ciprofloxacin tissue penetration, 398
*Helicobacter mustelae*
amoxicillin-metronidazole-bismuth subsalicylate, 1232
chloramphenicol, 1232
ferrets
*H. pylori* model, 1232
tetracycline-metronidazole-bismuth subsalicylate, 1232
*Helicobacter pylori*
cefixime, 2426
clindamycin, 25
ferret model
gastroduodenal disease, 1232
*H. mustelae*, 1232
guinea pig model
letter to the editor, 1462
high-pressure liquid chromatography, 25
penicillin-binding proteins
cefixime, 2426
resistance development
amoxicillin, 1637
bismuth subsalicylate, 1637
ciprofloxacin, 1637
erythromycin, 1637
furazolidone, 1637
metronidazole, 1637
serial passage, 1637
spontaneous, 1637
tobramycin, 1637
Hepatitis A virus
cell culture, 1112
atropine, 1112
atropine-protamine, 1112
protamine, 1112
Hepatitis B virus
3′-amino-5-methyl-deoxycytidine, 1986
3′-chloro-5-methyl-deoxycytidine, 1986
2′,3′-didehydro-2′,3′-dideoxythymidine, 1986
2′,3′-dideoxy-3′-fluorothymidine, 1986
3′-fluoro-5-methyl-deoxycytidine, 1986
pyrimidine nucleosides
modified, 1986
HEPT
analogs
human immunodeficiency virus type 1, 2358
pharmacokinetics, 2358
human immunodeficiency virus type 1, 2358
pharmacokinetics, 2358
Herpes simplex virus
acyclovir-alpha interferon
cell culture, 1178
nucleoside metabolism, 1178
alpha interferon-acyclovir
cell culture, 1178
nucleoside metabolism, 1178
thymidine kinase
explant ganglion cultures, 1285
mouse model, 1285
$N^2$-phenyl-2′-deoxyguanosine, 1285

$N^2$-(*m*-trifluoromethylphenyl)guanine, 1285
type 1
1-β-D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 691, 2431
brovavir, 691
cell culture, 1551
(±)-9-[[(*Z*)-2-(hydroxymethyl)cyclohexyl]methyl]guanine, 1551
L-653,180, 1551
mice, 691, 2431
type 2
deoxyadenosine, 808
deoxycytidine, 808
phosphorothioate oligodeoxynucleotides, 808
thymidine, 808
High-performance liquid chromatography
amphotericin B, 29
ofloxacin, 78
pentamidine
metabolites, 1678
High-pressure liquid chromatography
clindamycin, 25
dihydropteroate synthetase, 1075
*hipQ*
*E. coli*
reduced norfloxacin and ampicillin killing, 1938
Histamine
release
teicoplanin, 765
vancomycin, 765
vancomycin, 550
*Histoplasma capsulatum*
amphotericin B, 524
fluconazole, 524
Sch 39304, 524
Histoplasmosis
amphotericin B, 524
Bay R 3783, 1132
fluconazole, 524
mice, 524, 587, 1132
nikkomycin X, 587
nikkomycin Z, 587
Sch 39304, 524
2HM-HBG
human herpesvirus 6, 2417
HPH-4-I
*Enterobacteriaceae*
human and animal sources, 1915
*hphB*
*Enterobacteriaceae*
human and animal sources, 1915
HPMPA
equine herpesvirus 1, 709
$HSCH_2$ (DL)$CH[CH_2CH(CH_3)_2]CO$-Phe-Ala-$NH_2$
*P. aeruginosa*
elastase, 2065
*Pseudomonas* keratitis, 2065
Human albumin microspheres
chlorhexidine dihydrochloride
catheters, 2118
urinary pathogens, 2118
Human herpesvirus 6
acyclovir, 2417
1-β-D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 2417
3′-azido-3′-deoxythymidine, 2417
foscarnet, 2417
ganciclovir, 2417
2HM-HBG, 2417
9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, 2417
Human immunodeficiency virus
3′-azido-3′-deoxythymidine, 637
cyclobut-A, 287
cyclobut-G, 287
D4T, 637
dextran sulfate, 1991
dextran sulfate-dideoxynucleosides, 1991
2′,3′-didehydro-2′,3′-dideoxythymidine, 637
FddT, 637
3′-fluoro-3′-deoxythymidine, 637
oxetanocin analogs, 287
protease
bacteriological assay, 2337
reverse transcriptase
dTTP analogs, 1505
similarity to feline immunodeficiency virus enzyme inhibitor sensitivity, 1505
susceptibility testing
zidovudine, 436
thymidine analogs, 637
type 1
acrylic acid-vinyl alcohol copolymer, sulfated, 134
acyclouridine derivatives, 2358
5-azacytidine, 206
5-azadeoxycytidine, 206
3′-azido-3′-deoxythymidine, 1297
(−)-carbovir, 1297
2′,3′-dideoxynucleosides-dextran sulfate, 82
2′,3′-dideoxynucleosides-soluble CD4, 82
giant cell formation, 134
HEPT and analogs, 2358
1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine and analogs, 2358
polyvinyl alcohol, sulfated, 134
soluble CD4-dextran sulfate, 82
type 2
acrylic acid-vinyl alcohol copolymer, sulfated, 134
giant cell formation, 134
polyvinyl alcohol, sulfated, 134
zidovudine
pharmacokinetics, 394
zidovudine susceptible and resistant susceptibilities, 436
Human immunodeficiency virus type 1
3′-azido-3′-deoxythymidine
nucleoside dimers in infected lymphocytes, 1061
lymphocyte infection
3′-azido-3′-deoxythymidine nucleotide dimers, 1061
polymorphonuclear leukocytes
dideoxycytidine, 1672
dideoxyinosine, 1672
zidovudine, 1672
reverse transcriptase
illimaquinone, 2009
Human polymorphonuclear leukocyte cytoplasts
antibiotic uptake
chloramphenicol, 1189
clindamycin, 1189
erythromycin, 1189
imipenem, 1189
metronidazole, 1189
penicillin, 1189
roxithromycin, 1189
trimethoprim, 1189
14-Hydroxy-clarithromycin
combinations
clarithromycin, 1407
*H. influenzae*, 1407
*H. influenzae*, 1407
otitis media, 1407
1-[(2-Hydroxyethoxy)methyl]-6-phenylthiothymine
analogs
human immunodeficiency virus type 1, 2358
pharmacokinetics, 2358
human immunodeficiency virus type 1, 2358
pharmacokinetics, 2358
9-[4-Hydroxy-2-(hydroxymethyl)butyl]guanine
human herpesvirus 6, 2417
(±)-9-[[(*Z*)-2-(Hydroxymethyl)cyclohexyl]methyl]guanine
herpes simplex virus type 1
cell culture replication, 1551
reactivation suppression, 1551
Hydroxynaphthoquinones
*P. carinii*
experimental pneumonitis, 225
(*S*)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine
equine herpesvirus 1, 709
Hygromycin B 4-I phosphotransferase
*Enterobacteriaceae*
human and animal sources, 1915
Hysterectomy
cephem pharmacokinetics, 1160
vaginal
cefazolin, 1194
ceftriaxone, 1194

Illimaquinone
human immunodeficiency virus type 1 reverse transcriptase, 2009
Imipenem
*B. distasonis*
resistance, 117
*B. fragilis* group, 479, 671
*Bacteroides* spp., 657, 1546
cross resistance
ciprofloxacin, 2142
*P. aeruginosa*, 2142
*E. coli*
K1 serum resistance, 628
*E. rhusiopathiae*, 2038
*Fusobacterium* spp., 657, 1546
human polymorphonuclear leukocyte cytoplast uptake, 1189
*K. pneumoniae*, 1783
*L. monocytogenes* resistance
PBP 3 alteration, 1695
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
nocardiosis
murine pulmonary, 1766
*P. aeruginosa*
outer membrane proteins, 52
transport, 52
*P. pseudomallei*, 2027
*P. shigelloides*, 159
*Pediococcus* spp., 543
pharmacokinetics
premature infants, 1172

*S. typhimurium* SS-B, 853
serum, 2234
*Y. enterocolitica*
pigs and pork products, 2423
Imipenem-cilastatin
comparative activity
ceftazidime, 1336
neutropenic patients, 1336
pharmacokinetics
premature infants, 1172
Immunoglobulin A myeloma
vancomycin
pharmacokinetics, 1459
Influenza virus A
LY217896, 2156
mice, 2156
sodium salt, 2156
rimantadine
safety and prophylactic efficacy, 1633
1,3,4-thiadiazol-2-ylcyanamide, 2156
mice, 2156
sodium salt, 2156
Influenza virus B
LY217896, 2156
ferrets, 2156
mice, 2156
sodium salt, 2156
1,3,4-thiadiazol-2-ylcyanamide, 2156
ferrets, 2156
mice, 2156
sodium salt, 2156
Inoculum effect
*Staphylococcus* spp.
cephalosporins, 505
Interferon
alpha
cell culture, 1178
feline acquired immunodeficiency syndrome, 1749
herpes simplex virus, 1178
nucleoside metabolism, 1178
pharmacokinetics, 1749
liposomes
composition, 107
in vitro diffusion, 107
preparation, 107
Intravenous drug abusers
vancomycin pharmacokinetics, 792
Intravenous immunoglobulins
anti-infective agents
minireview, 1463
combinations
cytomegalovirus, 176
ganciclovir, 176
retinitis, 176
minireview, 1463
In vitro models
antibacterial activity
lomefloxacin, 1107
antimicrobial effect kinetics, 1312
capillary
extravascular protein binding, 98
Irloxacin
anaerobes, 1262
comparative activity
ciprofloxacin, enoxacin, nalidixic acid, norfloxacin, ofloxacin, and pefloxacin, 1262
gram-negative organisms, 1262
gram-positive organisms, 1262
Isoflavans
halogenated
mechanisms and activities, 460
poliovirus type 2, 460
Isoflavenes
poliovirus type 2
mechanisms and activities, 460
Isoniazid
amphipathic derivative
*M. avium* complex, 2061
combinations
chloroquine, 2217
tubercle bacilli, 2217
1-Isonicotinyl-2-palmitoyl hydrazine
combinations
*m*-fluorophenylalanine, 2061
*M. avium* complex, 2061
*M. avium* complex, 2061
Itraconazole
combinations
*C. albicans*, 2304
pentamidine, 2304

Joint infections
gram-positive organisms
teicoplanin, 2392
Josamycin
comparative activity
doxycycline, 937
Mediterranean spotted fever, 937

Kanamycin
*E. coli*
tricarboxylic acid cycle, 295
KB-5246
*E. coli*
DNA gyrase, 1323
outer membrane mutants, 1323
*S. typhimurium*
outer membrane mutants, 1323
Keratitis
*Pseudomonas* spp.
thiol-based peptide, 2065
Ketoconazole
*C. albicans*, 196
combinations
*C. albicans*, 2304
pentamidine, 2304
*T. cruzi*, 2097
terbinafine, 2097
comparative activity
amphotericin B, 196
polymorphonuclear leukocytes, 196
*T. cruzi*
ultrastructural alterations, 2097
*Klebsiella oxytoca*
U-78608, 884
*Klebsiella ozaenae*
cephalosporin resistance
SHV-2, 1725
*Klebsiella pneumoniae*
aztreonam, 1783
bacteremia
ceftazidime-amikacin failure, 1290
β-lactam resistance
MIR-1, 2200
β-lactamases, 2070
ceftazidime resistance, 1290
extended spectrum, 1783
MIR-1, 2200
nucleotide sequence, 2439
BMY 28100, 1783
cefaclor, 1783
cefadroxil, 1783
cefatrizine, 1783
cefcanel, 1783
cefetamet, 1783
cefixime, 1783
cefotaxime, 1783
cefotiam, 1783
cefpodoxime, 1783
ceftazidime, 1783
β-lactamase, 1290
resistance, 1290
ceftibuten, 1783
ceftriaxone-sulbactam, 2070
cefuroxime, 1783
cephalexin, 1783
cephradine, 1783
ciprofloxacin, 40
endocarditis
rabbits, 2070
imipenem, 1783
lomefloxacin, 1088
loracarbef, 1783
meningitis
ceftazidime-amikacin failure, 1290
meropenem, 1783
mice
WIN 57273, 568
moxalactam, 1783
osteomyelitis, 40
Ro 23-9424, 189
SHV-5
nucleotide sequence, 2439
TEM-3, 2070
tigemonam, 1783
WIN 57273, 568
*Klebsiella* spp.
ampicillin
resistance, 361
cefuroxime
resistance, 361
neonatal infections, 361

L-653,180
herpes simplex virus type 1
cell culture replication, 1551
reactivation suppression, 1551
*Lactobacillus casei*
combinations
*M. fortuitum*, 632
mice, 632
ofloxacin, 632
*Lactobacillus* spp.
chloramphenicol, 543
daptomycin, 543
gentamicin, 543
imipenem, 543
minocycline, 543
penicillin, 543
teicoplanin, 543
vancomycin, 543
vancomycin resistant
susceptibility testing, 543
*Legionella pneumophila*
pneumonia
guinea pigs, 2122
sparfloxacin, 2122
serogroup 1
ciprofloxacin, 1733
intracellular multiplication, 1733
ofloxacin, 1733
pefloxacin, 1733
postantibiotic effect, 1733

*Legionella* spp.
sparfloxacin, 2122
WIN 57273, 1154
*Leishmania donovani*
bis(benzyl)polyamine analog, 722
MDL 27695, 722
*Leishmania mexicana*
amphotericin B
heat-transformed amastigotes, 1584
promastigotes, 1584
*Leishmania mexicana amazonensis*
pentamidine, 1381
analogs, 1381
Leishmaniasis
berberine, 918
derivatives, 918
bis(benzyl)polyamine analog, 722
hamsters, 918
MDL 27695, 722
murine, 722
Letters to the editor
amikacin
*M. avium*, 378
*H. pylori*
guinea pig model, 1462
*M. avium*
amikacin, 378
*Leuconostoc* spp.
chloramphenicol, 543
daptomycin, 543
gentamicin, 543
imipenem, 543
minocycline, 543
penicillin, 543
teicoplanin, 543
vancomycin, 543
vancomycin resistant
susceptibility testing, 543
Liposomes
amphotericin B
cryptococcosis, 2055
mice, 2055
gentamicin
in vivo activity, 235
mice, 343
pharmacokinetics, 235
*S. dublin*, 343
interferon
composition, 107
in vitro diffusion, 107
preparation, 107
Lipoteichoic acid
daptomycin
mode of action, 1220
release
*E. faecium* penicillin susceptibility, 1901
*Listeria monocytogenes*
β-lactam resistance
PBP 3 alteration, 1695
β-lactams
penicillin-binding proteins, 539
imipenem resistance
PBP 3 alteration, 1695
mice
WIN 57273, 568
penicillin-binding proteins
β-lactams, 539
Ro 23-9424, 189
WIN 57273, 306, 568
*Listeria* spp.
dirithromycin, 1839
LJC10,627
*B. fragilis*, 994
β-lactamases, 994
*Branhamella* spp., 994
comparative activity
ceftazidime and imipenem, 994
dehydropeptidase I stability, 994
*E. coli*, 994
*Enterobacteriaceae*, 994
*Haemophilus* spp., 994
*Neisseria* spp., 994
*P. aeruginosa*, 994
*Staphylococcus* spp., 994
*X. maltophilia*, 994
Lomefloxacin
absorption
food, 1797
humans, 1797
*B. parapertussis*, 2287
*B. pertussis*, 2287
bronchial mucosal concentrations, 1017
comparative activity
ciprofloxacin, enoxacin, norfloxacin, and ofloxacin, 1088
concentrations in serum, 1017
*E. cloacae*, 1088
*E. coli*, 1088
gram-negative organisms, 1107
gram-positive organisms, 1107
in vitro model
antibacterial activity, 1107
*K. pneumoniae*, 1088
mode of action, 1088
*P. aeruginosa*, 1088
*P. pseudomallei*, 2027
pharmacokinetics
food, 1797
hemodialysis, 2364
humans, 17, 150, 1797, 2364
renal function, 17, 2364
prostate concentrations, 2398
*S. aureus*, 1088
*S. marcescens*, 1088
*S. pneumoniae*, 467
theophylline pharmacokinetics
humans, 1254
Loracarbef
*B. parapertussis*, 1442
*B. pertussis*, 1442
*K. pneumoniae*, 1783
middle ear fluid concentrations, 2030
*S. pneumoniae*, 467
Lovastatin
*S. cerevisiae*
azole activity, 1660
sterol levels, 1660
Lower respiratory tract infections
cefepime
safety and efficacy, 954
LY217896
influenza virus A, 2156
mice, 2156
influenza virus B, 2156
ferrets, 2156
mice, 2156
sodium salt
influenza virus A, 2156
influenza virus B, 2156
LY264826
*B. cereus*, 2137
*C. difficile*, 2007
*C. jeikeium*, 2137
cancer patient isolates, 2137
comparative activity
oxacillin, teicoplanin, and vancomycin, 2137
vancomycin, 2007
*Enterococcus* spp., 2137
gram-positive organisms, 2137
*S. aureus*, 2007
*S. pyogenes*, 2137
*Staphylococcus* spp., 2137
Lyme disease/borreliosis
hamsters
cefuroxime, 2133
Lymphadenectomy
cephem pharmacokinetics, 1160
Lymphomas
aminoglycosides
dosage, 702
pharmacokinetics, 702

Macrolides
ribosome binding rate constants
azithromycin, 426
erythromycin, 426
*S. epidermidis* resistance
energy-dependent efflux pump, 1973
plasmid pNE24, 1973
Magainin
analogs
*B. hominis*, 1824
*E. histolytica*, 1824
*T. cruzi*, 1824
Magnesium-aluminum hydroxide
ofloxacin
bioavailability, 2436
humans, 2436
pharmacokinetics, 2436
Malaria
ciprofloxacin, 2327
mice, 2327
pefloxacin, 2327
Mathematical model
murine pneumonia, 326
susceptibility data, 1769
MDL 27695
*L. donovani*
antimony susceptible and resistant, 722
MDL 73811
*T. b. brucei*
mice, 1485
*T. b. rhodesiense*
mice, 1485
*mec*
insertional inactivation, 1777
*mecA*
*Staphylococcus* spp.
methicillin resistant, 170
*mecR*
PBP 2′ expression, 1703
Mediterranean spotted fever
doxycycline, 937
josamycin, 937
Mefloquine
*P. falciparum*
peroxidase-hydrogen peroxide system, 1981
Meglumine antimonate
leishmaniasis
hamsters, 918

Membrane transfer assay
chlorhexidine, 153
mutans streptococci, 153
potassium iodide, 153
stannous fluoride, 153
Meningeal inflammatory response
rabbits
pentoxifylline, 837
Meningitis
*A. sativum*
cryptococcal, 651
humans, 651
cefepime, 733
coccidioidal
mice, 663
SCH39304, 663
*K. pneumoniae*
β-lactamase, 1290
ceftazidime-amikacin failure, 1290
mice
cefepime, 733
piperacillin-tazobactam, 697
rabbits
*E. coli*, 697
SCH39304, 663
Mercuric oxide
bacterial blepharitis
efficacy and safety, 610
humans, 610
Mercury
*E. faecalis* resistance
staphylococcal-like gene, 1287
Meropenem
inflammatory exudate penetration, 1515
*K. pneumoniae*, 1783
*P. pseudomallei*, 2027
pharmacokinetics
humans, 1515
*S. typhimurium* SS-B, 853
Methicillin
*S. typhimurium* SS-B, 853
3-Methoxysampangine
antifungal activity, 529
*C. patens*, 529
*N*-Methylthiotetrazole
pharmacokinetics and production
cefmetazole, 2369
cefoperazone, 2369
cefotetan, 2369
humans, 2369
Metronidazole
*B. fragilis* group, 479, 671
*Bacteroides* spp., 1546
combinations
amoxicillin, 1232
bismuth subsalicylate, 1232
*H. mustelae*, 1232
tetracycline, 1232
*Fusobacterium* spp., 1546
*H. pylori*
resistance, 1637
human polymorphonuclear leukocyte cytoplast uptake, 1189
pelvic peritoneal fluid penetration, 376
Mezlocillin
*B. fragilis* group, 671
*Bacteroides* spp., 657
*Fusobacterium* spp., 657
*P. shigelloides*, 159
Microbial kinetics
two-compartment radioassay, 1035
*Microsporum canis*
dermatophytosis
butenafine hydrochloride, 2250
guinea pigs, 2250
Middle ear fluid
loracarbef concentrations, 2030
Minireviews
amphotericin B
delivery systems, 381
mechanisms of action, 183
biofilm bacteria
susceptibility testing, 2043
cephalosporin biosynthesis
molecular biology, 943
chancroid
treatment, 1308
*Enterococcus* spp.
glycopeptide resistance, 2291
glycopeptides
*Enterococcus* resistance, 2291
*H. ducreyi*
susceptibility testing, 1303
intravenous immunoglobulins
anti-infective agents, 1463
*P. carinii* pneumonia
diagnosis, 499
prevention, 499
treatment, 499
penicillin biosynthesis
molecular biology, 943
quinolones
plasmid-mediated resistance, 681
susceptibility
biofilms, 1865
cell cycle, 1865
dormancy, 1865
growth rate, 1865
stringent response, 1865
susceptibility testing
batch and continuous culture studies, 1623
biofilm bacteria, 2043
cell envelope modification, 1623
growth rate, 1623
teicoplanin
*Enterococcus* resistance, 2291
topoisomerases
in vitro assays, 1, 8
quinolones, 1, 8
vancomycin
*Enterococcus* resistance, 2291
Minocycline
*A. calcoaceticus* biovar anitratus, 494
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
*P. pseudomallei*, 2027
*Pediococcus* spp., 543
MIR-1
characterization, 2200
Mitochondria
chloramphenicol, 167
ciprofloxacin, 167
clindamycin, 167
fusidic acid, 167
rifampin, 167
tetracyclines, 167
Mixed micelles
egg lecithin-glycocholic acid
amphotericin B toxicity to mammalian cells, 2415
Models
mathematical
murine pneumonia, 326
mouse
*M. avium*, 1629
thymectomized CD4 T-cell deficient, 1629
rats
foreign body infections, 2312
methicillin-resistant *S. aureus*, 2312
Monensin
*C. parvum*, 1498
*Moraxella catarrhalis*
amoxicillin-clavulanic acid, 2075
ampicillin, 2075
ampicillin-sulbactam, 2075
cefaclor, 2075
cefuroxime, 2075
cephalexin, 2075
cephalothin, 2075
chloramphenicol, 2075
erythromycin, 2075
penicillin, 2075
resistance patterns, 2075
sparfloxacin, 2283
tetracycline, 2075
tetracycline resistance
genetic basis, 1816
trimethoprim-sulfamethoxazole, 2075
Moxalactam
*B. fragilis* group, 479, 671
*K. pneumoniae*, 1783
Mupirocin
*S. aureus*
methicillin resistant, 2260
Murine acquired immunodeficiency syndrome
3′-azido-3′-deoxythymidine, 605
model
antiretrovirus drugs, 605
Murine leukemia virus
murine acquired immunodeficiency syndrome model, 605
Mutans streptococci
chlorhexidine
membrane transfer assay, 153
potassium iodide
membrane transfer assay, 153
stannous fluoride
membrane transfer assay, 153
*Mycobacterium avium*
amikacin
letter to the editor, 378
rifabutin
thymectomized, CD4 T-cell-deficient mouse model, 1629
*Mycobacterium avium* complex
beige mice, 967
clarithromycin
human macrophages, 1508
gentamicin, 967
isoniazid
amphipathic derivative, 2061
1-isonicotinyl-2-palmitoyl hydrazine, 2061
1-isonicotinyl-2-palmitoyl hydrazine–*m*-fluorophenylalanine, 2061
liposomal gentamicin, 967
rifabutin
human macrophages, 1508
sparfloxacin, 2442
sparfloxacin-ethambutol, 2442
sparfloxacin-ethambutol-rifampin, 2442
sulfisoxazole
human macrophages, 1508
susceptibility

cell envelope synthesis inhibitors, 759
colistin, 759
EDTA, 759
ethambutol, 759
*m*-fluoro-phenylalanine, 759
DL-norleucine, 759
*Mycobacterium avium-M. intracellulare*
A-56620, 1390
antibiogram patterns
strains from patients with and without acquired immunodeficiency syndrome and from animals, 1390
cefazolin, 1390
cefotaxime, 1390
ceftizoxime, 1390
cephapirin, 1390
difloxacin, 1390
SK&F 88070, 1390
spectinomycin, 1390
WIN 57273, 1154
*Mycobacterium fortuitum*
mice
ofloxacin-*L. casei*, 632
*Mycobacterium leprae*
A-62412, 229
A-63345, 229
A-67937, 229
A-69137, 229
amifloxacin, 229
AT-4140, 229
ciprofloxacin, 229
enoxacin, 229
fleroxacin, 229
fluoroquinolones, 229
norfloxacin, 229
ofloxacin, 229
OPC-17066, 229
OPC-17100, 229
PD-117596, 229
PD-124816, 229
PD-127391, 229
pefloxacin, 229
T-3262, 229
temafloxacin, 229
WIN-57273, 229
*Mycobacterium paratuberculosis*
amikacin, 366
cefazolin, 366
ciprofloxacin, 366
clofazimine, 366
ethambutol, 366
rifabutin, 366
streptomycin, 366
susceptibility testing
colonial morphology, 2300
Tween 80, 2300
*Mycobacterium* spp.
ciprofloxacin, 65
N-substitution analogs, 496
resistance, mutational, 65
ofloxacin, 65
Win 57273
MICs and MBCs, 770
*Mycobacterium tuberculosis*
$H_{37}Ra$
cell wall and membrane changes, 1773
ethambutol resistance, 1773
*Mycoplasma hominis*
clindamycin, 2297
doxycycline
resistance, 2297
tetracycline
resistance, 2297
Myeloperoxidase immunoconjugate
*C. tropicalis* cytotoxicity, 875

NAD
analogs
*H. influenzae*, 1473
Nafcillin
comparative activity
cefonicid, 654
*S. typhimurium* SS-B, 853
skin infections, 654
skin structure infections, 654
Nalidixic acid
*P. pseudomallei*, 2027
*S. typhimurium* SS-B, 853
*T. cruzi*
topoisomerase II, 1707
*Neisseria gonorrhoeae*
azithromycin
piliation and attachment, 2445
sub-MIC, 2445
cefpodoxime proxetil, 371
faeriefungin, 1762
penicillinase-producing and -nonproducing
ceftriaxone, 148
gonorrhea, uncomplicated, 148
ofloxacin, 148
tosufloxacin, 971
urethritis
ceftriaxone, 819
ciprofloxacin, 819
WIN 57273, 1154
*Neisseria lactamica*
genetic transformation
meningococcal β-lactam resistance, 2269
*Neisseria meningitidis*
β-lactam resistance
transmission from commensal neisseriae, 2269
faeriefungin, 1762
penicillin-binding proteins
genetic diversity, 1523
sulfonamide resistance
DNA probe, 2277
*Neisseria polysaccharea*
genetic transformation
meningococcal β-lactam resistance, 2269
*Neisseria* spp.
LJC10,627, 994
WIN 57273, 306, 568
Neonates
ampicillin, 361
cefuroxime, 361
*E. coli*
cross-resistance, 361
*Klebsiella* spp.
cross-resistance, 361
Nephrotoxicity
amphotericin B
mechanism, 241
pentoxifylline, 241
rat model, 241
gentamicin
endotoxemia, 889
endotoxin, 576
rats, 576, 889
tobramycin
daptomycin, 139
piperacillin, 1020
rats, 139
sodium, 1020
ticarcillin, 1020
vancomycin, 139
Netilmicin
combinations
end-stage renal disease, 128
pharmacokinetics, 128
piperacillin, 128
*E. coli*
phagocytosis, 332
polysaccharides, capsular, 332
tricarboxylic acid cycle, 295
*E. rhusiopathiae*, 2038
pharmacokinetics
end-stage renal disease, 128
humans, 128
Neutropenic patients
aminoglycosides
dosage, 702
pharmacokinetics, 702
ceftazidime, 1336
co-trimoxazole
prevention of infection after chemotherapy, 215
imipenem-cilastatin, 1336
infection prophylaxis after chemotherapy
co-trimoxazole, 215
ofloxacin, 215
ofloxacin
prevention of infection after chemotherapy, 215
sparfloxacin
gram-positive and gram-negative isolates, 2263
teicoplanin
coagulase-negative staphylococci, 901
pharmacokinetics, 1642
vancomycin
coagulase-negative staphylococci, 901
pharmacokinetics, 1642
*nfxC*
mapping, 1757
Nicotinamide ribosides
analogs
*H. influenzae*, 1473
Nikkomycin X
*A. fumigatus*, 587
*B. dermatitidis*, 587
blastomycosis
mice, 587
*C. immitis*, 587
coccidioidomycosis
mice, 587
histoplasmosis
mice, 587
pharmacokinetics
mice, 587
Nikkomycin Z
*A. fumigatus*, 587
*B. dermatitidis*, 587
blastomycosis
mice, 587
*C. immitis*, 587
coccidioidomycosis
mice, 587
histoplasmosis
mice, 587
pharmacokinetics
mice, 587
Nitrocefin competition assay
β-lactamases
inhibition profiles, 2184

Nitroguaiacol ether
streptomycin derivatives
properties, 1908
purification, 1908
synthesis, 1908
Nocardiosis
murine pneumonia
amikacin, 1766
ceftriaxone, 1766
ciprofloxacin, 1766
imipenem, 1766
sulfadiazine, 1766
Nonfermenters
cefoperazone, 2256
cefoperazone-sulbactam, 2256
sulbactam, 2256
Norfloxacin
absorption
antacids, 432
cholera, 939
comparative activity
trimethoprim-sulfamethoxazole, 939
*E. coli*
*hipQ*, 1938
reduced killing, 1938
*M. leprae*, 229
*P. aeruginosa* PAO
resistant mutant, 1757
*P. pseudomallei*, 2027
*X. maltophilia*, 1609
*Y. enterocolitica*
pigs and pork products, 2423
DL-Norleucine
*M. avium* complex
susceptibility, 759
Nosocomial infections
*E. coli*
β-lactam resistance, 739
β-lactamases, 739
plasmids, 739
*Enterobacteriaceae*
AAC(3)-5, 1827
*S. aureus*
carrier state, 1655
methicillin resistant, 1655
novobiocin-rifampin, 1655
Novobiocin
combinations
methicillin-resistant *S. aureus*, 1655
rifampin, 1655
*S. typhimurium* SS-B, 853
*T. cruzi*
topoisomerase II, 1707
$^{19}$F nuclear magnetic resonance
*C. glabrata*
fluoropyrimidine metabolism, 1996
Nucleic acid hybridization
aminoglycoside resistance
gram-positive cocci, 2164
Nucleoside analogs
combinations
alpha interferon, 1178
herpes simplex virus, 1178
comparative activity
duck hepatitis B virus, 1326
Nucleotide metabolism inhibitors
*P. falciparum*, 1393

Ocular infections
gentamicin
tear concentrations, 1602
ofloxacin
tear concentrations, 1602
tobramycin
tear concentrations, 1602
Ofloxacin
*B. parapertussis*, 2287
*B. pertussis*, 2287
bioavailability
antacids, 2436
calcium carbonate, 2436
humans, 2436
magnesium-aluminum hydroxide, 2436
combinations
*L. casei*, 632
*M. fortuitum*, 632
mice, 632
comparative activity
ceftriaxone, 148
co-trimoxazole, 215
vancomycin, 257
endocarditis
rabbits, 257
gonorrhea
uncomplicated, 148
high-performance liquid chromatography, 78
intraoperative concentrations
cholecystitis, 2354
humans, 2354
serum, bile, gall bladder tissue, 2354
*L. pneumophila*
intracellular multiplication, 1733
postantibiotic effect, 1733
serogroup 1, 1733
*M. leprae*, 229
*Mycobacterium* spp., 65
*N. gonorrhoeae*
penicillinase-producing and -nonproducing, 148
neutropenic patients
prevention of infection after chemotherapy, 215
*P. pseudomallei*, 2027
pharmacokinetics
antacids, 2436
calcium carbonate, 2436
humans, 78, 455, 2436
magnesium-aluminum hydroxide, 2436
renal impairment, 455
*S. aureus*, 257
methicillin resistant, 2260
*S. pneumoniae*, 467
septicemia
irradiated mice, 1387
*P. aeruginosa*, 1387
*T. cruzi*
topoisomerase II, 1707
tear concentrations, 1602
(−)-Ofloxacin
comparative activity
ofloxacin, 277
intracellular activity, 277
*S. aureus*, 277
uptake, 277
OHIO-1
cloning, 1577
DNA probe, 1570
SHV-1 family, 1570
Oligotyping
β-lactamases
TEM, 2210
OPC-17066
*M. leprae*, 229
OPC-17100
*M. leprae*, 229
Ornidazole
pharmacokinetics
colorectal surgery, 1921
humans, 1921
tissue concentrations
colorectal surgery, 1921
Osteomyelitis
cephalosporin, 40
ciprofloxacin, 40, 849, 1014
ciprofloxacin-rifampin, 1014
*E. aerogenes*, 40
*K. pneumoniae*, 40
nafcillin-aminoglycoside, 40
*P. aeruginosa*, 40
ciprofloxacin, 849
pefloxacin, 1014
pefloxacin-rifampin, 1014
rats
methicillin-resistant *S. aureus*, 1014
vancomycin, 1014
vancomycin-rifampin, 1014
Otitis media
clarithromycin, 1407
clarithromycin–14-hydroxy-clarithromycin, 1407
*H. influenzae*
gerbils, 1407
14-hydroxy-clarithromycin, 1407
Outer membrane proteins
*P. aeruginosa*
fosfomycin, 2093
imipenem transport, 52
*S. typhi*
chloramphenicol resistance, 1715
porinless, 1715
Outer membranes
cephalosporin penetration, 337
OXA-6
cloning, 1577
Oxacillin
comparative activity
ampicillin-sulbactam, 728
oxacillin-sulbactam, 728
endocarditis
rats, 728
*S. aureus*, 728
*S. lugdunensis*, 2434
Oxetanocin analogs
human immunodeficiency virus, 287
Oxoenoxacin
pharmacokinetics
humans, 1491
renal impairment, 1491
4-Oxoenoxacin
theophylline disposition
rats, 1739

Paradoxical effect
β-lactams
*P. vulgaris*, 94
cefmenoxime
*P. vulgaris*, 94
*E. faecalis*
penicillin, 314, 1518
*Pasteurella multocida*
BAY v 3522, 1855
PD-117558
*Pseudomonas* spp., 1812
*X. maltophilia*, 1609, 1812

PD-117596
*A. salmonicida*, 1819
*M. leprae*, 229
*Pseudomonas* spp., 1812
*S. aureus*
methicillin resistant, 2260
*X. maltophilia*, 1609, 1812
PD-124816
*M. leprae*, 229
PD-127391
*A. salmonicida*, 1819
*M. leprae*, 229
*Pseudomonas* spp., 1812
*S. aureus*
methicillin resistant, 2260
*X. maltophilia*, 1609, 1812
*Pediococcus* spp.
chloramphenicol, 543
daptomycin, 543
gentamicin, 543
imipenem, 543
minocycline, 543
penicillin, 543
teicoplanin, 543
vancomycin, 543
vancomycin resistant
susceptibility testing, 543
Pefloxacin
*B. parapertussis*, 2287
*B. pertussis*, 2287
comparative activity
ciprofloxacin, 2327
vancomycin and vancomycin-rifampin, 1014
*E. rhusiopathiae*, 2038
*L. pneumophila*
intracellular multiplication, 1733
postantibiotic effect, 1733
serogroup 1, 1733
*M. leprae*, 229
malaria
mice, 2327
osteomyelitis
rats, 1014
*P. yoelii*
mice, 2327
*S. aureus*
methicillin resistant, 1014, 2260
*S. pneumoniae*, 467
Pefloxacin-rifampin
comparative activity
vancomycin and vancomycin-rifampin, 1014
osteomyelitis
rats, 1014
*S. aureus*
methicillin resistant, 1014
Penicillin
biosynthesis
minireview, 943
molecular biology, 943
*E. faecalis*
paradoxical effect, 314, 1518
tolerance, 1518
*E. faecium* susceptibility
lipoteichoic acid release, 1901
penicillin-binding protein saturation, 1901
*E. rhusiopathiae*, 2038
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
human polymorphonuclear leukocyte cytoplast uptake, 1189
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
*M. catarrhalis*, 2075
*Pediococcus* spp., 543
*S. lugdunensis*, 2434
*S. pneumoniae*, 2075
autolysis-dependent and -independent killing mechanisms, 33
*Y. enterocolitica*
pigs and pork products, 2423
Penicillin G
*Bacteroides* spp., 657
combinations
endocarditis, experimental, 321
*S. sanguis*, 321
streptomycin, 321
*Fusobacterium* spp., 657
*S. pneumoniae*, 467
Penicillin G-streptomycin
comparative activity
amoxicillin and penicillin V, 321
endocarditis
rabbits, 321
*S. sanguis*, 321
Penicillin V
comparative activity
amoxicillin and penicillin G-streptomycin, 321
endocarditis
rabbits, 321
penicillin-binding protein labeling, 718
*S. sanguis*, 321
Penicillin-binding proteins
*E. faecium*, 1901
*H. influenzae*, 363
*H. pylori*
cefixime, 2426
*L. monocytogenes*
β-lactam resistance, 1695
β-lactams, 539
imipenem resistance, 1695
PBP 3 alteration, 1695
*N. meningitidis*
genetic diversity, 1523
*P. aeruginosa*
fosfomycin, 2093
PBP 2′
*mecR*, 1703
PBP 2A
methicillin-resistant *S. aureus*, 1777
*S. saprophyticus*, 1780
penicillin V labeling reagent, 718
*S. aureus*
methicillin resistant, borderline, 911
SM-7338, 484
*S. epidermidis*
methicillin resistant, 1691
*S. haemolyticus*
methicillin resistant, 1691
*S. hominis*
methicillin resistant, 1691
*S. simulans*
methicillin resistant, 1691
U-78608, 884
Penicillin-netilmicin
*E. faecalis*
aminoglycoside dose, 2387
endocarditis, 2387
rabbits, 2387
endocarditis
aminoglycoside dose, 2387
*E. faecalis*, 2387
rabbits, 2387
Pentamidine
analogs
*L. m. amazonensis*, 1381
*P. falciparum*, 1381
structure-activity relationships, 1381
*C. albicans*, 2304
combinations
amphotericin B, 470
*C. albicans*, 2304
humans, 470
itraconazole, 2304
ketoconazole, 2304
renal failure, 470
high-performance liquid chromatography, 1678
*L. m. amazonensis*, 1381
metabolites, 1678
N-hydroxylation, 1678
*P. falciparum*, 1381
*Staphylococcus* spp., 1795
structure-activity relationships, 1381
Pentamidine analogs
*P. carinii*
pneumonia, 1026
rats, 1026
Pentoxifylline
amphotericin B nephrotoxicity
rat model, 241
analogs
efficacy, 1100
mice, 1100
pharmacokinetics, 1100
*S. aureus* infection, 1100
toxicity, 1100
efficacy
mice, 1100
*S. aureus* infection, 1100
meningeal inflammatory response
rabbits, 837
pharmacokinetics
mice, 1100
*S. aureus*
mice, 1100
toxicity
mice, 1100
Peptidoglycan biosynthesis
ramoplanin, 413
Peritonitis
murine
ampicillin, 1800
*Enterococcus* spp., 1800
trimethoprim-sulfamethoxazole, 1800
Peroxidase-hydrogen peroxide system
chloroquine, quinine, and mefloquine potentiation
*P. falciparum*, 1981
Pharmacokinetics
amifloxacin
elderly subjects, 751
humans, 974
amikacin
humans, 614
preterm infants, 265
spinal cord injury serum and pressure sore tissue, 1422
aminoglycosides
hematologic malignancy, 702
neutropenic patients, 702
amphotericin B
aerosol, 29
intraperitoneal, 29
rats, 29
antipyrine

ciprofloxacin, 2148
rats, 2148
AT-4140
animals, 89
BMY-28100
humans, 202
cefaclor
food, 1210
humans, 1198, 1204, 1210
cefepime
humans, 1118, 1885
rats, 733
respiratory tract infections, 1885
cefetamet
hepatic cirrhosis, 1318
cefetamet pivoxil
antacid, 1744
food and fluid intake, 1556
hepatic cirrhosis, 1318
humans, 1556, 1744
ranitidine, 1744
cefmetazole
humans, 519
renal function, 519
young and elderly subjects, 1944
cefoperazone
elderly patients, 1007
cefotaxime
elderly patients, 1007
cefpodoxime
humans, 1094
cefpodoxime proxetil
humans, 232
cefprozil
food, 1210
humans, 1198, 1204, 1210
infants and children, 2152
ceftazidime
continuous and intermittent infusions, 2307
elderly patients, 1007
humans, 1139, 2307
renal function, 1139
tobramycin, 1139
ceftibuten
humans, 1053
ceftizoxime
elderly patients, 1007
ceftriaxone
elderly patients, 1007
cephalosporins
hysterectomy, 1160
lymphadenectomy, 1160
cilastatin
premature infants, 1172
cilofungin
rabbits, 2240
ciprofloxacin
azlocillin, 823
humans, 823, 1031
renal function, 1031
ciprofloxacin-rifampin
elderly patients, 442
cloxacillin
children, 1150
surgery with massive bleeding, 1150
cyclosporine
bone marrow transplant patients, 1048
ciprofloxacin, 1048
3′-deoxy-2′,3′-didehydrothymidine
rhesus monkeys, 1214
2′,3′-dideoxycytidine
cats, 1414
enoxacin
elderly patients, 1966
humans, 1491
renal impairment, 1491
urinary tract infections, 1966
FCE 22891
humans, 1001
fleroxacin
cholecystectomy, 2375
dogs, 58
humans, 58, 2375
rabbits, 58
skin and skin structure infections, 922
fluconazole
aluminum-magnesium hydroxide, 2032
antacids, 2032
humans, 2032
3′-fluoro-3′-deoxythymidine
rhesus monkeys, 1214
gentamicin
liposomal, 235
rats and mice, 235
HEPT, 2358
analogs, 2358
1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine, 2358
analogs, 2358
imipenem
premature infants, 1172
imipenem-cilastatin
premature infants, 1172
interferon
alpha, 1749
feline acquired immunodeficiency syndrome, 1749
lomefloxacin
food, 1797
hemodialysis, 2364
humans, 17, 150, 1797, 2364
renal function, 17, 2364
meropenem
humans, 1515
*N*-methylthiotetrazole
cefmetazole, 2369
cefoperazone, 2369
cefotetan, 2369
humans, 2369
netilmicin
end-stage renal disease, 128
humans, 128
netilmicin-piperacillin
end-stage renal disease, 128
humans, 128
nikkomycin X
mice, 587
nikkomycin Z
mice, 587
ofloxacin
antacids, 2436
calcium carbonate, 2436
humans, 78, 455, 2436
magnesium-aluminum hydroxide, 2436
renal impairment, 455
ornidazole
colorectal surgery, 1921
humans, 1921
oxoenoxacin
humans, 1491
renal impairment, 1491
pentoxifylline
mice, 1100
pentoxifylline analogs
mice, 1100
phosphonoformate
cats, 871
piperacillin-tazobactam, 697
quinolones
combined with clindamycin or imidazole derivative, 2407
rimantadine
humans, 2228
small-particle aerosol, 2228
Ro 23-9424
animals, 1895
roxithromycin
humans, 385
renal function, 385
SCH-39304
monkeys, 1281
SM-8668
mice, 980
sparfloxacin
guinea pigs, 2122
teicoplanin
bioassay, 1642
dosing regimens, 2114
humans, 2114
neutropenic patients, 1642
theophylline
enoxacin, 803
fleroxacin, 1249
humans, 1249, 1254
lomefloxacin, 1254
tobramycin
ceftazidime, 1139
end-stage renal disease, 128
humans, 128, 1139
renal function, 1139
tobramycin-piperacillin
end-stage renal disease, 128
humans, 128
trospectomycin
humans, 2342
vancomycin
Bayesian method, 1165
bioassay, 1642
burn patients, 792
immunoglobulin A myeloma, 1459
intravenous drug abusers, 792
neutropenic patients, 1642
renal function, 1165
zidovudine
hemophilia patients, 394
human immunodeficiency virus, 394
$N^2$-Phenyl-2′-deoxyguanosine
herpes simplex virus
explant ganglion cultures, 1285
mouse model, 1285
thymidine kinase, 1285
Phosphonoformate
feline immunodeficiency virus
reverse transcriptase, 1505
pharmacokinetics
cats, 871
Phosphorothioate oligodeoxynucleotides
herpes simplex virus
type 2, 808
*Pichia anomala*
anti-*Candida* toxin
mode of action, 1331
Pigs
*Y. enterocolitica*
susceptibilities, 2423
Piperacillin
*B. fragilis* group, 479
*Bacteroides* spp., 657

combinations
*P. aeruginosa*, 1666
tobramycin, 1666
*E. rhusiopathiae*, 2038
*Fusobacterium* spp., 657
*P. aeruginosa*, 1666
*P. pseudomallei*, 2027
*P. shigelloides*, 159
*S. typhimurium* SS-B, 853
tobramycin nephrotoxicity, 1020
Piperacillin-tazobactam
*B. fragilis* group, 1858
comparative activity
cefoxitin, ceftizoxime, chloramphenicol, clindamycin, imipenem, metronidazole, and piperacillin, 1858
ceftriaxone, 697
piperacillin, 697
tazobactam, 697
*E. coli*
meningitis, experimental, 697
*Enterobacteriaceae*
β-lactamases, 622
gram-negative organisms, 1858
*P. shigelloides*, 159
pharmacokinetics, 697
Plasma exchange pheresis
ceftriaxone clearance, 1276
Plasmids
*E. coli*
nosocomial, 739
*E. faecalis*
β-lactamases, 302
genetic relatedness, 302
*E. faecium*, 1565
pheromone response, 358
vancomycin resistance, 358
penicillinase
*S. aureus*, methicillin resistant, 600
quinolones
minireview, 681
resistance, 681
resistance
*S. typhi*, 161
*S. aureus*
gentamicin-tobramycin-kanamycin resistance transposonlike element, 2106
*S. epidermidis*
macrolide resistance, 1973
TEM-3
characterization, 219
*Plasmodium falciparum*
chloroquine
peroxidase-hydrogen peroxide system, 1981
chloroquine susceptible
chloroquine, 676
continuation of parasitemia, 676
humans, 676
mefloquine
peroxidase-hydrogen peroxide system, 1981
nucleotide metabolism inhibitors, 1393
pentamidine, 1381
analogs, 1381
purine analogs, 1393
pyrimidine analogs, 1393
quinine
peroxidase-hydrogen peroxide system, 1981
tubulozoles
mode of action, 1529
*Plasmodium yoelii*
ciprofloxacin
mice, 2327
5-fluoroorotate
mice, 1371
5-fluoroorotate-uridine
mice, 1371
pefloxacin
mice, 2327
*Plesiomonas shigelloides*
amikacin, 159
amoxicillin, 159
amoxicillin-clavulanate, 159
ampicillin, 159
ampicillin-sulbactam, 159
aztreonam, 159
cefamandole, 159
cefoperazone, 159
cefoperazone-sulbactam, 159
cefotaxime, 159
cefoxitin, 159
ceftazidime, 159
ceftriaxone, 159
cefuroxime, 159
cephalothin, 159
ciprofloxacin, 159
gentamicin, 159
imipenem, 159
mezlocillin, 159
piperacillin, 159
piperacillin-tazobactam, 159
ticarcillin, 159
ticarcillin-clavulanate, 159
tobramycin, 159
*Pneumocystis carinii*
566C80, 225
dihydropteroate synthetase
dapsone, 1075
high-pressure liquid chromatography, 1075
sulfadiazine, 1075
sulfadoxine, 1075
sulfamethoxazole, 1075
sulfaquinoxaline, 1075
hydroxynaphthoquinones, 225
minireview
pneumonia, 499
pentamidine analogs, 1026
pneumonia
deferoxamine, 1833
diagnosis, 499
eflornithine, 1833
minireview, 499
prevention, 499
rats, 1026, 1833
treatment, 499
pneumonitis
rats, 225
Pneumonia
gram-negative organisms, 269
model, mathematical, 326
murine
mathematical model, 326
*P. carinii*
rats, 1026
tobramycin
endotracheal, 269
Pokeweed antiviral protein
HeLa cell permeabilization
poliovirus, 2034
Poliovirus
6-(3,4-dichlorophenoxy)-3-(ethylthio)-2-pyridincarbonitrile
mode of action, 1259
HeLa cell permeabilization to pokeweed antiviral protein, 2034
type 2
dichloroflavan, 460
flavanoids, halogen substituted, 460
isoflavans, halogenated, 460
isoflavenes, 460
Polymerase chain reaction
*erm*, 2024
erythromycin resistance, 2024
Polymicrobial respiratory infections
model, 210
Polymorphonuclear leukocytes
cilofungin, 196
dideoxycytidine, 1672
dideoxyinosine, 1672
fluconazole, 196
flucytosine, 196
human immunodeficiency virus type 1
dideoxycytidine, 1672
dideoxyinosine, 1672
zidovudine, 1672
ketoconazole, 196
respiratory burst response
antibiotic inhibition, 863
Sch-39304, 196
zidovudine, 1672
Polyvinyl alcohol, sulfated
human immunodeficiency virus
giant cell formation, 134
type 1, 134
type 2, 134
Postantibiotic effect
β-lactams
bioluminescence assay, 102
*E. coli*, 102
bioluminescence assay
β-lactams, 102
*E. coli*, 102
ciprofloxacin
*L. pneumophila*, 1733
ofloxacin
*L. pneumophila*, 1733
pefloxacin
*L. pneumophila*, 1733
Potassium iodide
membrane transfer assay, 153
mutans streptococci, 153
Pressure sores
amikacin
pharmacokinetics, 1422
Preterm infants
amikacin
pharmacokinetics, 265
cilastatin
pharmacokinetics, 1172
imipenem
pharmacokinetics, 1172
Prostate
lomefloxacin concentrations, 2398
Protamine
combinations
atropine, 1112
hepatitis A virus, 1112
hepatitis A virus
cell culture, 1112
Protease
human immunodeficiency virus
bacteriological assay, 2337
Protein binding
in vitro capillary model, 98

*Proteus vulgaris*
β-lactams
paradoxical effect, 94
cefbuperazone, 94
cefmenoxime
paradoxical effect, 94
Proton motive force
macrolide accumulation
*H. influenzae*, 1787
*Pseudomonadaceae*
faeriefungin, 1762
*Pseudomonas aeruginosa*
amikacin, 614
β-lactamases
fosfomycin, 2093
chlorhexidine dihydrochloride
human albumin microspheres, 2118
ciprofloxacin, 40, 849
imipenem cross resistance, 2142
quinolone cross resistance, 2142
resistance, 2142
resistance, acquired, 281
ciprofloxacin-azlocillin, 1814
ciprofloxacin-aztreonam, 1814
ciprofloxacin-ceftazidime, 1814
E1040, 914
E-4441, 2318
E-4474, 2318
E-4480, 2318
E-4500, 2318
E-4501, 2318
E-4502, 2318
elastase
thiol-based peptide, 2065
fosfomycin
β-lactam antagonism, 2093
β-lactamases, 2098
outer membrane proteins, 2093
penicillin-binding proteins, 2093
*gyr* mutants
quinolone resistance, 1273
gyrase A gene probe
quinolone resistance, 1889
imipenem transport
outer membrane proteins, 52
in vitro chemostat system, 1666
LJC10,627, 994
lomefloxacin, 1088
mice, 2318
WIN 57273, 568
norfloxacin-resistant mutant
biochemical and genetic properties, 1757
ofloxacin
irradiated mice, 1387
septicemia, 1387
osteomyelitis, 40
ciprofloxacin, 849
outer membrane porins
β-lactam diffusion, 685
outer membrane proteins
fosfomycin, 2093
imipenem transport, 52
PAO
norfloxacin resistance gene, 1757
penicillin-binding proteins
β-lactam–fosfomycin antagonism, 2093
piperacillin, 1666
quinolone resistance
gyrase A gene probe, 1889
quinolone resistant
DNA gyrase mutants, 1273
quinolones
difluorinated, 2318
monofluorinated, 2318
Ro 23-9424, 189
septicemia
irradiated mice, 1387
ofloxacin, 1387
tobramycin, 1666
tobramycin-piperacillin, 1666
tosufloxacin, 2223
WIN 57273, 306, 568
*Pseudomonas cepacia*
faeriefungin, 1762
tosufloxacin, 2223
*Pseudomonas pseudomallei*
aztreonam, 2027
carumonam, 2027
cefepime, 2027
cefotaxime, 2027
ceftazidime, 2027
cefuzonam, 2027
chloramphenicol, 2027
ciprofloxacin, 2027
CS-533, 2027
E1040, 2027
enoxacin, 2027
fleroxacin, 2027
fosfomycin, 2027
imipenem, 2027
lomefloxacin, 2027
meropenem, 2027
minocycline, 2027
nalidixic acid, 2027
norfloxacin, 2027
ofloxacin, 2027
piperacillin, 2027
rifampin, 2027
sulfamethoxazole, 2027
temafloxacin, 2027
tetracycline, 2027
tosufloxacin, 2027
trimethoprim, 2027
trimethoprim-sulfamethoxazole, 2027
*Pseudomonas* spp.
A-56620, 1812
aztreonam-ceftazidime, 487
aztreonam-ciprofloxacin, 487
cancer patients, 1812
ciprofloxacin-ceftazidime, 487
fleroxacin, 1880
keratitis
thiol-based peptide, 2065
PD-117558, 1812
PD-117596, 1812
PD-127391, 1812
sparfloxacin, 1812
temafloxacin, 1812
U-78608, 884
Purine
analogs
*P. falciparum*, 1393
Pyrazinamide
combinations
chloroquine, 2217
tubercle bacilli, 2217
Pyrimethamine
combinations
mice, 1467
sulfadiazine, 1467
*T. gondii*, 1467
*T. gondii*
mice, 1467
Pyrimidine
analogs
*P. falciparum*, 1393
Pyrimidine nucleosides
modified
hepatitis B virus, 1986

Qinghaosu
derivatives
*T. gondii*, 1961
*T. gondii*, 1961
Quaternary ammonium compounds
antimicrobial activities, 1949
hydrolysis rates, 1949
Quinine
*P. falciparum*
peroxidase-hydrogen peroxide system, 1981
Quinolones
combinations
clindamycin, 2407
metronidazole, 2407
ornidazole, 2407
pharmacokinetics, 2407
serum bactericidal activity, 2407
cross resistance
ciprofloxacin, 2142
*P. aeruginosa*, 2142
difluorinated
in vitro and in vivo activities, 2318
DNA inhibition, 2331
*E. cloacae*
resistance, 173
*E. coli*
*hipQ*, 1938
reduced killing, 1938
resistance, 173
mechanism of action, 2331
monofluorinated
in vitro and in vivo activities, 2318
morphological changes, 2331
*P. aeruginosa* resistance
*gyr* mutation, 1273
plasmid-mediated resistance
minireview, 681
protein synthesis inhibition, 2331
*recA* induction, 2331
resistance
*gyrA* region, 1271
gyrase A gene probe, 1889
*P. aeruginosa*, 1889
RNA inhibition, 2331
*S. marcescens*
resistance, 173
SOS response induction, 2331
topoisomerases
inhibition, 1955
in vitro assays, 1, 8
minireviews, 1, 8

Radioassays
$^{14}CO_2$ measurement, 1035
effect of protein synthesis inhibitors on microbial growth kinetics, 1035
two-compartment, 1035
Ramoplanin
peptidoglycan biosynthesis, 413
Ranitidine
cefetamet pivoxil
pharmacokinetics, 1744
*recA*
quinolone induction, 2331

"Red man syndrome"
teicoplanin, 765
vancomycin, 550, 765
Respiratory burst response
antibiotic inhibition, 863
Respiratory infections
ampicillin-sulbactam
alveolar lining fluid penetration, 958
Respiratory syncytial virus
ribavirin
health care worker exposure, 668
Respiratory tract pathogens
resistance patterns, 2075
Retinitis
cytomegalovirus, 176
ganciclovir, 176
ganciclovir-intravenous immune globulin, 176
Retroperitoneal infections
cephem pharmacokinetics, 1160
Reverse transcriptase
feline immunodeficiency virus
inhibitor sensitivities, 1505
human immunodeficiency virus
inhibitor sensitivities, 1505
human immunodeficiency virus type 1
illimaquinone, 2009
Rhinovirus
human type 2
clinical study, 963
pathogenicity, 963
Ro 09-0410 resistant or dependent, 963
Ribavirin
health care worker exposure, 668
hemodialysis clearance, 489
Ribosomes
macrolide binding rate constants
azithromycin, 426
erythromycin, 426
Rifabutin
*M. avium*
thymectomized, CD4 T-cell deficient mouse model, 1629
*M. paratuberculosis*, 366
Rifampin
combinations
ciprofloxacin, 442
fleroxacin, 2312
methicillin-resistant *S. aureus*, 1655, 2312
novobiocin, 1655
pharmacokinetics, 442
vancomycin, 2312
*E. sennetsu*
P388D$_1$ murine macrophages, 1593
mitochondria, 167
*P. pseudomallei*, 2027
*S. aureus*
foreign body infections, 2312
methicillin resistant, 2312
rat model, 2312
*S. lugdunensis*, 2434
*S. typhimurium* SS-B, 853
Rimantadine
influenza A
safety and prophylactic efficacy, 1633
pharmacokinetics
humans, 2228
small-particle aerosol, 2228
safety
humans, 2228
small-particle aerosol, 2228
small-particle aerosol
pharmacokinetics, 2228
safety, 2228
Ro 09-0410
human rhinovirus type 2
clinical study, 963
resistant and dependent mutants, 963
Ro 23-9424
*B. fragilis*, 189
*C. freundii*, 189
*C. perfringens*, 189
comparative activity
cefotaxime, ciprofloxacin, desacetylcefotaxime, fleroxacin, and ofloxacin, 189
*E. cloacae*, 189
*E. coli*, 189
*E. faecalis*, 189
*Enterobacteriaceae*, 189
*K. pneumoniae*, 189
*L. monocytogenes*, 189
*P. aeruginosa*, 189
pharmacokinetics
animals, 1895
*S. marcescens*, 189
*Staphylococcus* spp., 189
*Streptococcus* spp., 189
ROB-1
comparative studies, 1354
nucleotide sequence, 1354
Rokitamycin
*C. jejuni*, 1440
comparative activity
ciprofloxacin, clindamycin, erythromycin, fosfomycin, minocycline, norfloxacin, ofloxacin, and tetracycline, 1440
Roxithromycin
human polymorphonuclear leukocyte cytoplast uptake, 1189
pharmacokinetics
humans, 385
renal function, 385

S25930
*X. maltophilia*, 1609
S25932
*X. maltophilia*, 1609
*Saccharomyces cerevisiae*
azole activity
lovastatin, 1660
fenpropimorph
sterol synthesis, 989
β-galactosidase
antimycotic screen, 660
KT28
antimannoprotein antibodies, 1615
blockage of cell wall receptors, 1615
sterols
lovastatin, 1660
Salicyl alcohol
*E. coli*
cadmium accumulation and toxicity, 2402
Salicylate
aminoglycoside susceptibility
*E. coli*, 786
*E. coli*
cadmium accumulation and toxicity, 2402
*Salmonella dublin*
gentamicin
liposomal, 343
*Salmonella enteritidis*
tosufloxacin
intracellular activity, 949
*Salmonella* spp.
tosufloxacin, 368
*Salmonella typhi*
chloramphenicol resistance
outer membrane protein deficiency, 1715
resistance
in vivo acquisition, 161
plasmid, 161
*Salmonella typhimurium*
outer membrane mutant SS-B
susceptibility profile, 853
outer membrane mutants
KB-5246, 1323
Sarafloxacin
*A. salmonicida*, 1819
Sch-22591
*X. maltophilia*, 1609
Sch-24120
*X. maltophilia*, 1609
Sch-39304
blastomycosis, pulmonary
mice, 896
*C. albicans*, 196
candidiasis
rabbits, 1560
cerebrospinal fluid penetration
monkeys, 1281
coccidioidal meningitis
mice, 663
coccidioidomycosis
mice, 928
comparative activity
amphotericin B, 196
amphotericin B and fluconazole, 896
amphotericin B, fluconazole, and flucytosine, 1560
fluconazole, 928
fluconazole and itraconazole, 663
*H. capsulatum*, 524
histoplasmosis
mice, 524
pharmacokinetics
monkeys, 1281
polymorphonuclear leukocytes, 196
SDZ89-485
coccidioidomycosis
murine, 13
comparative activity
fluconazole, 13
Septicemia
*P. aeruginosa*
irradiated mice, 1387
ofloxacin, 1387
*Serratia marcescens*
amikacin, 614
β-lactamases, 755
lomefloxacin, 1088
quinolones
resistance, 173
Ro 23-9424, 189
Serum bactericidal activity
cefoperazone
elderly patients, 1007
cefotaxime
elderly patients, 1007
ceftazidime
elderly patients, 1007
ceftizoxime
elderly patients, 1007

ceftriaxone
elderly patients, 1007
quinolones
combined with clindamycin or imidazole derivative, 2407
Serum protein binding
broth dilution, 1257
ceftriaxone
broth dilution, 1257
supraphysiologic temperature, 1257
supraphysiologic temperature, 1257
Serum sickness-like reactions
ciprofloxacin, 904
*Shigella* spp.
tosufloxacin, 368
SHV-1
cloning, 1577
DNA probe, 1577
OHIO-1, 1570
sequencing, 1577
SHV-2
cloning, 1577
gene nucleotide sequence, 1725
nucleotide sequence, 1444
phylogeny, 1725
SHV-5
nucleotide sequence, 2439
Sisomicin
*E. coli*
tricarboxylic acid cycle, 295
SK&F 88070
*M. avium-M. intracellulare*, 1390
Skin infections
cefepime
safety and efficacy, 954
cefonicid, 654
fleroxacin
pharmacokinetics, 922
nafcillin, 654
Skin structure infections
cefonicid, 654
fleroxacin
pharmacokinetics, 922
nafcillin, 654
SM-7338
*S. aureus*
penicillin-binding proteins, 484
SM-8668
aspergillosis
mice, 980
candidiasis
mice, 980
comparative activity
fluconazole, 980
cryptococcosis
mice, 980
pharmacokinetics
mice, 980
Sodium
nephrotoxicity
tobramycin, 1020
Sodium dodecyl sulfate
*S. typhimurium* SS-B, 853
Soft tissue infections
cefepime
safety and efficacy, 954
SOS response
azidothymidine, 1237
dideoxynucleosides, 1237
quinolones, 2331
Sparfloxacin
cancer patient isolates, 2263
combinations
ethambutol, 2442
*M. avium* complex, 2442
rifampin, 2442
comparative activity
ampicillin, BMY 28100, ceftibuten, cefuroxime, ciprofloxacin, fleroxacin, lomefloxacin, loracarbef, ofloxacin, temafloxacin, and vancomycin, 2283
ciprofloxacin, 2442
ciprofloxacin and erythromycin, 2122
ciprofloxacin and fleroxacin, 2263
ciprofloxacin, norfloxacin, and ofloxacin, 1123
ciprofloxacin and ofloxacin, 1843
*Enterococcus* spp., 2283
gram-negative organisms, 2263
gram-positive organisms, 2263
*H. influenzae*, 2283
*L. pneumophila*
guinea pigs, 2122
pneumonia, 2122
*Legionella* spp., 2122
*M. avium* complex, 2442
*M. catarrhalis*, 2283
*M. leprae*, 229
pharmacokinetics
animals, 89
guinea pigs, 2122
*Pseudomonas* spp., 1812
respiratory tract pathogens, 2283
*S. aureus*, 1843
methicillin resistant, 1123
quinolone resistant, 1123
*S. epidermidis*, 1843
*Staphylococcus* spp., 2283
susceptibility testing, 2122
*X. maltophilia*, 1812
Spectinomycin
*Campylobacter* resistance, 1294
*M. avium-M. intracellulare*, 1390
Spinal cord injury
amikacin
pharmacokinetics, 1422
Stannous fluoride
membrane transfer assay, 153
mutans streptococci, 153
*Staphylococcus aureus*
ampicillin-sulbactam, 728, 1830
β-lactamase variants
extracts versus whole-cell suspensions, 420
β-lactamases
cation-exchange and affinity chromatography, 2177
purification, 2177
BK-218, 349
BMY-28271, 555
cefoperazone-sulbactam, 1830
chlorhexidine dihydrochloride
human albumin microspheres, 2118
ciprofloxacin resistance
emergence, 1862
clarithromycin, 562
daptomycin, 245, 2081
pharmacodynamic model, 1925
protein binding, 1925
E-4441, 2318
E-4474, 2318
E-4480, 2318
E-4500, 2318
E-4501, 2318
E-4502, 2318
endocarditis
daptomycin, 2348
intravenous drug users, 1227
rabbits, 257, 2081
rats, 728, 2348
fleroxacin, 1880
guinea pig prophylaxis, 21
gentamicin-tobramycin-kanamycin resistance
transposonlike element, 2106
guinea pigs
fleroxacin prophylaxis, 21
inoculum effect
cefamandole, 505
cefazolin, 505
cefuroxime, 505
lomefloxacin, 1088
LY 264826, 2007
methicillin resistance
penicillinase plasmids, 600
stability, 600
methicillin resistant
AT-4140, 1123
carrier state, 1655
ciprofloxacin, 1014
ciprofloxacin resistance, 2050
ciprofloxacin-rifampin, 1014
endocarditis, 1143
foreign body infection, 2312
fosfomycin, 2260
fusidic acid, 2260
*mec*, 1777
mupirocin, 2260
nosocomial infections, 1655
novobiocin-rifampin, 1655
ofloxacin, 2260
osteomyelitis, 1014
PBP 2A, 1777
PD-117596, 2260
PD-127391, 2260
pefloxacin, 1014, 2260
pefloxacin-rifampin, 1014
rat model, 2312
rats, 1014, 1143
rifampin, 2312
rifampin-fleroxacin, 2312
rifampin-vancomycin, 2312
temafloxacin, 1143, 2260
temafloxacin-rifampin, 1143
tetracycline resistance determinant, 2273
transposon mutants, 1777
vancomycin, 1014, 1143, 2260
vancomycin-rifampin, 1014, 1143
methicillin resistant, borderline
β-lactamase, 911
characterization, 911
methicillin, 911
oxacillin, 911
penicillin-binding proteins, 911
mice, 555, 2318
autobacteriography, 562
teicoplanin, 1869
vancomycin, 1869
ofloxacin, 257
(−)-ofloxacin, 277
oxacillin, 728
oxacillin resistant
dapsone, 1453
sulfamethoxazole, 1453
trimethoprim-dapsone, 1453
trimethoprim-sulfamethoxazole, 1453
penicillin-binding proteins

SM-7338, 484
pentoxifylline
mice, 1100
pentoxifylline analogs
mice, 1100
quinolone resistant
AT-4140, 1123
quinolones
difluorinated, 2318
monofluorinated, 2318
SM-7338
penicillin-binding proteins, 484
sparfloxacin, 1843
teicoplanin, 1869, 2081
tosufloxacin, 2223
vancomycin, 245, 1227, 1869, 2081
pharmacodynamic model, 1925
protein binding, 1925
ventriculitis
rabbits, 245
WIN 57273, 1376
*Staphylococcus epidermidis*
inoculum effect
cefamandole, 505
cefazolin, 505
cefuroxime, 505
macrolide resistance
energy-dependent efflux pump, 1973
plasmid pNE24, 1973
methicillin resistant
ciprofloxacin, 273
endocarditis, 273
penicillin-binding protein, 1691
sparfloxacin, 1843
WIN 57273, 1376
*Staphylococcus haemolyticus*
methicillin resistant
penicillin-binding protein, 1691
*Staphylococcus hominis*
methicillin resistant
penicillin-binding protein, 1691
*Staphylococcus lugdunensis*
amoxicillin-clavulanate, 2434
ampicillin, 2434
ampicillin-sulbactam, 2434
β-lactamase, 2434
cephalothin, 2434
erythromycin, 2434
gentamicin, 2434
oxacillin, 2434
penicillin, 2434
penicillinase, 2434
rifampin, 2434
vancomycin, 2434
*Staphylococcus saprophyticus*
methicillin resistant
β-lactam resistance, 1780
PBP 2a, 1780
*Staphylococcus simulans*
methicillin resistant
penicillin-binding protein, 1691
*Staphylococcus* spp.
Bay v 3522, 813, 1849, 1855
BMY-28232, 555
coagulase negative
biofilm, 390
cefamandole, 390
methicillin resistance, 1691
neutropenic patients, 901
teicoplanin, 901
teicoplanin resistant, 899
vancomycin, 390, 901
vancomycin resistant, 899
dirithromycin, 1839
DNA probe
methicillin resistance, 1720
E1040, 914
LJC10,627, 994
LY264826, 2137
methicillin resistance
DNA probe, 1720
*mecR*, 1703
methicillin resistant
*mecA*, 170
mice
WIN 57273, 568
pentamidine, 1795
Ro 23-9424, 189
sparfloxacin, 2283
tetracycline resistance
DNA-DNA hybridization, 1611
gene heterogeneity, 1611
WIN 57273, 306, 568
*Streptococcus agalactiae*
gentamicin
high-level chromosomal resistance, 985
*Streptococcus anginosus*
resistance
genetic and molecular basis, 1685
*Streptococcus pneumoniae*
amoxicillin-clavulanic acid, 2075
ampicillin, 467, 2075
ampicillin-sulbactam, 2075
Bay v 3522, 813
BMY-28100, 467
cefaclor, 467, 2075
cefamandole, 467
ceftibuten, 467
cefuroxime, 2075
cephalexin, 2075
cephalothin, 2075
chloramphenicol, 2075
ciprofloxacin, 467
clindamycin, 467
enoxacin, 467
erythromycin, 467, 2075
fleroxacin, 467
lomefloxacin, 467
loracarbef, 467
ofloxacin, 467
pefloxacin, 467
penicillin, 2075
autolysis-dependent and -independent killing mechanisms, 33
penicillin G, 467
resistance patterns, 2075
temafloxacin, 467
tetracycline, 467, 2075
trimethoprim-sulfamethoxazole, 467, 2075
*Streptococcus pneumoniae-Staphylococcus aureus*
amoxicillin, 210
amoxicillin-clavulanic acid, 210
respiratory infection model, 210
*Streptococcus pyogenes*
LY264826, 2137
*Streptococcus sanguis*
amoxicillin, 321
endocarditis
rabbits, 321
penicillin G-streptomycin, 321
penicillin V, 321
*Streptococcus* spp.
BAY v 3522, 1849, 1855
dirithromycin, 1839
E1040, 914
group B
high-level chromosomal gentamicin resistance, 985
mice
WIN 57273, 568
Ro 23-9424, 189
WIN 57273, 306, 568
*Streptomyces fradiae*
fatty acids
tylactone biosynthesis, 1535
Streptomycin
*Campylobacter* resistance, 1294
combinations
brucellosis, 881
chloroquine, 2217
doxycycline, 881
tubercle bacilli, 2217
*E. coli*
abnormal membrane proteins, 534
*M. paratuberculosis*, 366
mode of action
abnormal membrane proteins, 534
*E. coli*, 534
nitroguaiacol ether derivatives
properties, 1908
purification, 1908
synthesis, 1908
Sucralfate
ciprofloxacin bioavailability
humans, 931
Sulbactam
β-lactamases
class I, 156
*Enterobacteriaceae*, 2256
nonfermenters, 2256
Sulbactam-ceftriaxone
*E. coli*
SHV-2-like β-lactamase, 581
endocarditis
*E. coli*, 581
rabbits, 581
Sulfadiazine
combinations
mice, 1467
pyrimethamine, 1467
*T. gondii*, 1467
nocardiosis
murine pulmonary, 1766
*P. carinii*
dihydropteroate synthetase, 1075
*T. gondii*
mice, 1467
Sulfadoxine
*P. carinii*
dihydropteroate synthetase, 1075
Sulfamethoxazole
combinations
oxacillin-resistant *S. aureus*, 1453
trimethoprim, 1453
*P. carinii*
dihydropteroate synthetase, 1075
*P. pseudomallei*, 2027
*S. aureus*
oxacillin resistant, 1453
Sulfaquinoxaline
*P. carinii*
dihydropteroate synthetase, 1075

Sulfated polymers
  human immunodeficiency virus
    giant cell formation, 134
    type 1, 134
    type 2, 134
Sulfisoxazole
  comparative activity
    rifabutin, 1508
  *M. avium* complex
    human macrophages, 1508
Sulfonamides
  *N. meningitidis* resistance
    DNA probe, 2277
Surfactants
  *B. subtilis*
    aberrant morphology, 781
    autolysins, 781
    lysis, 781
Susceptibility
  growth rate
    minireview, 1865
Susceptibility testing
  *B. fragilis* group
    cefoxitin, 2246
    resistance rate differences due to different methods, 179
  biofilm bacteria
    minireview, 2043
  *C. burnetii*
    lysosomotropic agents, 1512
  cefoxitin
    *B. fragilis* group, 2246
    reader, 2246
    replicates, 2246
    trial, 2246
  disk elution
    comparative studies, 2128
    MICs and MBCs, 2128
  E1040, 914
  *Enterococcus* spp.
    vancomycin, 1846
  *Fusobacterium* spp.
    fastidious anaerobe agar, 2280
  *H. ducreyi*
    minireview, 1303
  *H. influenzae*
    problems with current recommendations, 1480
  human immunodeficiency virus
    zidovudine, 436
  *Lactobacillus* spp.
    vancomycin resistant, 543
  *Leuconostoc* spp.
    vancomycin resistant, 543
  *M. paratuberculosis*
    colonial morphology, 2300
    Tween 80, 2300
  mathematical modeling techniques, 1769
  minireview
    batch and continuous culture studies, 1623
    cell envelope modification, 1623
    growth rate, 1623
  *Pediococcus* spp.
    vancomycin resistant, 543
  sparfloxacin, 2122
  yeasts
    incubation time, 1648
    macro-microdilution result agreement, 1542
    medium, 1648
    temperature, 1648
T-3262
  *M. leprae*, 229
Tazobactam
  β-lactamases
    class I, 156
Teicoplanin
  bactericidal rate, 510
  bioassay, 1642
  cardiac surgery
    serum and tissue concentrations, 1699
  comparative activity
    daptomycin and vancomycin, 2081
    vancomycin, 827, 901
  concentrations in serum, 510
  dosage, 510
  *E. faecalis*, 827
  *E. rhusiopathiae*, 2038
  endocarditis
    rabbits, 510, 2081
    rats, 827
    *S. aureus*, 2081
  *Enterococcus* resistance
    minireview, 2291
  gram-positive bacterial infections
    bone, 2392
    joint, 2392
    vascular access associated, 2392
  histamine release, 765
  *Lactobacillus* spp., 543
  *Leuconostoc* spp., 543
  neutropenic patients
    coagulase-negative staphylococci, 901
  *Pediococcus* spp., 543
  pharmacokinetics
    dosing regimens, 2114
    humans, 2114
    neutropenic patients, 1642
  protein binding, 510
  "red man syndrome," 765
  *S. aureus*, 510, 1869
    murine, 1869
  *S. sanguis*, 510
  *Staphylococcus* spp., coagulase negative
    neutropenic patients, 901
    resistance, 899
TEM
  characterization, 2210
  molecular epidemiology, 2210
  oligotyping, 2210
TEM-3
  *K. pneumoniae*, 2070
  molecular epidemiology, 219
Temafloxacin
  *B. parapertussis*, 2287
  *B. pertussis*, 2287
  combinations
    methicillin-resistant *S. aureus*, 1143
    rat endocarditis, 1143
    rifampin, 1143
  comparative activity
    vancomycin, 1143
  endocarditis
    methicillin-resistant *S. aureus*, 1143
    rats, 1143
  *M. leprae*, 229
  *P. pseudomallei*, 2027
  *Pseudomonas* spp., 1812
  *S. aureus*
    methicillin resistant, 2260
  *S. pneumoniae*, 467
  *X. maltophilia*, 1609, 1812
Terbinafine
  combinations
    ketoconazole, 2097
    *T. cruzi*, 2097
  *T. cruzi*
    ultrastructural alterations, 2097
*tetA*(M)
  cloning and sequencing, 2273
*tetA-lacZ* fusion system
  tetracycline detection, 111
Tet M
  determinant characterization, 476
  *F. nucleatum*
    transferable, 1836
Tet(O)
  molecular studies, 71
Tetracycline
  biological detection
    *tetA-lacZ* fusion system, 111
  combinations
    bismuth subsalicylate, 1232
    *H. mustelae*, 1232
    metronidazole, 1232
  *E. rhusiopathiae*, 2038
  *F. nucleatum* resistance
    transfer, 1836
  *H. influenzae*, 2075
  *M. catarrhalis*, 2075
  *M. catarrhalis* resistance
    genetic basis, 1816
  *M. hominis*
    resistance, 2297
  mitochondria, 167
  *P. pseudomallei*, 2027
  resistance
    genetic basis, 261
    molecular studies, 71
    *S. aureus*, methicillin resistant, 2273
    Tet M determinant characterization, 476
    Tet(O), 71
    urogenital bacteria, 261
  resistance determinants
    erroneous class N, 1447
  *S. pneumoniae*, 467, 2075
  *S. typhimurium* SS-B, 853
  *Staphylococcus* spp.
    resistance gene heterogeneity, 1611
  urogenital bacteria
    resistance, genetic basis of, 261
Tetrahydroberberine
  leishmaniasis
    hamsters, 918
Theophylline
  clearance
    enoxacin, 1739
    4-oxoenoxacin, 1739
    rats, 1739
    renal and metabolic, 1739
  dosage
    enoxacin coadministration, 803
  metabolism
    fluoroquinolones, 594
    human liver microsomes, 594
  pharmacokinetics
    enoxacin, 803
    fleroxacin, 1249
    humans, 1249, 1254
    lomefloxacin, 1254
1,3,4-Thiadiazol-2-ylcyanamide
  influenza virus A, 2156
    mice, 2156
  influenza virus B, 2156

ferrets, 2156
mice, 2156
sodium salt
influenza virus A, 2156
influenza virus B, 2156
Thymidine
analogs
human immunodeficiency virus, 637
mouse toxicity, 637
S-oligomers
herpes simplex virus type 2, 808
Ticarcillin
*Bacteroides* spp., 1546
*Fusobacterium* spp., 1546
gram-negative organisms
serum, 2234
*P. shigelloides*, 159
tobramycin nephrotoxicity, 1020
Ticarcillin-clavulanate
*B. fragilis* group, 479
*Bacteroides* spp., 1546
*C. albicans*
mouse gastrointestinal tract colonization, 2420
*Enterobacteriaceae*
β-lactamases, 622
*Fusobacterium* spp., 1546
*P. shigelloides*, 159
*Y. enterocolitica*
pigs and pork products, 2423
Tigemonam
*K. pneumoniae*, 1783
Tinea pedis
butenafine hydrochloride, 2254
guinea pigs, 2254
Tissue cage models
fleroxacin, 21
*S. aureus*, 21
vancomycin, 21
Tn*2921*
fosfomycin resistance gene
sequence, 2016
Tobramycin
*A. calcoaceticus* biovar anitratus, 494
combinations
*C. trachomatis*, 1399
ceftazidime, 1139
clindamycin, 1399
end-stage renal disease, 128
*P. aeruginosa*, 1666
pharmacokinetics, 128, 1139
piperacillin, 128, 1666
endotracheal
gram-negative organisms, 269
pneumonia, 269
*H. pylori*
resistance, 1637
nephrotoxicity
daptomycin, 139
piperacillin, 1020
rats, 139
sodium, 1020
ticarcillin, 1020
vancomycin, 139
*P. aeruginosa*, 1666
*P. shigelloides*, 159
pharmacokinetics
ceftazidime, 1139
end-stage renal disease, 128
humans, 128, 1139
renal function, 1139
resistance
4′-aminoglycoside nucleotidyltransferase, 2381
ANT(4′)-II, 2381
gram-negative organisms, 2381
tear concentrations, 1602
*Tolypocladium niveum*
cyclosporin production, 121
Topoisomerase II
*T. cruzi*
inhibitors, 1707
proliferation and differentiation, 1707
Topoisomerases
in vitro assays, 1, 8
minireviews, 1, 8
quinolones, 1, 8
inhibitory effects, 1955
Tosufloxacin
*A. hydrophila*, 368
*C. trachomatis*, 971
*Campylobacter* spp., 368
comparative activity
A-56620, ciprofloxacin, norfloxacin, temafloxacin, and trimethoprim-sulfamethoxazole, 368
ampicillin, aztreonam, ceftazidime, cefuroxime, cephalexin, ciprofloxacin, chloramphenicol, enoxacin, gentamicin, imipenem, nafcillin, norfloxacin, ofloxacin, tobramycin, and trimethoprim-sulfamethoxazole, 2223
ceftriaxone, ciprofloxacin, doxycycline, spectinomycin, and temafloxacin, 971
ofloxacin and norfloxacin, 949
cystic fibrosis respiratory pathogens, 2223
*E. coli*, 2223
*H. influenzae*, 2223
*N. gonorrhoeae*, 971
*P. aeruginosa*, 2223
*P. cepacia*, 2223
*P. pseudomallei*, 2027
*S. aureus*, 2223
*S. enteritidis*
intracellular activity, 949
*Salmonella* spp., 368
*Shigella* spp., 368
tissue culture cell penetration, 949
*Vibrio* spp., 368
*Toxoplasma gondii*
clindamycin
mice, 1467
doxycycline
macrophages, 775
mice, 775
macrophages
doxycycline, 775
mice
doxycycline, 775
parasitic load kinetics
mice, 1467
pyrimethamine
mice, 1467
pyrimethamine-sulfadiazine
mice, 1467
qinghaosu, 1961
derivatives, 1961
sulfadiazine
mice, 1467
Transposonlike elements
*S. aureus* plasmids
gentamicin-tobramycin-kanamycin resistance, 2106
*Trichophyton mentagrophytes*
dermatophytosis
butenafine hydrochloride, 2250
guinea pigs, 2250
tinea pedis
butenafine hydrochloride, 2254
guinea pigs, 2254
*Trichophyton mentagrophytes* var. *granulare*
G2
guinea pigs, 1600
$N^2$-(*m*-Trifluoromethylphenyl)guanine
herpes simplex virus
explant ganglion cultures, 1285
mouse model, 1285
thymidine kinase, 1285
Trimethoprim
combinations
dapsone and sulfamethoxazole, 1453
oxacillin-resistant *S. aureus*, 1453
*E. coli* resistance
DNA hybridization studies, 2013
human polymorphonuclear leukocyte cytoplast uptake, 1189
*P. pseudomallei*, 2027
resistance
*dhfrI* location, 642
Trimethoprim-sulfamethoxazole
*A. calcoaceticus* biovar anitratus, 494
comparative activity
amifloxacin, 665
ampicillin, 1792, 1800
*E. rhusiopathiae*, 2038
endocarditis
*Enterococcus* spp., 1792
rats, 1792
*Enterobacteriaceae*
infrequent, 1605
*H. influenzae*, 2075
*M. catarrhalis*, 2075
*P. pseudomallei*, 2027
peritonitis
*Enterococcus* spp., 1800
murine, 1800
*S. pneumoniae*, 467, 2075
urinary tract infections
uncomplicated, 665
*Y. enterocolitica*
pigs and pork products, 2423
Triton X-100
*S. typhimurium* SS-B, 853
Trospectomycin
*Bacteroides* spp.
oral, 1597
comparative activity
cefoxitin, clindamycin, penicillin G, piperacillin, and tetracycline, 1597
*E. coli*
serum sensitivity, 2086
pharmacokinetics
humans, 2342
safety
humans, 2342
*X. maltophilia*, 1609
*Trypanosoma brucei brucei*
5′-{[(*Z*)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine
mice, 1485
MDL 73811
mice, 1485
*Trypanosoma brucei rhodesiense*
5′-{[(*Z*)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine

mice, 1485
DL-α-difluoromethylornithine, 1183
MDL 73811
mice, 1485
*Trypanosoma cruzi*
ketoconazole
ultrastructural alterations, 2097
magainin
analogs, 1824
terbinafine
ultrastructural alterations, 2097
topoisomerase II
nalidixic acid, 1707
novobiocin, 1707
ofloxacin, 1707
proliferation and differentiation, 1707
dTTP analogs
feline immunodeficiency virus
reverse transcriptase, 1505
human immunodeficiency virus
reverse transcriptase, 1505
ddTTP
feline immunodeficiency virus
reverse transcriptase, 1505
Tubercle bacilli
human macrophages
chloroquine, 2217
chloroquine-isoniazid, 2217
chloroquine-pyrazinamide, 2217
chloroquine-streptomycin, 2217
chloroquine-vitamin $D_3$ metabolites, 2217
Tubulozoles
*P. falciparum*
mode of action, 1529
Tumor necrosis factor induction assay
amphotericin B toxicity, 906
Tylactone
biosynthesis
fatty acid intermediates, 1535
Typhoid fever
chloramphenicol, 1809
concentrations in serum, 1809
chloramphenicol succinate, 1809
chloramphenicol concentrations in serum, 1809

U-78608
*Acinetobacter* spp., 884
β-lactamases, 884
comparative activity
aztreonam and SQ 83,360, 884
*E. coli*, 884
*K. oxytoca*, 884
penicillin-binding proteins, 884
*Pseudomonas* spp., 884
Urethritis
gonococcal
cefetamet pivoxil, 674
ceftriaxone, 819
ciprofloxacin, 819
uncomplicated, 674
uncomplicated
cefetamet pivoxil, 674
gonococcal, 674
Uridine
combinations
5-fluoroorotate, 1371
mice, 1371
*P. yoelii*, 1371
Urinary pathogens
chlorhexidine dihydrochloride
human albumin microspheres, 2118
Urinary tract infections
amoxicillin-clavulanate, 1803
aztreonam, 1045
cefepime
safety and efficacy, 954
cephradine, 1803
complicated
fleroxacin, 409
uncomplicated
amifloxacin, 665
trimethoprim-sulfamethoxazole, 665
Urogenital bacteria
tetracycline
resistance, genetic basis of, 261

*vanA*
cloning, 924
gram-positive organisms, 1875
Vancomycin
bioassay, 1642
coagulase-negative staphylococci
biofilm, 390
combinations
methicillin-resistant *S. aureus*, 1143
rat endocarditis, 1143
rifampin, 1143
comparative activity
daptomycin, 245
daptomycin and teicoplanin, 2081
fleroxacin, 21
teicoplanin, 901
temafloxacin, 1143
dosage monitoring and adjustment
Bayesian method, 1165
renal function, 1165
*E. faecalis*, 1068
*E. faecium*
resistance, 358
*E. rhusiopathiae*, 2038
endocarditis
intravenous drug users, 1227
methicillin-resistant *S. aureus*, 1143
rabbits, 1068, 2081
rats, 1143
*S. aureus*, 2081
*Enterococcus* resistance, 252
in vitro detection, 1846
minireview, 2291
histamine release, 550, 765
*Lactobacillus* spp., 543
*Leuconostoc* spp., 543
neutropenic patients
coagulase-negative staphylococci, 901
*Pediococcus* spp., 543
pharmacokinetics
Bayesian method, 1165
burn patients, 792
immunoglobulin A myeloma, 1459
intravenous drug abusers, 792
neutropenic patients, 1642
renal function, 1165
protein binding
pharmacodynamic model, 1925
*S. aureus*, 1925
"red man syndrome," 550, 765
resistance
cell wall peptide binding, 1342
*Enterococcus* spp., 252
membrane-associated protein, 1342
*S. aureus*, 245, 1227, 1869
guinea pig prophylaxis, 21
methicillin resistant, 2260
murine, 1869
pharmacodynamic model, 1925
protein binding, 1925
*S. lugdunensis*, 2434
*S. typhimurium* SS-B, 853
serum inhibitory activity, 1068
*Staphylococcus* spp., coagulase negative
neutropenic patients, 901
resistance, 899
tobramycin nephrotoxicity
rats, 139
ventriculitis
rabbits, 245
*Y. enterocolitica*
pigs and pork products, 2423
Vascular access
bacteremia
gram-positive organisms, 2392
teicoplanin, 2392
Ventriculitis
daptomycin, 245
*S. aureus*
rabbits, 245
vancomycin, 245
*Vibrio* spp.
tosufloxacin, 368
Vitamin $D_3$
combinations
chloroquine, 2217
tubercle bacilli, 2217
Vitamin K
metabolism
aztreonam, 1045

WIN 57273
*Actinetobacter* spp., 306
*B. catarrhalis*, 1154
*B. fragilis* group, 306, 1858
*Bacillus* spp., 306
*Branhamella* spp., 306
comparative activity
amifloxacin, ceftazidime, ciprofloxacin, erythromycin, penicillin G, and ofloxacin, 568
ampicillin, cephalexin, ciprofloxacin, clindamycin, imipenem, oxacillin, and vancomycin, 1154
ampicillin, ciprofloxacin, daptomycin, gentamicin, imipenem, ofloxacin, and vancomycin, 1376
cefoxitin, ceftizoxime, chloramphenicol, clindamycin, imipenem, metronidazole, and piperacillin, 1858
ciprofloxacin, enoxacin, fleroxacin, norfloxacin, and ofloxacin, 306
ciprofloxacin and ofloxacin, 770
*E. coli*
mice, 568
*E. faecalis*, 306, 1376
*E. faecium*, 1154
*Enterobacteriaceae*, 306, 1154
*Enterococcus* spp., 568
gram-negative organisms, 568, 1154, 1858
gram-positive organisms, 568, 1154
*H. influenzae*, 1154
*Haemophilus* spp., 306, 568
*K. pneumoniae*
mice, 568

*L. monocytogenes*, 306
mice, 568
*Legionella* spp., 1154
*M. avium-M. intracellulare*, 1154
*M. leprae*, 229
*Mycobacterium* spp., 770
*N. gonorrhoeae*, 1154
*Neisseria* spp., 306, 568
*P. aeruginosa*, 306
mice, 568
*S. aureus*, 1376
*S. epidermidis*, 1376
*Staphylococcus* spp., 306, 568
mice, 568
*Streptococcus* spp., 306
mice, 568
Woodchuck hepatitis virus
1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-ethyluracil, 473
1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine, 473
1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluracil, 473
FEAU, 473
FIAC, 473
2′-fluorinated arabinosyl-pyrimidine nucleosides, 473
FMAU, 473
Wound dressings
*N*-carboxybutyl chitosan
antimicrobial properties, 2019

*Xanthomonas maltophilia*
A-56620, 1609, 1812
amifloxacin, 1609
cancer patients, 1812
ciprofloxacin, 1609
fleroxacin, 1609
LJC10,627, 994
norfloxacin, 1609
PD-117558, 1609, 1812
PD-117596, 1609, 1812
PD-127391, 1609, 1812
S25930, 1609
S25932, 1609
Sch-22591, 1609
Sch-24120, 1609
sparfloxacin, 1812
temafloxacin, 1609, 1812
trospectomycin, 1609

Yeast killer toxins
KT28
antimannoprotein antibodies, 1615
blockage of cell wall receptors, 1615
*P. anomala*
mode of action, 1331
Yeasts
susceptibility testing
incubation time, 1648
macro-microdilution result agreement, 1542
medium, 1648
temperature, 1648
*Yersinia enterocolitica*
aminoglycosides, 2423
aztreonam, 2423
cefazolin, 2423
cefotaxime, 2423
ceftazidime, 2423
ceftriaxone, 2423
cephalothin, 2423
ciprofloxacin, 2423
clindamycin, 2423
erythromycin, 2423
imipenem, 2423
norfloxacin, 2423
penicillin, 2423
pigs and pork products
susceptibilities, 2423
ticarcillin-clavulanic acid, 2423
trimethoprim-sulfamethoxazole, 2423
vancomycin, 2423

Zidovudine
combinations
alpha interferon, 1749
feline acquired immunodeficiency syndrome, 1749
feline acquired immunodeficiency syndrome, 1749
human immunodeficiency virus
antiviral susceptibilities, 436
susceptibility testing, 436
susceptible and resistant isolates, 436
pharmacokinetics
hemophilia patients, 394
human immunodeficiency virus, 394
polymorphonuclear leukocyte function, 1672
human immunodeficiency virus type 1, 1672